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ABSTRACT 
A general screening method for the detection and characterisation of drugs and their 
metabolites in biological fluids based upon high-performance thin-layer chromatography 
(HPTLC) has been developed, and its potential value in drug research and development 
has been assessed. 
Novel linear multiple development gradients using normal-phase chromatography on 
silica gel HPTLC plates were developed. The need for linear gradients was shown by an 
examination of the elutropic strength profiles of a number of "universal" Automated 
Multiple Development gradients, which each contained an abrupt change in elutropic 
strength at which many components of a complex mixture might cluster. 
The hypothesis was proposed that particular metabolite types have a characteristic 
retention relative to their parent compound following development on linear normal- 
phase gradients. Model compounds were selected which were representative of the major 
metabolic pathways and included structural components, such as phenols, indoles, 
coumarins and biphenols, found in many drugs. A correlation was found between 
relative retention and metabolite type which supported the hypothesis described above. 
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Thus "rules" were proposed concerning the ranges of relative retention which were 
characteristic of particular metabolic changes. The rules showed the potential of HPTLC 
with linear multiple development for predicting the structures of unknown metabolites 
from their retention data. 
Biological fluid samples required extracting prior to HPTLC analysis. A general solid- 
phase extraction procedure was developed using Bond Elut Certify TM II cartridges with 
mixed reversed-phase and anion-exchange properties. Following their retention from 
plasma and urine, drugs and their metabolites were eluted in three different eluents which 
provided some discrimination between classes of compound. Non-acidic and some 
weakly acidic components were eluted first followed by weakly acidic components, 
including glucuronides, in the second eluent and finally strongly anionic components, 
including sulphates. Extraction efficiencies from plasma in excess of 90% were obtained 
for most model compounds examined, with limits of detection in the range 1 to lOµg/ml. 
The proposed rules were tested by analysing samples of plasma and urine obtained 
following oral administration of ibuprofen and loxtidine to dogs and rats, and antipyrine 
and diazepam to rats. The data obtained, in terms of the extent of Phase I or Phase II 
metabolism which occurs, were in broad agreement with published data. Thus species 
differences in the metabolism of ibuprofen and loxtidine were detected. In a number of 
cases the type of metabolite formed was predicted correctly using relative retention data. 
The screening method will provide data on the extent of drug metabolism and indicate the 
number of metabolites formed. The structures of metabolites can be proposed from their 
relative retention data and their properties during sample extraction. The present studies 
indicated that a reasonable likelihood of successful structural assignment can be expected. 
The method may be applied to the analysis of plasma and urine samples following 
administration of drugs to animals at high dose-levels, and may provide valuable early 
information in drug research and development programmes in the future. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
1.1 Introduction 
Considerable effort is expended to study the effects of chemicals upon biological systems 
in order, for example, to control the environment, improve quality of life, combat disease 
and increase productivity. Thus in the areas of ecology, medicinal research and 
agrochemical research, chemicals are sought for use as herbicides, fungicides, drugs and 
pesticides. The effect of chemicals on biological systems may be exerted by interaction 
with enzymes, genes or receptors resulting in a change to the biochemistry of the system. 
Highly selective and potent chemicals may be found which act specifically and 
effectively on the biological system to effect the control required. 
In studying the effect of chemicals upon biological systems, the effect of the system on 
the chemical itself cannot be neglected. An active chemical may be rendered inactive by 
interaction with the metabolic pathways within the system. Thus an understanding of the 
means by which biological systems metabolise foreign chemicals is important to the 
development of effective products. 
In this thesis, the application of drug metabolism studies within drug research and 
development is considered, and the value of high-performance thin-layer chromatography 
for the detection and characterisation of drugs and their metabolites in biological fluids is 
assessed. 
-1- 
1.2 Drug Metabolism 
The pharmacological action of a drug is related to the concentration of the drug at the site 
of action, which may be a receptor, an enzyme, a gene or an organism. The concentration 
of drug at the site of action cannot usually be 'measured directly, therefore it is estimated 
by measuring the concentrations of drug in the systemic circulation. Pharmacokinetic 
analysis is used to measure exposure to the drug, the extent to which drug is distributed 
throughout the body and the rate at which drug is removed from the systemic circulation. 
The processes of absorption, distribution, metabolism and excretion (ADME) describe the 
fate of a drug following administration. These processes involve input of the drug into 
the systemic circulation, transfer of the drug from the blood into other tissues within the 
body and elimination of the drug from the body. The processes of metabolism and 
excretion both contribute to elimination. 
The most facile route for drug elimination is by excretion of the unchanged drug via the 
urine. Foreign compounds are removed from the blood by glomerular filtration, and flow 
down tubules in the kidney which are lined with epithelial cells packed closely together 
to form a lipid membrane between the blood and urine. The membrane allows transfer of 
lipid-soluble, non-ionised molecules, therefore lipid-soluble compounds which are 
present in the glomerular filtrate in the non-ionised form are re-absorbed into the 
bloodstream. 
The physico-chemical properties of molecules, in particular whether they are acids or 
bases, their pKa and their lipophilicity determine whether they are subject to re- 
absorption from the kidney tubules. Strong acids and bases are highly ionised at 
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physiological pH and are therefore excreted in the urine readily without tubular re- 
absorption taking place. However, many drugs are weak organic acids or bases, and at 
physiological pH are present partly in the non-ionic form thus being subject to tubular re- 
absorption. Furthermore, the pH of urine is variable, usually in the range pH5 to pH8, 
and can therefore be a significant factor which determines whether a compound is 
excreted in the urine or re-absorbed. 
Biliary excretion is another important means by which foreign compounds are removed 
from the body. The boundary between blood and bile is a porous membrane which 
allows the passage of most molecules and ions which are smaller than proteins. Thus 
drugs may appear in the bile in concentrations similar to those found in the plasma. 
However highly polar compounds, including conjugated metabolites (see Section 1.2.1), 
are excreted in the bile in much higher concentrations by a process of active transport. 
The processes of excretion alone do not provide an efficient means of eliminating all 
drugs from the body. It is therefore necessary for the body to modify drugs chemically to 
form compounds which are excreted more readily in the urine and bile. Drug metabolism 
is the process by which drugs undergo chemical modification by living organisms with 
the principal purpose of eliminating them from that organism. 
The chemical modifications that take place to form metabolites generally increase the 
water solubility and acidity of a substance. Metabolites are therefore generally less 
susceptible to tubular re-absorption than their parent drug because of their lower 
lipophilicity, and because the presence of anionic groups on acidic metabolites means that 
they are highly ionised at physiological pH. Thus metabolites are usually more easily 
excreted via the urine or bile than the original substance. 
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The important contribution provided by metabolism to the overall elimination of some 
drugs is evident because without the process of metabolism their rate of disappearance 
from the body would be changed drastically. For example, the half-life of thiopental 
(penthiobarbital), a short acting anaesthetic, would be about 100 years if its elimination 
was by excretion of the unchanged drug alone (Brodie, 1964) which would make it 
useless as an anaesthetic! 
In the following sections, the routes and mechanisms of drug metabolism are described, 
and kinetic considerations are discussed. 
1.2.1 Metabolic Transformations 
The chemical and biochemical aspects of drug metabolism have been described by Testa 
and Jenner (1976) and Low and Castagnoli (1991) with detailed information about the 
routes and mechanisms involved. Knowledge of drug metabolism is increasing rapidly 
with advances in instrumentation and technology enabling minor metabolic pathways to 
be identified which were previously unknown. Thus Jenner and Testa (1978) reviewed 
novel pathways in drug metabolism, and reviews have been published in recent years 
(Hawkins, 1989; Hawkins, 1990; Hawkins, 1991; Hawkins, 1992). 
Foreign molecules which enter the body are often referred to as xenobiotics, a term first 
used by Mason, North and Vanneste (1965) from the Greek, xenos and bios for "stranger 
to life". The metabolic reactions undergone by xenobiotics can be classified into two 
main types. Phase I reactions involve the introduction of a new chemical group into a 
molecule, examples being hydroxylation, dealkylation, hydrolysis, deamination, and 
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oxidation. Phase II reactions involve conjugation of a drug or a Phase I metabolite with 
an endogenous molecule to form for example, a glucuronide, an ethereal sulphate, a 
glycine, or an acetyl derivative. The metabolites formed by Phase II reactions are often 
referred to as conjugates. Williams (1974) represented the basic pattern of xenobiotic 
metabolism as follows: 
Phase I Oxidation, Phase II Synthetic or 
Xenobiotic -------> reduction, ------> conjugation 
enzymes hydrolysis enzymes products 
products 
Examples of Phase I metabolic transformations are shown in Figure 1.1. Ondansetron 
(I), a 5-hydroxytryptamine3 antagonist used in the treatment of chemotherapy and 
radiotherapy-induced nausea and vomiting (Stables, Andrews, Bailey, Costall, Gunning, 
Hawthorn, Naylor and Tyers, 1987) is metabolised by hydroxylation at the 6,7 and 8 
positions on the indole ring, and by N-demethylation of the indole nitrogen (Saynor and 
Dixon, 1989). Ranitidine (II), a histamine H2-receptor antagonist used in the treatment 
of peptic ulcers (Brittain, Jack and Price, 1981) undergoes N-demethylation and is also 
oxidised to form N- and S-oxides (Bell, Dallas, Jenner and Martin, 1980). Salmeterol 
(III), a ß-2 adrenoreceptor agonist used for the treatment of asthma (Ball, Coleman, 
Denyer, Nials and Sheldrick, 1987; Sandstrom, Frederiksen, Rosenhall and Sandstrom, 
1989), is metabolised by O-dealkylation and aliphatic hydroxylation (Manchee et al. ). 
Examples of Phase II metabolic transformations are shown in Figure 1.2. Paracetamol, a 
widely used analgesic, is conjugated to form glucuronide and sulphate metabolites and is 
also metabolised via a reactive Phase I intermediate, N-acetyl-p-benzoquinoneimine 
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Figure 1.1 
Examples of Phase I metabolic transformations 
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Figure 1.2 
Examples of Phase II metabolic transformations 
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(NABQI) to form cysteine and mercapturic acid conjugates (Prescott, 1980). Salbutamol, 
a ß-2 adrenoreceptor agonist widely used for the treatment of asthma, is metabolised to 
form a sulphate conjugate in man (Lin, Li, McGlotten, Morton and Symchowicz, 1977). 
The Phase I metabolites of ondansetron (II, Figure 1.1) are metabolised further by 
conjugation to form glucuronides and sulphates (Saynor and Dixon, 1989). 
1.2.2 Mechanisms of Drug Metabolism 
Metabolic transformations are catalysed by a variety of enzymes found particularly in the 
liver, but also in other tissues. The cytochromes P450 are a family of haemoproteins that 
catalyse the metabolism of a large number of diverse substrates by a variety of oxidative 
transformations. The reactions catalysed by the cytochromes P450 include aromatic and 
aliphatic hydroxylation, epoxidation, O-dealkylation, N-dealkylation and deamination, all 
of which involve the addition of an oxygen atom into the drug molecule (or the fragment 
which is lost in the case of N-dealkylation) to give a hydroxylated product. These have 
been reviewed recently (Guengerich, 1990). The electron transport systems involved in 
the oxidative processes carried out by these enzymes are shown in Figure 1.3. In recent 
years, numerous forms of cytochrome P450 have been isolated from humans and 
laboratory animals. A number of these have been sequenced and classified into families, 
for example CYP1, CYP2 and CYP3. It is now apparent that some P450s are specific for 
the metabolism of particular classes of substrate and some are implicated in the formation 
of reactive metabolites which may be precursors to chemical carcinogenicity. The current 
state of knowledge of the P450 metabolising enzymes has been reviewed recently 
(Gonzalez, 1992; Wrighton and Stevens, 1992; Soucek and Gut, 1992). 
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Figure 1.3 
The electron transport system involved in oxidations by P450 enzymes 
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Nri SOH+H2O 
Xenobiotics are also metabolised by other enzyme systems, including monoamine 
oxidases (MAO), alcohol dehydrogenases and esterases. MAO catalyses the 
deamination of primary, secondary and tertiary aliphatic amines and is widely distributed 
throughout the body. Alcohol dehydrogenases are present in the liver, kidneys and lungs 
of many species, and catalyse the metabolism of primary alcohols to their corresponding 
aldehydes. Esterases are present in the blood plasma and the liver, and catalyse the 
hydrolysis of foreign esters and amides. 
The intestinal microflora can play an important part in the metabolism of xenobiotics 
(Scheline, 1973). The importance of metabolism by the microflora should not be 
underestimated because many drugs are administered orally to man, and many drug 
metabolites are excreted via the bile into the gastrointestinal tract. Metabolic 
transformations which may be carried out by the intestinal microflora include 0- 
dealkylation, N-dealkylation, a number of reductions and hydrolyses. 
In Phase II or conjugation reactions, the endogenous substrate is transferred from a 
coenzyme onto the drug or Phase I metabolite substrate. Examples are shown in Figure 
1.4. The formation of glucuronides is probably the most important conjugation 
mechanism and has been the subject of recent reviews (Tephly and Burchell, 1990; 
Kroemer and Klotz, 1992; Mulder, 1992). Glucuronide formation occurs in the liver and 
to a lesser extent in the kidney, gastrointestinal tract and the skin. The mechanism 
involves biosynthesis of the coenzyme donor uridine diphosphate glucuronic acid 
(UDPGA) followed by the transfer by uridine diphosphate transglucuronylases, of the 
glucuronyl moiety from UDPGA to the substrate. Another common class of conjugate is 
sulphate esters or "ethereal sulphates" (Mulder, 1988). Sulphate esters are biosynthesised 
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Figure 1.4 
Mechanisms of glucuronide and sulphate conjugate formation 
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by the transfer of sulphate from adenosine-3'-5'-phosphosulphate (APPS) to a phenol, 
alcohol or amine by sulphate transferring enzymes known as sulphotransferases or 
sulphokinases. APPS is formed from adenosine-5'-triphosphate (ATP) in mammalian 
liver and other sites. 
1.2.3 Kinetic Considerations 
The route by which a drug is administered, for example intravenously or orally, can 
influence the extent to which it is metabolised (Cassidy and Houston, 1980). When a 
drug is administered intravenously all of the compound reaches the systemic circulation, 
and is completely (100%) bioavailable. The drug is then distributed rapidly throughout 
the systemic circulation and is metabolised, or excreted, as the blood in which it is 
dissolved passes through the organs such as the liver, lungs and kidneys which perform 
these functions. The process is illustrated in Figure 1.5. After oral administration, a 
drug is absorbed through the gastrointestinal tract into the portal vein, and passes through 
the liver before entering the systemic circulation. The liver has a very large capacity for 
metabolism, and a proportion of the dose may be metabolised during the first pass 
through this organ, thus not reaching the systemic circulation and leading to a reduction 
in the bioavailability of the drug with respect to that obtained following intravenous 
administration. This is referred to as first-pass metabolism, and is often the reason for a 
drug's low oral bioavailability, the other main reason being poor absorption through the 
gastrointestinal tract. Orally administered drugs may also be metabolised in the 
gastrointestinal tract, as discussed in Section 1.2.2, or during passage through the gut 
wall. 
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Figure 1.5 
Schematic representation of sites of metabolism with reference to intravenous and 
oral drug administration 
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Adapted from Cassidy and Houston, 1980 
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1.3 The Role of Drug Metabolism in Drug Research and Development 
Drug metabolism studies have an important role in drug research and in drug 
development. In the following sections the objectives of the two functions are discussed, 
and the role of drug metabolism studies is described. Finally the current status of drug 
metabolism studies in drug research and development is discussed. 
1.3.1 Drug Research 
The broad objective of the research function is to discover potential new drugs which are 
specific in their action. More detailed objectives may require a compound with oral 
activity and a long duration of action. In drug research, a hypothesis is proposed that a 
particular compound will have therapeutic benefit in man. The evidence for the 
hypothesis is obtained from in vitro pharmacological studies which indicate whether the 
compound interacts with a particular receptor, enzyme, gene or organism, and from 
studies in animal models. 
The role of drug metabolism studies in new drug discovery has been described recently 
(Humphrey and Smith, 1992), and the importance of drug metabolites in drug research 
has been discussed (Marten, 1985). Drug metabolism studies can provide answers to 
problems often encountered during drug research. During research, compounds may be 
found which are active in vitro, but inactive in vivo. Sometimes a compound is active 
when administered intravenously, but inactive following oral administration. Reasons for 
these findings may be that the compound is cleared from the body too rapidly either by 
renal excretion or by metabolism. Lack of oral activity may be due to extensive first-pass 
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metabolism, metabolism in the gastrointestinal tract or the gut wall, or because the drug is 
not absorbed from the gastrointestinal tract. 
During drug research, knowledge of routes of metabolism can be used to build either 
metabolic stability or metabolic instability into a molecule. If the metabolism of a 
compound is known, its duration of action can often be increased by replacing 
metabolically unstable groups, or by adding metabolically stable groups at the site of the 
preferred reaction. This increases the metabolic stability of the drug and reduces the rate 
at which it is cleared from the body. It was known, for example, that isoprenaline was 
inactive as an oral bronchodilator because its 3-hydroxyl group was subject to rapid 
metabolism during absorption through the gut wall. Replacement of the 3-hydroxyl 
group of isoprenaline by a 3-hydroxymethyl group resulted in AH3021, which is less 
readily metabolised than isoprenaline and orally active (Hartley, Jack, Lunts and Ritchie, 
1968). From this compound the bronchodilator salbutamol (AH3365) was developed 
(Brittain, Farmer, Jack, Martin and Simpson, 1968). 
If a compound is metabolised rapidly by aromatic hydroxylation, addition of a fluorine 
atom or a trifluoromethyl group onto the aromatic ring can often render the molecule less 
susceptible to metabolism because the electron withdrawing properties of these 
substituents cause de-activation of the ring. An example of this is the antiobesity drug 
fenfluramine, a derivative of amphetamine, which has a trifluoromethyl group on the 
phenyl ring. Fenfluramine does not undergo aromatic hydroxylation (Bruce and 
Maynard, 1968), a common metabolic route for amphetamine derivatives, and is cleared 
slowly from the plasma in man with a half-life of about 20 hours (Campbell, 1971). 
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In contrast, metabolic instability can be advantageous in some cases. An inactive 
compound that when administered is metabolised readily to a pharmacologically active 
compound is referred to as a prodrug. The absorption of some compounds after oral 
dosing can be improved by administering prodrugs, an example being the antibiotic 
pivampicillin. Ampicillin is a penicillin derivative that, when administered orally, is 
incompletely absorbed because of its high water solubility. In order to increase the 
lipophilicity, the pivaloyloxymethyl ester is prepared which is more readily absorbed. 
The ester is hydrolysed rapidly to the active compound during passage from the 
gastrointestinal tract to the systemic circulation (Ehrnebo, Nilsson and Boreus, 1979). 
Another example is the antibiotic cefuroxime axetil which is metabolised rapidly after 
absorption from the gastrointestinal tract to yield the active cefuroxime moiety by 
hydrolysis of the ester (Harding, Williams and Ayrton, 1984). 
1.3.2 Drug Development 
The primary objective during the early stage of drug development is to test the hypothesis 
proposed during drug research that a compound will have particular efficacy in man. 
Therefore as soon as possible initial studies in human volunteers are carried out to 
investigate the safety and tolerance of the drug, and to demonstrate that the hypothesis for 
efficacy developed in animal models translates to man (Posvar and Sedman, 1989). 
Although demonstration of a compound's efficacy is of vital importance during drug 
development, demonstration of its safety is no less important. It is not possible to use 
human volunteers to test the effects of lifetime exposure to a drug, or to assess the 
toxicity following administration at high doses. Furthermore, some evidence of safety in 
animals is required before a drug can be administered to man for the first time. Animals 
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are therefore used as models for man in which to perform the toxicity tests which are 
carried out as part of drug development. 
The validity of the toxicity species as models for man depends upon the disposition of the 
drug and its metabolites in both animals and man, and upon whether the animals are 
exposed to the same metabolites as are formed in man. Pharmacokinetic and drug 
metabolism studies provide information which is used to validate these models. The 
information obtained from these studies is discussed in the following paragraphs. 
During toxicity studies, the systemic exposure of animals to the drug is monitored and 
pharmacokinetic parameters are determined. These studies are referred to as 
toxicokinetic studies, and their importance and design have been reviewed recently 
(Smith, Humphrey and Charuel, 1990). During toxicokinetic studies, both acute and 
chronic exposure of animals to the drug are determined, and the pharmacokinetic 
parameters following single and repeated administration are obtained. Demonstration of 
exposure to the drug following oral administration is particularly important to prove that 
drug has been absorbed, and comparison of the concentrations of drug, in the plasma 
following single and repeated administration show whether the drug accumulates in the 
plasma between doses. Differences in the pharmacokinetic parameters between single 
and repeated administration may indicate that the enzymes responsible for metabolising 
the drug are either induced (activity increased) or inhibited (activity decreased). 
The acute and chronic exposure data obtained in animals during toxicity studies are 
compared with the exposure to man following clinical doses of the drug to determine the 
safety margin, or "cover", that has been achieved during the toxicity studies. These data 
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are required to help assess the risk associated with the clinical use of a drug against the 
therapeutic benefit to patients. 
Metabolism studies are carried out to investigate the absorption, distribution, metabolism 
and excretion (ADME) of the drug in the animal species used for toxicity testing. Drug 
labelled with a radioactive isotope, usually 14C, is generally used for ADME studies to 
enable the fate of all drug-related material (drug and drug metabolites) to be determined. 
Absorption of the drug following oral administration is demonstrated by the presence of 
drug-related material in the plasma, and differences in the concentrations of unchanged 
drug and total drug-related material indicate the concentrations of metabolites in the 
circulation. It is important to compare the exposure of animals and man to metabolites as 
well as parent drug. 
Distribution studies are carried out to identify the tissues and organs to which drug- 
related material is distributed following administration, and those which are exposed to 
drug or metabolites at high concentrations or for long periods of time. Generally 
compounds which are non-ionised at physiological pH are distributed widely because of 
their solubility in lipid membranes and fat. Thus weak bases are generally distributed 
widely throughout the body, whereas many acidic compounds and strong bases, which 
are largely ionised in the plasma, are not widely distributed. As discussed previously 
(Section 1.2), metabolites are generally less lipophilic and more acidic than their parent 
drug and are therefore generally less widely distributed. 
The routes of metabolism of a drug are investigated by examining urine, faeces or bile to 
determine the nature and concentrations of drug and metabolites which these excreta 
contain. The metabolites are isolated and identified thus providing information about the 
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metabolism of the drug in animals which can be compared with the routes of metabolism 
of the drug in man. 
The routes by which drug-related material is excreted are determined by comparing the 
levels of radioactive material in the various excreta; urine, faeces and bile. Similar 
information is obtained from man (except bile is not collected) allowing comparison of 
the rates and extent of excretion to be made between man and the animal species used in 
the toxicity testing. 
Drug metabolism studies may also assist in the interpretation of toxicity data in addition 
to providing validation of the studies themselves. In the majority of cases drug 
metabolism, particularly conjugation, produces metabolites which are less active 
pharmacologically than the parent drug. In some cases however, metabolism of an active 
drug molecule can result in the formation of metabolites which are themselves 
pharmacologically active, either with the same properties as the parent drug or different 
properties. An example of this is the tranquilliser diazepam which is metabolised via N- 
demethylation and hydroxylation to oxazepam an anticonvulsant drug (Ruelius, Lee and 
Alburn, 1965). Tamoxifen, a non-steroidal oestrogen inhibitor used in the treatment of 
early and advanced breast cancer, is metabolised by aromatic hydroxylation to form the 
4-hydroxy metabolite which is one hundred times more potent than the parent drug 
(Robinson and Jordan, 1988). For a long time, glucuronylation has been considered a 
metabolic reaction that terminates the pharmacological activity of drugs. However this 
view is no longer tenable since it has been shown that the glucuronide conjugate formed 
at the 6-position of morphine is a much more potent agonist of the morphine receptor 
than morphine itself, and the glucuronide at the 3-position is a potent antagonist (Mulder, 
1992). 
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In some cases the toxicity of a drug is attributable to metabolites rather than the drug 
itself. Thus identification of metabolites, particularly those in the systemic circulation, 
may provide interpretation of the toxicity data. Paracetamol is known to cause liver 
toxicity at high doses in both experimental animals and man (Mitchell, Jollow, Potter, 
Davies, Gillette and Brodie, 1973). This is thought to occur by an initial N-hydroxylation 
reaction and subsequent rearrangement of the hydroxylamine producing a reactive 
intermediate (NABQI), which following very high doses of paracetamol binds covalently 
to liver macromolecules leading to liver necrosis (Figure 1.6). However, at therapeutic 
doses NABQI is conjugated rapidly with glutathione and rendered non-toxic (Corcoran, 
Mitchell, Vaishnav and Horning, 1980). 
Metabolic reactions which lead to the formation of epoxides often result in toxicity. The 
anticonvulsant carbamazepine, used in the treatment of epilepsy, undergoes aromatic 
hydroxylation which is thought to proceed via an arene oxide. In some patients, inability 
to convert this intermediate to the non-toxic hydroxylated metabolite has resulted in 
serious toxicity which is believed to have, been caused by covalent binding of the arene 
oxide to cellular macromolecules leading to cytotoxic reactions (Shear and Speilberg, 
1988). The polycyclic aromatic hydrocarbons are another class of compound from which 
toxic metabolites are formed. These compounds are metabolised to form diol-epoxide 
metabolites which are capable of covalent binding to nucleic acids and hence of initiating 
chemical carcinogenesis (Jerina and Daly, 1974). Potential drugs containing similar 
structures may also be associated with similar toxicity. 
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Figure 1.6 
The role of metabolism in the toxicological activation of paracetamol 
Hg NH detoxication 
'aracetamol 
<)ý 
°H 
monoxygenase 
(N-hydroxylation) 
OH 
Hg 
I 
N-h' 
Paracetamol "%-- -OH 
monoxygenase 
(N-hydroxylation) 
rearrangement 
H3 N 
NABQI 
Hg NH 
Glucuronide OLO_ 
c, H, o. 
Hg NH 
Sulphate 
IIL.. 0_ so; 
N-hydroxyparacetamol 
detoxication H3 NH s" glutathione 
with glutathione 
off 
electrophilic 
attack on nucleophilic 
acdvadon macromolecules 
Covalent 
binding 
Urinary 
Excretion 
1Urinary 
LExcretion 
t Hepatocellular 
L necrosis 
-21- 
1.3.3 Current Status of Drug Metabolism Studies 
Drug metabolism studies, particularly those comprising the "ADME package" required 
by regulatory authorities in support of a Product Licence Application, are well 
established. In addition, the use of pharmacokinetic and metabolism studies in support of 
drug research has increased during recent years (Humphrey and Smith, 1992). 
Often radiolabelled drug is used during ADME studies to act as a tracer and to facilitate 
separation of drug-related and endogenous material. Synthesis of radiolabelled drug may 
be carried out early in the drug development programme and is rarely available when a 
compound is in drug research. Metabolic information has therefore rarely been obtained 
during drug research because of the technical difficulties associated with metabolite 
detection and isolation in the absence of radiolabelled drug. However early metabolic 
information may greatly aid drug research. 
A general method to study the metabolism of compounds during drug research would 
provide information to complement the pharmacokinetic data which are being provided 
increasingly as part of drug research support. Identification of metabolic routes may help 
design compounds with improved bioavailability or longer duration of action. 
Often little information is known about the nature or extent of metabolism of a compound 
at the start of drug development. If a compound is shown to be toxic during initial 
toxicity studies, radiolabelled drug may never be synthesised, or the metabolism of the 
compound may not be defined. It is therefore often the case that little information is 
obtained about the metabolism of compounds which are shown to be toxic early in drug 
development. However, metabolic information from toxic compounds might provide 
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some indication of why they are toxic while others are not, and may thus aid the process 
of drug design. Furthermore, early information on the metabolism of compounds which 
are successful in drug development might lead to the discovery of active metabolites 
which may themselves be drug candidates. 
A method to screen for drugs and metabolites in plasma and urine which does not require 
customising for each compound, and does not rely upon radioactivity detection, would 
therefore be very valuable. In the following section, the methods used for the study of 
drug metabolism are discussed and their suitability as general screening methods is 
assessed. 
1.4 The Study of Drug Metabolism 
There are a number of technical challenges encountered in the study of drug metabolism. 
The drug and metabolites have first to be separated from other material in the biological 
matrix that is being studied. Those studied most commonly, being plasma, urine, and 
bile, are complex matrices which vary in composition from species to species, between 
subjects, and from time to time. In addition to the complexity of the matrices, the 
concentration of drug and metabolites present is frequently small in comparison with the 
concentration of the endogenous material. Plasma is a more consistent matrix than urine, 
and generally contains less endogenous material which might interfere in an assay for 
drugs and metabolites. Offset against this however, for a drug which is cleared via the 
urine, concentrations of drugs and metabolites are usually higher in urine than in plasma. 
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The development of drugs with greater specificity and increased potency has meant that 
doses and hence concentrations of drug and metabolites in biological fluids are often very 
low. This is particularly true at the dose-levels used for ADME studies which often 
correspond to the lowest dose-level used in toxicity studies; a low multiple of the dose 
projected for clinical use in man. After oral administration of ondansetron to the rat at a 
dose-level of lmg/kg, the maximum concentrations of drug and metabolites in the plasma 
(indicated by the levels of radioactive material) were approximately 200ng/ml while the 
maximum concentrations of parent drug were less than 10ng/ml (Saynor and Dixon, 
1989). Similar results were obtained in the dog. An analytical method to determine the 
concentrations of drugs and metabolites in biological fluids must therefore have high 
sensitivity if the compounds of interest are to be detected. The challenges that have been 
described need to be overcome even if drug and known metabolites are being studied. If 
the metabolism is unknown, as is the case when novel compounds are being studied, the 
challenges are multiplied because an unknown number of unknown compounds is 
involved. 
Techniques used to study drug metabolism can be divided broadly into indirect and direct 
methods. Indirect methods, which include chromatography and enzymic or chemical 
tests, rely upon circumstantial evidence such as co-chromatography with authentic 
standards or changes in the metabolic profile to provide information on the nature of 
metabolites. Direct methods comprise spectroscopic techniques such as mass 
spectrometry and nuclear magnetic resonance (nmr) spectroscopy, and provide 
unequivocal characterisation of metabolites. 
In the following sections, chromatographic and spectroscopic techniques used in the 
study of drug metabolism are discussed, and the chromatographic methods are considered 
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alongside criteria for a general screening method for drugs and metabolites in biological 
fluids. 
1.4.1 Chromatographic Techniques 
Traditionally, techniques based upon chromatography have been used to separate drugs 
and metabolites from each other and from endogenous material. The history of 
chromatography is usually traced to Michael Tswett's separation of plant pigments during 
the early 1900s (Jupille, 1977). Chromatography is the separation of a mixture by 
differential migration resulting from the different distributions of its components between 
immiscible stationary and mobile phases. The three main chromatographic techniques 
are gas chromatography (GC), liquid chromatography (LC) and thin-layer 
chromatography (TLC). 
In GC a sample (as a vapour) is carried by a moving gas through a column containing 
stationary material. The stationary material selectively retains different sample 
components either by adsorption on the solid surface or by partition between the gas and 
a stationary liquid coated onto the column walls or onto an inert solid support. In LC a 
sample in solution is carried by a moving liquid solvent through a column packed with 
stationary material. Selective retention of the components may occur by adsorption or 
partition as described for GC. LC can be operated in "normal-phase" in which the 
stationary phase is more polar than the mobile phase (as is the case with a silica column 
using adsorption chromatography), or "reversed-phase" when the stationary phase is less 
polar than the mobile phase as is often the case when using the partition mode. In TLC a 
sample in solution is carried by a flowing liquid through a thin bed of stationary material 
deposited on a rigid backing. The choice of stationary phases and separation mechanisms 
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for TLC and LC are similar. Compounds are separated by these chromatographic 
techniques as a function of their polarity, structure, and size or molecular weight. Drugs 
and their metabolites are usually molecules of low molecular weight, for which polarity 
and structural differences are the most important factors exploited to effect separation. 
Early drug metabolism studies were carried out using paper chromatography and the 
technique was reviewed by Nestler (1979). Adams and Cliffe (1965) used paper 
chromatography to separate the metabolites of ibuprofen from parent compound in order 
to estimate the concentration of the drug in human serum. Thin-layer chromatography 
has been used extensively as a means of separating and isolating drug metabolites. More 
recently Wilson and Morden (1991) have successfully combined TLC with mass- 
spectrometry. 
In recent years, high-performance liquid chromatography (HPLC) has emerged as a 
leading technique in the field of drug metabolism and analysis due to the ease with which 
it can be automated, and improvements in detector sensitivity and versatility. HPLC in 
conjunction with diode array detectors is able to provide both multi-wavelength and 
spectral information from a single injection of sample onto a HPLC column. This gives 
increased possibilities for identification in comparison with single wavelength detection, 
and the opportunity to test for peak purity. A diode array detector was used in 
conjunction with HPLC to screen bile for drug and metabolites following administration 
of butoprozine to man, and ticlopidine to rats (Overzet, Rurak, Van der Voet, Drenth, 
Ghijsen and De Zeeuw, 1983). The usefulness of diode array detection was demonstrated 
because metabolite peaks were detected which would not have been found by single 
wavelength detection. The authors commented, however, that further spectroscopic 
analysis was necessary for metabolite identification. Recently, HPLC-diode array 
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analysis of rat bile samples obtained following administration of a calcium antagonist Ro 
40-5967, enabled the metabolites to be classified by reference to their ultraviolet spectra 
(Wiltshire, Harris, Prior, Kozlowski and Worth, 1992). 
HPLC has also been combined successfully with mass-spectrometry, particularly using 
thermospray techniques (Rudewicz and Straub, 1987). This is discussed further in 
Section 1.4.2. 
GC has been used less widely for metabolism studies, due largely to the need for 
derivatisation of many compounds before they will volatilise efficiently and 
chromatograph using this technique. However, with its high resolving power GC is 
particularly useful for the separation of drugs and known Phase I metabolites for assay 
purposes. 
1.4.2 Spectroscopic Techniques 
In recent years, nmr spectroscopy has been used to study drugs and metabolites in 
biological fluids (Nicholson, Sadler, Tulip and Timbrell, 1986; Nicholson and Wilson, 
1987a; Nicholson and Wilson, 1987b; Everett, 1991). The basic theory of nmr 
spectroscopy is described by Nicholson and Wilson (1987b). 
Advantages of nmr spectroscopy over traditional chromatographic methods are that it is a 
non-destructive technique, little or no sample preparation is required other than the 
addition of a small amount of deuterated water to the sample, sample throughput is fast 
(typically proton NMR spectra can be obtained in 5 minutes or less), and nmr 
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spectroscopy gives direct structural information on all the molecules it detects in a 
biological sample. 
There are however a number of disadvantages to set against the benefits of the technique. 
Nmr spectroscopy is relatively insensitive and analytes must normally be present at 
concentrations of >54M (equivalent to 15µg/ml for a drug with a molecular weight of 
300). The sensitivity is greater for drugs containing fluorine atoms when 19F-nmr can be 
used (Ghauri, Blackledge, Wilson and Nicholson, 1990; Wade, Wilson, Troke and 
Nicholson, 1990; Gilbert, Hartley, Troke, Turcan, Vose and Watson, 1992) although 
relatively high dose-levels are often still required to achieve the concentrations of drugs 
and metabolites needed for detection. 
Further disadvantages are that nmr spectrometers are expensive instruments requiring 
skilled operators. 
Mass spectrometry is particularly useful for providing information which together with 
nmr data can often identify metabolites unequivocally: Usually samples need to be 
isolated from biological matrices before mass spectral data can be obtained. The isolation 
can be carried out by extraction, but in recent years HPLC-mass spectrometry (HPLC- 
MS) has been used very extensively for drug and metabolite screening. 
Application of HPLC-MS'in drug metabolite identification and in screening for drugs and 
metabolites has been reviewed (Niesson and Van der Greef, 1992). Following separation 
by HPLC, compounds are detected by mass, and therefore the instrument can be set up to 
detect specific molecular ions related to the molecular weight of the drug. Further mass 
spectral information can be obtained for the components of interest, and preliminary 
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identification of metabolites can often be made. In addition to providing specific 
structural information, HPLC-MS is a sensitive technique, and because of the selective 
detection afforded by the mass spectrometer, only limited sample preparation may be 
required. The main disadvantages of using HPLC-MS are the need for expensive mass 
spectrometers and skilled operators. 
1.4.3 General Screen for Drugs and Metabolites 
The spectroscopic techniques described in the previous section have a number of 
important advantages over chromatographic techniques, and could be used routinely to 
screen biological fluids for drugs and metabolites. However, the instrumentation required 
for these techniques is expensive, so consideration of an alternative screening method 
using chromatographic techniques which are relatively inexpensive, and therefore more 
widely available, is worthwhile. 
There are a number of criteria necessary for a chromatographic technique to provide a 
general method for the detection of drugs and their metabolites in biological fluids. 
These are shown below: 
1. The technique must have high resolution. 
2. The technique must be sensitive. 
3. It must be non-destructive. 
4. It needs to be flexible both in terms of chromatography and detection. 
These criteria largely preclude the use of GC. Derivatisation is often necessary before 
samples can be chromatographed by GC, and this can be a destructive process. In 
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addition, the application of sample into a hot injection port can cause breakdown of labile 
compounds. Although techniques now exist for cool injecting onto GC (Poy, Visani and 
Terrosi, 1981), these may be restricted to certain compound types and the behaviour of 
novel drugs and metabolites cannot be predicted easily. 
HPLC and TLC are both non-destructive unless the compounds are unstable on the 
chromatographic medium or in the mobile phase used, and derivatisation is not necessary 
prior to separation by these techniques. A comparison of HPLC and TLC has been made 
recently (Sherma, 1991). The techniques have similar chromatographic capabilities; both 
can be operated under normal or reversed-phase conditions, isocratically or with a solvent 
gradient, and similar stationary phases are available for each technique. The ultraviolet 
and fluorescent modes of detection are common to both techniques, but each also has 
alternatives (HPLC : refractive index and electrochemical; TLC : fluorescence 
quenching). The detection limits are approximately the same ranging from picogram to 
nanogram amounts depending upon the mode of detection employed. 
There are however some properties of TLC which make it a more flexible technique to be 
considered for the development of a general method for the detection of drugs and their 
metabolites in biological fluids. An important difference between the techniques is that 
whereas HPLC is dynamic, TLC is ultimately static. With HPLC, after the eluent has 
passed through the detector, it is lost unless a sample fractionating system is used for its 
collection. In the case of TLC, after development, the plate can be scanned and re- 
scanned, derivatised if necessary and scanned again. Post-chromatographic derivatisation 
on TLC is more flexible than with HPLC because reaction times are less important and 
heating can be used to encourage slow reactions. TLC is an archivable technique in terms 
, of detection and for retrieval of separated components for identification. The open planar 
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chromatographic bed provides a degree of flexibility that the closed tubular columns of 
HPLC do not have. A further advantage of TLC, particularly when an unknown number 
of metabolites is present, is that at all times the whole of the sample that has been applied 
to the plate must be between the origin and the solvent front; two limits which are defined 
clearly. When a complex mixture of components with a wide range of polarities has been 
injected into an HPLC system one cannot be certain if the entire sample has been eluted 
at any time unless it is accounted for by radioactivity measurement. Thus in HPLC there 
can be loss of peaks, or unexpected appearance of peaks from previous samples. 
A final point of comparison is that HPLC is a re-usable system whereas TLC is 
disposable. A TLC plate is used once therefore it can be destroyed in use, but the 
conditions under which HPLC can be operated are limited by the need for the column to 
be used repeatedly. This might be of importance in analysing for drugs and metabolites 
because it may be necessary to apply biological fluids directly to the chromatographic 
system or to apply crude extracts to ensure that all drug and metabolites are recovered. 
Similarly, the choice of solvent is not limited in TLC, whereas in HPLC it must be 
compatible with the column packing material. Furthermore, because the solvent is 
evaporated completely from the stationary phase in TLC before detection, the use of 
solvents with ultraviolet absorbing properties is feasible, whereas in HPLC their use 
would hamper detection of the components of interest. 
It is concluded from the preceding discussion that thin-layer chromatography has a 
number of advantages which make it an appropriate technique to use for a general method 
to detect drugs and their metabolites in biological fluids. 
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1.5 Thin-Layer Chromatography 
The historical development of thin-layer chromatography (TLC) has been documented by 
Stahl (1969), and Jupille (1977) reviewed the principles, practice and potential of TLC 
with particular reference to high-performance (HP)TLC which was emerging as a 
technique with significant advantages over traditional TLC at about that time. 
According to Kirchner (1973), the principle of TLC was first known in 1889 when the 
Dutch biologist Beyerinck allowed a drop of a mixture of hydrochloric and sulphuric 
acids to fall through a thin layer of gelatin. The hydrochloric acid travelled faster, 
forming a ring round the sulphuric acid. Meinhard and Hall (1949) were the first to use a 
binder to hold their stationary phase onto a microscope slide. Stahl first used the term 
"thin-layer chromatography" in 1956, and in 1958, recommended standard conditions for 
the technique were published following production of special grade silica by Merck, and 
the manufacture of basic equipment and accessories by Desaga (Stahl, 1983). TLC was 
used extensively up until, and during the 1970s. The instrumental development of gas 
chromatography occurred in parallel with further development of TLC, and the separating 
capacity of the fine particle size layers used in TLC stimulated attempts to pack tubular 
columns with these materials. Success with this led to the development of high- 
performance liquid chromatography (HPLC), a technique which lends itself readily to 
jnstrumentalisation and automation. The popularity of HPLC meant that in many areas it 
fradually replaced TLC during the 1980s in particular. This is reflected by the large 
increase in publications referring to HPLC during this period (Lochmuller, 1987), and the 
, tendency 
of some authors to ignore the current value and potential of TLC. 
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However Zlatkis and Kaiser (1977) edited a book on high-performance thin-layer 
chromatography which helped to stimulate renewed interest in TLC. In an article entitled 
"HPTLC: Taking Off, " Borman (1982) described the differences between conventional 
and high-performance TLC. These are listed in Table 1.1, and show that the main feature 
which resulted in the increased performance was the use of finer sized silica material with 
a much tighter particle size distribution. The greater resolution obtained meant that 
shorter development distances were required to effect separation, and hence the 
separation time was reduced. The thinner layer on HPTLC plates has a lower sample 
capacity than conventional TLC plates, thus to prevent overloading and to minimise spot 
spreading on sample application, small volumes are applied. However it has been shown 
that much larger volumes (up to 4Oµ1) can be applied successfully if a solvent in which 
the sample does not migrate is selected in which to apply the samples (Colthup, 1988). 
Various authors described the advances in instrumentation, mainly in sample application, 
plate development and quantitation which occurred around 1980 (Fenimore and Davis, 
1981; Wall, 1982; Moi and Schmutz, 1982). These increased the sample throughput of 
HPTLC, and also the accuracy and precision of the technique. Many of these early 
reviews, and a recent review on modern TLC (Poole and Poole, 1989) emphasise the 
economy of HPTLC in terms of high sample throughput in comparison with HPLC. This 
may be true in cases where minimal sample preparation is required (for example Kreuzig, 
1983), however for the routine analysis of drugs in biological matrices at low 
concentrations, where extensive sample preparation is required, HPLC may be more 
appropriate because it can be automated and allowed to run overnight. Although similar 
sensitivities (lng/ml) were obtained with HPTLC (Colthup, 1988) and HPLC (Colthup, 
Felgate, Palmer and Scully, 1991) for the determination of ondansetron concentrations in 
plasma, there was a clear advantage for the use of HPLC in terms of sample throughput. 
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Table 1.1 
Comparison of conventional and high-performance TLC 
Parameter Conventional TLC 
Sample volume 1-5µl, 
Starting spot diameter 3-6mm 
Diameter of separated spots 6-15mm 
Solvent migration distance 10-15cm 
Separation time 30-200min 
Particle size (average) 20µm 
Particle size (distribution) 10-60µm 
Adsorbent layer thickness 100-250µm 
Detection limits (absorption) 
Detection limits (fluorescence) 
1-5ng 
50-100pg 
HPTLC 
0.1-0.2 µ1 
1-1.5mm 
2-5mm 
3-6cm 
3-20min 
5um 
Tight 
200µm 
0.1-0.5ng 
5-10pg 
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HPTLC has been used to measure the concentrations of drugs in plasma and urine, but in 
comparison with HPLC, applications are few. Imipramine, an antidepressant drug, and 
its desmethyl metabolite were quantified in human plasma down to 2ng/ml, and in urine 
down to 60 and 126ng/ml respectively following derivatisation with nitrous gases to form 
intense yellow derivatives (Sistovaris, Dagrosa and Keller, 1983). Chlorpromazine and 
thioridazine, drugs used in the treatment of psychotic disorders, were quantified in plasma 
down to lOng/ml using ultraviolet absorption densitometry (Davies and Harrington, 
1984). Tetrahydrocannabinol, the active principle in marijuana, was measured in plasma 
down to ing/ml following derivatisation and fluorescence detection (Vinson and Patel, 
1984). Salbutamol was quantified in human plasma down to ing/ml and in urine down to 
20ng/ml following derivatisation to form an indoaniline dye (Colthup, Dallas, Saynor, 
Carey, Skidmore, Martin and Wilson, 1985), and ondansetron was measured in plasma 
using fluorescence detection down to ing/ml (Colthup, 1988). These applications 
demonstrate that HPTLC has the sensitivity required to measure the concentrations of 
drugs in biological fluids. 
There have also been a number of examples where HPTLC has been used to separate 
drugs and metabolites for quantitative purposes. Haefelfinger (1979) measured the 7- 
amino-metabolites of the benzodiazepine drugs flunitrazepam and clonazepam in plasma 
down to ing/ml. Mount, Nahlen, Patchen and Churchill (1987) described a method to 
determine concentrations of chloroquine, an antimalarial drug, and desethylchloroquine 
in urine down to 250ng/ml. Ifosfamide, a DNA-alkylating agent used in the treatment of 
tumours, and its five principal metabolites were measured by HPTLC in plasma, 
cerebrospinal fluid and urine down to concentrations of 1 pg/ml (Boddy and Idle, 1992). 
These applications show that HPTLC has the resolution required to separate drugs and 
their metabolites. 
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It is concluded from the preceding discussion that HPTLC has, in addition to the 
advantages of TLC, the resolution and sensitivity required of a general method to detect 
drugs and their metabolites in biological fluids. The perceived advantages of HPTLC 
warrant an assessment of the technique to determine whether it has value as a general 
method for drug and metabolite analysis which might provide valuable information about 
drug metabolism early in drug research and development programmes. 
1.6 Aims of the Present Studies 
Consideration of the role of drug metabolism studies in drug research and development 
has shown that there is a place for a general method to detect drugs and their metabolites 
in biological fluids. HPTLC has a number of advantages which make it an appropriate 
analytical technique to use for this application, and has the resolution and sensitivity 
required. The aims of this thesis therefore include the following: 
1. Assess the value of HPTLC for the detection and characterisation of drugs and 
metabolites in biological fluids. 
2. Devise a general HPTLC development system to separate drugs and their 
metabolites. 
3. Examine relationships between chromatographic properties and structural 
changes which occur during drug metabolism. 
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4. Develop general techniques to extract drugs and metabolites from plasma and 
urine as required. 
5. Examine the utility of a general method for the detection of drugs and 
metabolites by analysing plasma and urine from animals collected after 
administration of drugs with known metabolism. 
6. Assess the value of information provided by a general method in relation to 
drug research and development. 
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CHAPTER TWO 
SEPARATION OF DRUGS AND METABOLITES BY 
HPTLC WITH MULTIPLE DEVELOPMENT 
2.1 Introduction 
High-performance thin-layer chromatography (HPTLC) has a number of attributes which 
make it potentially useful for detecting drugs and metabolites in biological fluids, which 
have been discussed in the previous chapter. HPTLC itself provides two main 
chromatographic mechanisms and various modes of operation each of which has 
advantages in certain applications. 
The modes of operation available for use in HPTLC are represented in Figure 2.1. The 
mode used most widely is linear development on either square or rectangular 
chromatographic plates. Other modes, are circular in which development is performed 
from the centre of a circle out towards the circumference, and anti-circular in which 
development occurs from the circumference towards the centre (Kaiser, 1988). Their use 
can improve resolution of compounds which are adsorbed strongly on the plate in the 
case of the circular mode, and those which are less strongly retained in the case of the 
anti-circular mode. Although there may be advantages in using the circular mode, 
particularly for the separation of strongly retained conjugated metabolites, both these 
techniques require specialist equipment, and may not be generally applicable. Linear 
development is thus considered to be the most suitable technique to use for a general 
screening method for drugs and metabolites. 
Chromatographic mechanisms in HPTLC (and other liquid chromatographic techniques) 
can be divided broadly between normal-phase (adsorption) and reversed-phase (partition) 
chromatography. As discussed in Chapter 1, the metabolites formed during drug 
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Figure 2.1 
Modes of operation available for development using HPTLC 
The Linear Mode 
The Circular Mode 
r 
The Anti-circular Mode 
-1 
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metabolism generally have a greater polarity (are more water soluble) than the parent 
drug, and this property can be utilised to obtain a chromatographic separation. 
Chromatographic retention on TLC is described by the term Rf which is defined as the 
ratio of the spot and solvent front displacements from the origin after one development. 
Metabolites usually have a smaller Rf than the parent drug in normal-phase 
chromatography and in reversed-phase chromatography the Rf of metabolites is usually 
larger. The separation of drugs and their metabolites from other components of similar 
molecular weight and polarity in biological fluids requires that the chromatography used 
must be selective to small structural changes as well as being operable over a wide 
polarity range. 
Reversed-phase chromatography embraces a wide range of different stationary phases, 
the most popular being alkyl bonded silicas. Those commonly available for HPTLC are 
C189 C8, C2, CN, and NH2. (The CN and NH2 phases can be used in either the normal 
or reversed-phase mode. ) Until recently, the non-polar C18, C8, and C2 stationary 
phases have had a pronounced hydrophobic character. This has led to difficulties in 
wetting the plate surface when using developing solvents that contain greater than 35% 
water, and made the plates suitable for separating non-polar or only slightly polar 
substances (Brinkman and de Vries, 1982). Thus in 93 references to the use of reversed- 
phase TLC published in 1982 there were only a few applications to drug analysis, and 
these were mainly for fairly lipophilic molecules. For the same reason silica is still the 
stationary phase preferred by the large majority of workers, and reversed-phase TLC 
occupies a rather modest second place. In the last few years wettable C18 plates have 
become available commercially and these could be of more use (Fischer, Hauck and Jost, 
1988). It is probable that with alkyl bonded plates a gradient system with forced flow as 
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in over-pressure thin-layer chromatography (Tyihak and Mincsovics, 1991) would be 
required to achieve the separations required for drugs and metabolites. 
Adsorption chromatography can be carried out on a number of stationary phases, but 
silica and alumina are used most commonly. Silica is used more widely than alumina, 
partly because silica HPTLC plates are commercially available, but also, alumina has the 
capacity to alter some analytes chemically (Neher, 1958). These factors make silica the 
most reasonable choice between the two phases for the present studies. 
The interactions that occur between silica and molecules on its surface are polar, 
including hydrogen bonding, dipole-dipole, induced dipole-dipole, and pi-pi interactions 
(Unger, 1979). As a result of these interactions, the distribution of electrons between 
individual atoms in the functional groups is made unequal causing positive and negative 
polarity, and allowing interaction of the functional groups to occur with polar groups on 
the silica surface. Groups that exhibit this type of interaction are hydroxyls, amines, 
carbonyls, aromatic rings, double-bonds, and groups containing heteroatoms such as 
oxygen, nitrogen, sulphur, and phosphorus. Some of these functional groups are those 
that are involved in Phase I metabolic transformations, and their presence on or absence 
from a molecule can have a considerable effect on the retention of that molecule on silica. 
This makes silica a particularly useful chromatographic medium for the separation of 
drugs and metabolites. The suitability of silica may be enhanced further by using it with 
a solvent gradient. 
The use of isocratic TLC to separate drugs and metabolites can often lead to a situation in 
which a polar mobile phase required for the separation of conjugated metabolites causes 
the drug and Phase I metabolites to migrate near the solvent front. Conversely a solvent 
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of lower strength used to give good separation of the Phase I metabolites leaves the 
conjugates on the origin. This is referred to as the "general elution problem" (Snyder and 
Kirkland, 1979), and one way in which it can be overcome is by use of gradient elution. 
In this chapter methods which have been used for the formation of gradients on silica 
TLC plates are discussed. In particular the technique of Manual Multiple Development 
(MMD) is assessed in terms of its application to the separation of drugs and metabolites, 
and is compared with Automated Multiple Development (AMD). The retention data 
from model compounds and a number of drugs and metabolites are used to propose a 
relationship between relative retention and metabolite type. The application of the 
system to the direct analysis of plasma and urine is examined. 
2.1.1 Gradient Formation in Normal-Phase TLC 
According to Golkiewicz (1991), gradient elution was applied to column liquid 
chromatography in 1952 by Hagdahl, Williams and Tiselius. However, it was not until 
1962 that gradient elution was applied to TLC when LDH-isozymes and nucleotides were 
separated on DEAE-Sephadex (Wieland and Determann, 1962). In contrast to column 
liquid chromatography, gradient development in TLC has been applied relatively rarely 
because of the complexity of the devices required for the production of reproducible 
gradients. Recently however, gradient development in TLC has become more popular as 
measured by the publication of papers on the theory and devices for gradient 
development. These have been reviewed recently (Golkiewicz 1991). 
Gradient elution in column liquid chromatography operates by use of a continuous 
gradient as solvents are mixed in varying proportions, and the composition and elution 
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strength of the eluent is modified with time. Various devices have been proposed for the 
formation of continuous gradients on TLC using combinations of burettes and magnetic 
stirrers to modify the mobile phase composition with time, and wick arrangements to 
carry the solvent to the TLC plates. More recently Matysik and Soczewinski (1988) have 
described a miniaturised generator of continuous gradients for equilibrium sandwich 
chambers using a glass distributor to spread the solvent along the bottom edge of the TLC 
plate. A small volume of the weaker solvent (e. g. 2ml) was placed into a reservoir from 
which a syphon tube delivered solvent to the distributor plate in the sandwich chamber 
and hence onto the TLC plate. Meanwhile, the stronger solvent was fed into the reservoir 
by means of a syringe which was driven by a syringe pump, and the composition of the 
solvent delivered to the TLC plate thus changed with time. The slope of the gradient 
could be regulated by altering the speed of the syringe pump. A modification of this 
system, in which the reservoir was replaced by a coil of fine tubing, was used to obtain 
stepwise gradients (Soczewinski and Matysik, 1988). A number of pre-mixed solvents 
were drawn into the coil one after the other, separated by small air gaps, by means of the 
syringe, and were then delivered to the plate. Recently a further modification to the 
technique was reported in which the sandwich chamber was replaced by a horizontal 
chamber (Dzido, Matysik and Soczewinski, 1991). Although interesting data have been 
obtained in the hands of the group using these methods, the techniques are limited 
because some of the equipment is essentially "home made" and unavailable 
commercially. 
In practice, a continuous gradient is preferred in liquid chromatography (Snyder, 1979). 
However, stepwise gradients are easier to obtain in TLC, and it has been shown in 
column liquid chromatography that if a stepwise gradient comprises several steps then the 
gradient obtained is almost identical to a continuous gradient (Golkiewicz, 1981a; 
-43- 
Golkiewicz, 1981b). One method of obtaining stepwise gradients on TLC is by multiple 
development. The term programmed multiple development (PMD), in relation to TLC, 
was first used by Perry, Haag and Glunz (1973). In PMD, a TLC plate was developed 
repeatedly in the same direction with the same solvent, each subsequent development 
being longer than the previous one, and between developments the plate was dried by 
radiant heat, optionally assisted by a flow of gas. The lower edge of the plate remained in 
contact with the solvent in the reservoir at all times, and solvent migration distances were 
controlled by the length of intervals between heating cycles. During this process of 
repeated development the solvent passed over the material on the plate a number of times 
and caused spot concentration. This was achieved because on the second and subsequent 
passes, the solvent flowed over the trailing edge of the spot before reaching the leading 
edge, compressing the spot into a band of material thus increasing resolution and 
sensitivity (Jupille and Perry, 1975). The process is illustrated in Figure 2.2. 
The principle of developing the chromatogram in the same direction over increasing 
solvent migration distances, as in PMD, was maintained by Burger (1984) when he 
introduced automated multiple development (AMD), however all other characteristics of 
AMD were different. Instead of developing the plate with the same solvent repeatedly, 
for at least a major portion of the total AMD process, a developing solvent different to 
that used for the preceding step was employed for each run. Whereas the plate was 
pontinuously in contact with the solvent in PMD, in AMD the solvent was removed 
Completely from the developing device after each run to ensure that the solvent used in 
4he next cycle had its intended composition and was not contaminated by traces of the 
Previous solvent. After removal of the solvent, the plate was dried by vacuum in AMD - 
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Figure 2.2 
Representation of spot concentration on TLC by multiple development 
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no heat was applied. This procedure has been automated by Camag (Muttenz, 
Switzerland) in an AMD instrument (Jaenchen, 1985) which is described in detail in 
Section 2.2.2. 
The features of AMD described above allow a reproducible gradient elution to be 
achieved using normal-phase adsorption chromatography on a silica TLC plate. In 
contrast to column liquid chromatography, the elution gradient in AMD starts with the 
solvent of greatest elutropic strength and each successive development is carried out with 
a solvent of lower elutropic strength over an increased distance. In its original form, the 
technique of PMD described by Perry et al. (1973) had the tendency to concentrate 
sample spots into narrow bands on the chromatographic plate. This is enhanced 
dramatically when the first solvent passing over the spot has the strongest eluting power 
for all the components present, as is typical with AMD. The effect is thus similar to that 
which occurs in a layer with a concentration zone. 
AMD has been used for a variety of separations including psychopharmaceutic drugs 
(Bigalke, Ebel, Ullrich and Voelkl, 1987), ecdysteroids (Wilson and Lewis, 1987), plant 
extracts (Trypsteen, Van Severen and De Spiegeleer, 1989), pesticides in water (Burger, 
1984; Burger, Kohler and Jork, 1990; De La Vigne and Janchen, 1990; De La Vigne, 
Janchen and Weber, 1991) and PTH amino acids, analgesics, corticosteroids, dyes and 
barbiturates (Jaenchen, 1985). The technique has been found to be particularly useful for 
Oeparating substances in those samples where the components differ appreciably in 
polarity (Burger et al., 1990). This is particularly true in the field of drug metabolism 
research, thus AMD was selected as the separatory approach to investigate the usefulness 
of HPTLC for the detection and characterisation of drugs and metabolites in biological 
jtuids in the present studies. 
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The term manual multiple development (MMD) has been used in two contexts. It has 
been used to describe the procedure by which the process of AMD is carried out manually 
as opposed to using the instrument which is commercially available (Wilson and Lewis, 
1987). The term MMD has also been used to describe all multiple development 
procedures which were employed before PMD was proposed (Poole and Belay, 1991). In 
the present studies MMD refers to the manually operated AMD process. 
2.1.2 Assessment of Manual Multiple Development 
Prior to assessing the usefulness of MMD for separating drugs and their metabolites, the 
MMD process itself was investigated. Five phenolic compounds; phenol, m-cresol, m- 
chlorophenol, resorcinol and m-hydroxybenzoic acid (m-HBA), were selected to 
investigate the MMD process. Their structures are shown below. 
Structures of phenolic compounds used to investigate MMD 
Phenol m-Cresol m-Chlorophenol 
off OH 
off COON 
Resorcinol m-Hydroxybenzoic Acid 
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These compounds were selected because; (i) they cover a reasonable polarity range, (ii) 
phenol, m-cresol and m-chlorophenol are difficult to separate by isocratic TLC (Dietz, 
Traud, Koppe and Rubelt, 1976) and (iii) resorcinol and m-HBA differ from phenol by 
the addition of functional groups that are added in common Phase I metabolic 
transformations. 
In order to assess fully the usefulness of MMD for separating drugs and metabolites the 
chromatographic properties of all known drugs and metabolites would need to be 
examined. Clearly this would be impractical, therefore model compounds were selected 
to carry out the investigation. The criteria for the selection of model compounds were as 
follows: 
1. The compounds should be based upon simple chemical structures which 
form the molecular building blocks of many drugs. 
2. Typical Phase I and Phase II metabolic transformations must be 
modelled by the compounds. 
3. A number of "real" drugs and their metabolites must be included. 
A series of phenols, indoles, coumarins and biphenyls (structures which form the 
molecular building blocks of many drugs) were selected to examine the changes in 
retention brought about by typical Phase I transformations. The structures of these 
, compounds and the manner in which they correspond as models of metabolism are shown 
1n Figures 2.3-2.6. Additional compounds; ondansetron, ranitidine, loxtidine and their 
fnetabolites were also chosen for examination by multiple development because they are 
examples of "real" drugs developed recently. Their structures are shown in Figures 2.7- 
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2.9. A series of glucuronides and sulphates was selected to examine the effect of 
conjugation on retention. These were selected because, as discussed in Chapter 1, 
glucuronylation and sulphation are the most common Phase II metabolic transformations. 
The structures of the compounds are shown in Figures 2.10 and 2.11. 
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Figure 2.3 
Phenolic models of Phase I transformations 
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Figure 2.4 
Some potential Phase I metabolites of aspirin 
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Figure 2.5 
Indole models of Phase I transformations 
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Figure 2.6 
Coumarin and biphenyl models of Phase I transformations 
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Figure 2.7 
Phase I metabolism of ondansetron (Saynor and Dixon, 1989) 
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intended to infer a reaction order. 
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Figure 2.8 
Metabolism of ranitidine (Bell et aL, 1980) 
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Figure 2.9 
Metabolism of loxtidine (Bell et aL, 1983) 
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Figure 2.10 
Compounds used as models of Phase II metabolic transformations 
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Figure 2.11 
Compounds used as models of Phase II metabolic transformations 
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Phenolphthalein disulphate 
M 
Epiandrosterone 4 
2.1.3 Aims of the present studies 
The main aim of the studies described in this chapter is to assess the usefulness of 
multiple development techniques on normal-phase HPTLC for the separation of drugs 
and metabolites with a view to developing a generally applicable gradient. Further aims 
are to assess the sensitivity of HPTLC for detecting drugs and metabolites in biological 
fluids. 
2.2 Methodology I 
In this section the multiple development methods used are described in detail. 
2.2.1 Manual Multiple Development 
Chromatography was carried out on glass-backed silica gel 60 HPTLC plates (lOx20cm 
or 10x10cm) without fluorescent indicator (Merck, Poole, UK). Prior to use, the plates 
were pre-developed with methanol to remove any material which may have been 
adsorbed to the surface, and were marked on the reverse side to indicate the development 
distance for each solvent mixture. Samples were applied as solutions in a suitable 
organic solvent (about lmg/ml), 5mm from the bottom of the plates either as spots using 
micro-capillaries (1,2, or 5µl), or as bands using a Camag Linomat IV sample applicator 
(BDH, Poole, UK). 
Application of samples as spots using micro-capillaries is rapid, however, the sample 
volumes which can be applied are limited if compact spots are to be achieved. The size 
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of initial spots can be minimised if solutions are prepared in the least polar solvent in 
which the compounds of interest will dissolve (Colthup, 1988). Compact spots are then 
achieved because although the solvent spreads out from the applicator, the dissolved 
material has an Rf of approximately zero in the solvent and hence remains at or near the 
origin; the point of application. 
However, if samples contain many components it is unlikely that a non-polar solvent will 
dissolve all the components, and in this situation a compromise is necessary. Application 
of small volumes (e. g. 1 j. cl) from micro-capillaries results in solvent spread to 
approximately 5mm and enables a reasonable amount of material to be applied (1 µg if the 
solution is 1mg/ml). A spot of this size is reduced to a narrow band by the use of 
multiple development. The use of micro-capillaries for aqueous samples however is less 
successful, and when samples of this nature need to be applied use of a Camag Linomat 
IV sample applicator is more appropriate. The Linomat IV is a semi-automated 
instrument for applying samples to TLC plates as bands. The sample is loaded into a 
syringe and applied onto the plate in a stream of air or nitrogen through a fine nozzle as 
an aerosol. The aerosol droplets dry rapidly and hence band broadening on sample 
application is minimised. 
Solvent mixtures (10ml) for MMD were prepared using Gilson pipettes (Anachem, 
Luton, UK) to dispense the required volumes accurately, and were stored prior to use in 
glass scintillation vials. The plates were then developed in a Camag horizontal 
development chamber (BDH, Poole, UK) for the prescribed distances. A schematic 
diagram of the chamber is shown in Figure 2.12. The use of a horizontal development 
chamber has two main advantages over conventional tank development. Firstly, because 
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Figure 2.12 
A schematic diagram of the Camag horizontal linear development chamber 
Glass cover slip to prevent solvent evaporation 
Solvent reservoir 
TLC plate - placed adsorbent side facing down. 
Glass counter plate 
Small air space between TLC plate and counter plate 
Glass strip - pushed forward against TLC plate to start development. 
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of the small air volume surrounding the plate surface, the atmosphere in contact with the 
plate rapidly becomes saturated with solvent vapour. This helps to maintain reproducible 
conditions from one plate to another. Secondly, the volume of solvent required for 
development of the plate is very small, 1 to 3m1, depending upon the development 
distance. This reduces solvent consumption which would otherwise be considerable with 
multiple development systems. 
Between successive developments the plates were dried under vacuum in a glass 
desiccator. In some cases the compounds under investigation were sufficiently volatile to 
be lost during the drying process, and in these cases the plates were allowed to dry in the 
air between developments. Air drying was more time consuming and was used only 
when necessary. ti 
When development was complete the plates were scanned from the origin to the solvent 
front using a Camag TLC Scanner II (BDH, Poole, UK), and material on the plate was 
detected by ultraviolet absorbance. The signal output was recorded on a Trilab 2000 
Chromatography Data System (Trivector, Sandy, UK). 
2.2.2 Automated Multiple Development 
Chromatography was performed on glass-backed Silica Gel 60 HPTLC plates, as used for 
MMD, and samples were applied as solutions in methanol (about lmg/ml) using a Camag 
Linomat IV sample applicator. Plates were then developed in a Camag AMD instrument 
(BDH, Poole, UK). The plates were scanned and the output recorded as described for 
MMD. 
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A simplified flow diagram of the AMD instrument is presented in Figure 2.13. 
Chromatographic development occurs in an enclosed chamber (1) which has inlet and 
outlet connections for supplying and withdrawing solvent, and for pumping gas phase in 
for plate conditioning and out for drying under vacuum between developments. Solvent 
mixtures are prepared in the gradient mixer (2) from up to six reservoirs (3) which 
contain the individual solvent components. The mixing chamber and reservoirs are 
connected by an electronic valve (4). Flow of liquids around the system is achieved by 
means of nitrogen gas pressure. Gas phase for plate conditioning is prepared by passing 
nitrogen through a wash bottle (5) which may contain sulphuric acid, ammonia solution 
or other reagents depending upon the conditioning required, into a bladder (6), from 
where it is released into the developing chamber at the appropriate time. The system is 
operated from a central microprocessor control unit. 
A typical AMD step consists of the following sequence: the content (8ml) of the upper 
part of the gradient mixer (2) is transferred into the development chamber (1) which 
contains the chromatographic plate. Migration of the solvent starts immediately, and 
when the prescribed time (which determines the development distance) has elapsed, the 
remaining solvent is withdrawn from the chamber to the waste collection bottle (8). 
When all the liquid has been removed from the chamber, vacuum is applied by a pump 
(7) and the silica gel layer is dried for the required time which can be programmed into 
the sequence. Prior to starting the next development the plate is conditioned by 
introducing gas phase from the bladder (6) into the chamber. While the drying phase is in 
progress, solvent for the next step is prepared in the gradient mixer. 
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2.3 Experimental 
All MMD and AMD solvent schemes used in the present studies are presented in 
Appendix I. A summary of the schemes giving their elutropic strength ranges is shown 
in Table 2.1. Methanol and hexane were HPLC grade, and all other solvents were of 
AnalaRTM grade. 
2.3.1 MMD Universal Gradients 
Universal gradients in AMD describe systems which start with a very polar solvent which 
is varied via a "basis" solvent of medium polarity to a very non-polar solvent (Jaenchen 
and Issaq, 1988). 
Initial experiments to study MMD were carried out using a test mixture comprising 
phenol, m-cresol, resorcinol, m-hydroxybenzoic acid (m-HBA) and m-chlorophenol. The 
mixture was developed using a modified version of a universal AMD gradient (Jaenchen, 
1985). The solvents for the universal gradient were prepared by combining methanol, 
dichloromethane (DCM), and hexane to form a series of binary mixtures of gradually 
decreasing elutropic strength (MMD Scheme 1). Considerable bowing of the solvent 
front occurred with this system, particularly when the solvent mixtures contained DCM. 
This led to the solvent front having a concave profile and caused variation in retention 
across the HPTLC plate. The use of chloroform instead of DCM (MMD Scheme 2), 
overcame the problem. 
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Table 2.1 
Summary table of MMD and AMD Schemes used in the present studies 
Description Elutropic Strength 
Range 
9 
MMD Scheme 1 Modified Universal with DCM 0.73 to 0.0 
MMD Scheme 2 Modified Universal with CHC13 0.73 to 0.0 
MMD Scheme 3 Linear Stepwise System 0.73 to 0.0 
MMD Scheme 4 Linear Stepwise System 0.3 to 0.1 
MMD Scheme 5 Linear Stepwise System 0.49 to 0.0 
MMD Scheme 6 Linear Stepwise System 0.348 to 0.0 
MMD Scheme 7 Linear Stepwise System 0.73 to 0.598 
MMD Scheme {8 Linear Stepwise System 0.73 to 0.688 
MMD Scheme 9 Linear Stepwise System 0.73 to 0.51 
MMD Scheme 10 Linear Stepwise System 0.69 to 0.57 
MMD Scheme 11 Linear Stepwise System 0.654 to 0.604 
MMD Scheme 12 Linear Stepwise System 0.65 to 0.61 
AMD Scheme 1 Linear Stepwise Approximation 0.73 to 0.057 
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MMD Scheme 2 separated the phenols into two groups; resorcinol and m-HBA had Rfs 
of approximately 0.3, and the remaining phenols had Rfs of approximately 0.6. Previous 
work had indicated that although phenol, m-cresol and m-chlorophenol are difficult to 
separate by TLC, resorcinol and m-HBA should be resolved easily (Dietz et al., 1976). 
As it was considered likely that the migration distance of analytes is a function of the 
elutropic strengths of the solvents forming the MMD gradient, the elutropic strengths of 
the solvents in MMD Scheme 2 were calculated using Snyder's equation (Snyder, 1968a). 
log (Nb * 10 anb(Eb - F, )+ 1- Nb) Ebb_ -Ea+ b 
Eab = Solvent strength of binary mixture of solvents A&B. 
Ea = Solvent strength of solvent A. 
Eb = Solvent strength of solvent B. 
Nb = Mole fraction of solvent B in the binary solvent mixture. 
nb = The effective molecular area of an absorbed solvent molecule B. 
(B is the stronger component of a binary mixture. ) 
a= Adsorbent surface activity function (0.7 for water deactivated silica). 
The mole fraction of B in the solvent mixture is calculated as follows: 
_ 
No. molecules of B Nb 
No. molecules of A+ No. molecules of B 
No. molecules of A is proportional to 
Weight of A (WA) 
Molecular Weight of A (MWA) 
and Weight A= Volume of A (VA) * Density of A (DA) 
It therefore follows that 
= 
(Ds * VB)/MWB Nb 
((DA*VA)/MWA )+( (Da*VB)/MWB ) 
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The constants used for the calculations are shown in the table below (Snyder, 1968a). 
Constants used for the calculation of elutropic strengths of binary mixtures. 
Solvent Strength D/MW Molecular Area 
(Eo) (n) 
n-Hexane 0.00 0.87 10 
Chloroform 0.26 1.26 10 
Dichloromethane 0.32 1.57 10 
Ethyl Acetate 0.38 1.02 5.7 
Acetonitrile 0.50 1.91 10 
Propan-2-ol 0.63 1.34 8 
Methanol 0.73 2.49 8 
A graph of elutropic strength against development distance for MMD Scheme 2 is shown 
in Figure 2.14. A large change in elutropic strength occurred at a position corresponding 
to Rf=0.3, thus explaining the results obtained with the phenols. Such an abrupt change 
in elutropic strength could cause a large number of compounds to cluster at the point of 
change, and might be a particular problem when screening for novel compounds in 
biological fluids. Other universal gradients have similar elutropic strength profiles 
(Figure 2.15), so the separation of drugs and unknown metabolites might therefore be 
compromised by that feature of universal gradients. Wilson and Lewis (1987) found that 
six ecdysteroids migrated with an Rf of approximately 0.5 when developed with a 
universal gradient (Figure 2.15), which is consistent with the abrupt change in solvent 
strength which occurs with the gradient used. 
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Figure 2.14 
Graph of elutropic strength against development distance in MMD Scheme 2 
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An ideal profile for multiple development would therefore be linear across the full 
elutropic strength range (0.73 - 0.00, methanol to hexane). In order to construct a linear 
profile, the elutropic strengths of binary solvent mixtures were calculated using Snyder's 
equation. The data are shown in Figures 2.16 and 2.17. The constants used in the 
calculations were as shown previously. From the data obtained a linear multiple 
development gradient comprising 12 steps with a regular series of elutropic strengths 
from methanol to hexane was constructed (MMD Scheme 3), Figure 2.18. 
2.3.2 MMD Linear Gradients 
The linear MMD gradient (MMD Scheme 3) was constructed by using four solvents 
instead of the three employed in universal gradients. Polar solvents were obtained with 
methanol and ethyl acetate mixtures, intermediate strength solvents were mixtures of 
ethyl acetate and chloroform and the non-polar solvents were chloroform and hexane 
mixtures. 
2.3.2.1 Mixture of Phenols 
The test mixture of phenols was developed using the linear MMD gradient (MMD 
Scheme 3). An additional linear gradient over a reduced elutropic strength range using 
binary mixtures of chloroform and ethyl acetate, then chloroform and hexane, was 
constructed to improve further the separation obtained (MMD Scheme 4), Figure 2.19. 
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Solvent B (% by volume) 
Figure 2.17 
Solvent strengths of binary solvent mixtures 
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Figure 2.18 
Graph of elutropic strength against step number in linear MMD Scheme 3 
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Figure 2.19 
Graph of elutropic strength against step number in linear MMD Scheme 4 
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2.3.2.2 Compounds to model Phase I transformations 
The series of phenols, indoles, coumarins and biphenyls which differ from each other by 
typical Phase I metabolic transformations (Figures 2.3 to 2.6) were applied to a HPTLC 
plate and developed using the full linear MMD gradient (MMD Scheme 3). Linear 
gradients over smaller elutropic strength ranges (MMD Schemes 5 and 6) were used to 
increase the separation in some cases. 
Further compounds; ondansetron, ranitidine and loxtidine, and their Phase I metabolites 
(Figures 2.7 to 2.9) were applied to HPTLC plates and developed using the full linear 
gradient (MMD Scheme 3), and additional linear gradients over reduced elutropic 
strength ranges (MMD Schemes 7 to 12). The effect on migration and peak shapes of 
acidic and basic compounds was investigated when acetic acid, ammonia or triethylamine 
(TEA) were added to the solvent mixtures (1% v/v). 
2.3.2.3 Compounds to model Phase II transformations 
A series of compounds and their glucuronide and sulphate conjugates (Figures 2.10 and 
2.11) were applied to HPTLC plates and developed using the full linear gradient (MMD 
Scheme 3). A mixture of paracetamol (Pa), Pa glucuronide and Pa sulphate was used to 
determine the reproducibility of retention from one track to another on a single HPTLC 
plate. Seven spots of the mixture were applied 1cm apart across a 10xlOcm plate, the 
plate was developed using the full linear gradient, and the retention data were evaluated 
to determine the intra-plate reproducibility. The reproducibility of retention between 
plates was evaluated using the range of compounds and their glucuronide and sulphate 
conjugates. The mixtures were each applied 1cm apart to four different 1Ox10cm plates 
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which were then developed using the full linear gradient. The retention data were 
evaluated to determine the inter-plate reproducibility. 
Linear gradients over reduced elutropic strength ranges (MMD Schemes 7 and 9) were 
used to increase the separation of the glucuronides and sulphates, and additional plates 
were developed with acetic acid and TEA (1% v/v) in the solvent mixtures to investigate 
the effect of these modifiers on the retention of the conjugated metabolites. 
The epiandrosterone compounds do not contain ultraviolet absorbing chromophores, and 
were detected on the HPTLC plates by dipping the plates in 0.5% vanillin in sulphuric 
acid (98%) and ethanol (4: 1) and heating at 100* C for 5 minutes. The compounds 
formed blue bands against a yellow background. 
2.3.3 Automated Multiple Development 
There are two major differences between the way in which the automated multiple 
development (AMD) instrument operates, and the MMD procedure. Firstly, development 
of each step is controlled by time instead of distance in AMD, and secondly the AMD 
instrument cannot be programmed to prepare solvent mixtures to any desired 
specification. 
In order to estimate the times needed to run each step, the times taken for various solvents 
to migrate up a HPTLC plate were measured, and graphs of time against distance plotted, 
Figure 2.20. A curve for each solvent was obtained which fitted well to the equation 
Y=X21k. This is in agreement with Poiseuille's Law which states that capillary flow is 
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Figure 2.20 
Solvent migration times on silica gel IIPTLC plates, and curves fitted to y= X2 /k 
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inversely proportional to the length of a capillary (Perry et al., 1973). In TLC, this means 
that the velocity of solvent advance is inversely proportional to the distance of solvent 
travel. Thus the time taken for solvent to advance increases as the square of that distance 
(if v=dx/dt=k/X, then X dx =k dt, and t= (k/2)X2). The curves obtained were used to 
estimate the times needed for the various development distances that were required for 
AMD. 
The AMID instrument prepares solvent mixtures by diluting the original solvent (i. e. that 
selected for Step 1) with solvents from subsequent reservoirs. Prior to Step 1 the mixer is 
filled with Solvent 1, and approximately 33% of the total volume present in the mixer is 
dispensed to the chamber for the first development. The solvent for Step 2 is prepared by 
filling the mixer while mixing the solvents by means of magnetic stirrers. Thus if the 
original solvent is methanol and the second reservoir contains ethyl acetate the solvent 
mixtures prepared by the instrument approximate to those shown in the table below. 
Approximate compositions of solvents prepared by AMD if the initial solvent 
methanol is diluted repeatedly with ethyl acetate 
Step No Methanol Ethyl Acetate 
1 100 0 
2 67 33 
3 45 55 
4 30 70 
5 20 80 
6 14 86 
7 9 91 
8 6 94 
9 4 96 
10 3 97 
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Thus the precise solvent mixtures required to automate the linear gradient could not be 
used, and in order to approximate the linear gradient a number of steps had to be 
"missed" by developing the plate for 0.1min only before removing the solvent and drying 
the plate. The unwanted solvent mixtures did not therefore migrate up the plate sufficient 
distance to affect the samples chromatographically. The gradient using methanol, ethyl 
acetate, chloroform and hexane (AMD Scheme 1) is shown in Appendix I, Table 14. 
Four AMD runs were carried out with the compounds selected to model Phase II 
transformations (Figures 2.10 and 2.11) to determine the reproducibility of the system 
between runs. 
2.3.4 Detection Limits 
The success of a method to screen for drugs and metabolites in biological fluids is 
dependent largely upon whether the components of interest can be detected in small 
enough quantity and against the background of biological matrices. 
2.3.4.1 Analyte against plate background 
Whether HPTLC has sufficient sensitivity to detect drugs and metabolites in biological 
fluids was examined by determining the limits of detection for paracetamol and its 
glucuronide and sulphate metabolites on a HPTLC plate. Paracetamol was selected 
because it has relatively poor ultraviolet absorption with maximum absorbance 
(approximately 250nm) at a wavelength at which many other compounds absorb. Use of 
paracetamol would therefore test the system rigorously and not provide over optimistic 
data. 
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2.3.4.2 Analyte against control urine and plasma 
An ideal system to screen for drugs and metabolites in biological fluids would comprise 
application of plasma or urine to the chromatographic system without prior preparation, 
followed by chromatographic separation with no further modification of the sample. In 
order to test whether HPTLC with MMD would fulfil these criteria, samples of control 
plasma (2µl diluted 1: 1 with water) and urine (5 µl) and of plasma and urine spiked with 
paracetamol and conjugates (1 and lOµg/ml) were applied as 5mm bands to 10x10cm 
silica gel HPTLC plates using a Camag Linomat IV sample applicator, and the plates 
were developed using the full linear gradient (MMD Scheme 3). The Linomat did not 
apply plasma satisfactorily when undiluted, hence samples were diluted 1: 1 with water 
prior to application. If volumes of the diluted plasma in excess of 2µl were applied, the 
band of material on the plate did not wet when the solvent reached it and thus caused the 
solvent front to break up. 
2.4 Results 
The results from the assessment of multiple development on HPTLC and the examination 
of detection limits are presented in the following sections. 
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2.4.1 Linear Gradients Using MMD 
2.4.1.1 Test mixture of phenols 
The full linear gradient (MMD Scheme 3) separated m-HBA and resorcinol from each 
other, and from the remaining phenols (Figure 2.21), thus overcoming the compound 
clustering which occurred with the universal gradient at the point of abrupt elutropic 
strength change. Phenol, m-cresol and m-chlorophenol were not separated from each 
other which may have been due to their similar polarities or a lack of selectivity in the 
solvents used. 
The expanded gradient (MMD Scheme 4) improved the separation of the previously 
unresolved phenols, Figure 2.21. 
2.4.1.2 Compounds to model Phase I transformations 
Jupille and Perry (1975) showed that for PMD, the Rf value is not of great significance 
because all identical spots tend towards the same position on the plate. They stated that a 
better measure is distance travelled from the bottom of the plate or the elution distance 
(ED). In MMD or AMD, the concept of Rf is equally inappropriate because of the 
multiple development steps and the continually changing distances of solvent travel. 
Thus, chromatographic characteristics of compounds after MMD and AMD are described 
in the present studies as elution distances (ED), measured as distances travelled from the 
origin. 
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Figure 2.21 
HPTLC chromatograms of phenols after separation using MMD Scheme 3 and an 
expanded gradient MMD Scheme 4 
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MMD Scheme 3 
The EDs of indoles, coumarins, biphenyls and phenols obtained after development using 
the full linear gradient (MMD Scheme 3) are presented in Table 2.2. Most compounds 
migrated more than half way up the plate (ED>50mm) which would be expected of 
compounds with moderately low polarity. The metabolites of aspirin (salicylic acid, 
gentisic acid and 2,3-dihydroxybenzoic acid) migrated less far than the remaining 
compounds, and the peaks from these compounds were very broad. Other acidic 
compounds (indole-6-carboxylic acid, indole-3-carboxylic acid) also had broad peaks 
indicating the presence of the strong silanol interactions known to occur with acidic 
compounds on silica gel. 
The elution distances of compounds which differed from others by typical Phase I 
transformations were calculated relative to the elution distances of the "parent" 
compounds. These relative elution distances (RED) are presented in Table 2.2, and 
ranged between 0.566 and 1.087. The RED data are summarised in Table 2.3 showing 
the factors obtained for each type of Phase I transformation. REDs of compounds 
differing by aromatic hydroxylation, with the exception of 3 compounds, were greater 
than 0.9, whereas REDs of compounds differing by aliphatic hydroxylation were 
generally in the range 0.78 to 0.88. Oxidation to carboxylic acids resulted in REDs of 
approximately 0.8 with the formation of broad peaks on the chromatograms. 0- 
dealkylation had a similar effect to aromatic hydroxylation which is consistent with the 
formation of phenolic compounds in the examples examined. 
Separation of the indoles, coumarins and biphenyls was increased by the use of expanded 
linear gradients (MMD Schemes 5 and 6), Table 2.4. Thus the separation of indole and 
5-hydroxyindole was increased from 6.4mm using MMD Scheme 3 to 12.4mm 
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Table 2.2 
Elution distances of indoles, coumarins, biphenyls and phenols following manual 
multiple development using a linear gradient (MMD Scheme 3) on silica gel 60 
HPTLC plates 
Compound Peak ED(mm) RED 
Shape 
1-Methylindole s 69.2 - 
Indole m 75.2 1.087 
5-Hydroxyindole s 68.8 0.915 
5-Methoxyindole s 74.0 - 
6-Methylindole s 76.0 - 
Indole-6-carboxylic acid b 61.2 0.805 
3-Methylindole s 76.8 - 
Indole-3-carboxylic acid b 63.2 0.823 
3-Indolemethanol s 61.6 0.802 
Coumarin s 72.0 - 
4-Hydroxycoumarin vb 50.0 0.694 
7-Hydroxycoumarin s 67.2 0.933 
7-Methoxycoumarin s 70.4 - 
Aspirin vb 58.0 
Salicylic Acid vb 42.8 0.738 
Gentisic Acid vb 41.6 0.972 
2,3-Dihydroxybenzoic acid vb 32.8 0.766 
Biphenyl s 76.4 - 
2-Phenylphenol m 78.0 1.021 
4; Phenylphenol m 74.0 0.969 
4 4-Biphenol b 70.0 0.946 
4-Pentylphenol m 68.8 - 
1-[4-Hydroxyphenyl]pentan-l-ol s 56.8 0.826 
4-Ethyiphenol m 67.6 
4-Hydroxyphenylethanol s 53.6 0.793 
2-Ethylphenol m 69.6 
2-[2-Hydroxyphenyl]ethanol m 60.4 0.868 
2-Hydroxyphenylethan-l-ol s 54.8 0.787 
Phenol m 67.2 
Catechol s 60.8 0.905 
Resorcinol s 58.4 0.869 
Hydroquinone s 58.8 0.875 
o-Cresol m 68.0 
2-Hydroxybenzyl alcohol s 59.2 0.871 
m-Cresol m 67.2 
3-Hydroxybenzyl alcohol s 54.0 0.804 
p-Cresol m 66.0 - 4-Hydroxybenzyl alcohol s 54.0 0.818 
s: sharp m: moderate b: broad vb: very broad 
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Table 2.3 
Summary table of transformation type and RED values obtained following 
development of model compounds on silica gel HPTLC plates using MMD scheme 3 
N-Demethylation Aromatic Aliphatic Oxidation 
Hydroxylation Hydroxylation to COOH 
1.087 0.915 
0.933 
0.972 
0.766a 
1.021b 
0.969 
0.946 
0.905 
0.869c 
0.8754 
Mean 0.917 
S. D. 0.070 
0.802 0.805 
0.694 0.823 
0.828 
0.793 
0.868 
0.787 
0.871 
0.804 
0.818 
0.807 
0.052 
a 2,3-Dihydroxybenzoic acid from salicylic acid b 2-Phenylphenol from biphenyl 
c Resorcinol from phenol d Hydroquinone from phenol 
O-dealkylation 
0.930 
0.954 
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Table 2.4 
Elution distances of indoles, coumarins and biphenyls following manual multiple 
development on silica gel 60 HPTLC plates with expanded linear gradients 
MMD Scheme 5 
Compound Peak ED(mm) 
Shape 
MMD Scheme 6 
Peak ED(mm) 
Shape 
1-Methylindole s 50.0 m 77.6 
Indole m 60.0 m 56.4 
5-Hydroxyindole s 47.6 s 32.4 
5-Methoxyindole s 54.4 s 45.6 
6-Methylindole s 61.2 s 58.0 
Indole-6-carboxylic acid m 39.2 m 18.4 
3-Methylindole s 62.8 s 60.4 
Indole-3-carboxylic acid m 41.2 m 18.8 
3-Indolemethanol s 46.8 s 38.4 
Coumarin s 53.2 s 44.4 
4-Hydroxycoumarin m 29.2 m 14.4 
7-Hydroxycoumarin s 45.2 s 28.4 
7-Methoxycoumarin s 50.0 s 39.6 
Biphenyl ND s 87.6 
2-Phenylphenol m 59.6 m 57.2 
4; Phenylphenol m 52.0 m 42.4 
4 4-Biphenol m 45.6 m 26.8 
ND: Not detected 
s: sharp m: moderate 
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with MMD Scheme 5 and 24.0mm with MMD Scheme 6. Similarly the separation of 
coumarin and 7-hydroxycoumarin increased from 4.8mm using MMD Scheme 3 to 
8.0mm and 16. Omm with MMD Schemes 5 and 6 respectively. 
Inclusion of acetic acid (1%v/v) in each solvent mixture increased the migration of some 
acidic compounds (4-hydroxycoumarin, aspirin, salicylic acid, gentisic acid and 2,3- 
dihydroxybenzoic acid) and generally improved the peak shapes of all acidic compounds 
examined, Table 2.5. The retention of the non-acidic compounds was unaffected by the 
addition of acetic acid to the solvent mixtures. Thus the ED of aspirin increased from 
58.0mm to 64.0mm, salicylic acid increased from 42.8mm to 65.6mm, gentisic acid 
increased from 41.6mm to 58.0mm and 2,3-dihydroxybenzoic acid increased from 
32.8mm to 55.2mm. 
The EDs obtained for ondansetron, ranitidine, loxtidine and their metabolites following 
development with the full gradient (MMD Scheme 3) are shown in Table 2.6. The EDs 
were very small, probably due to cation-exchange interactions between the silanol groups 
on the silica and the amine functions on the molecules. EDs were increased by use of 
expanded linear gradients (MMD Schemes 7 and 8), Table 2.6, but the separation 
between ondansetron and its metabolites in particular was not increased. Addition of 
ammonia solution (l %v/v) to each solvent mixture in both the full gradient and an 
expanded gradient did not change the retention of the compounds, and had only minimal 
effect on their separation, Table 2.7. The use of TEA (1% v/v), however, increased 
migration of the compounds on the full gradient, Table 2.8, and expanded gradients with 
TEA in the solvent mixtures (MMD Schemes 9-12) increased migration further. The use 
of very shallow gradients designed to increase the separation of the ondansetron 
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Table 2.5 
Elution distances of selected acidic indoles, coumarins, and phenols following 
manual multiple development on silica gel 60 HPTLC plates using MMD Scheme 3 
with and without 1% glacial acetic acid 
Without Acid With Acid 
Compound Peak ED(mm) Peak ED(mm) 
Shape Shape 
Indole m 75.2 m 72.8 
6-Methylindole s 76.0 s 73.6 
Indole-6-carboxylic acid b 61.2 s 62.8 
3-Methylindole s 76.8 s 75.2 
Indole-3-carboxylic acid b 63.2 m 62.8 
Coumarin s 72.0 s 69.2 
4-Hydroxycoumarin vb 50.0 s 58.4 
7-Hydroxycoumarin s 67.2 s 63.2 
Aspirin vb 58.0 s 64.0 
Salicylic Acid vb 42.8 s 65.6 
Gentisic Acid vb 41.6 b 58.0 
2,3-Dihydroxybenzoic acid vb 32.8 b 55.2 
s: sharp m: moderate b: broad vb: very broad 
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Table 2.6 
Elution distances of ondansetron, ranitidine, loxtidine and metabolites following 
manual multiple development on silica gel 60 HPTLC plates 
MMD Scheme 3 
Compound ED(mm) RED 
Scheme 7 Scheme 8 
ED(mm) ED(mm) 
Ondansetron 11.2 - 44.0 72.0 
N-desmethyl ondansetron 13.6 1.214 48.4 76.8 
5-OH ondansetron 12.8 1.143 47.2 - 
6-OH ondansetron 11.2 1.000 42.4 71.2 
7-OH ondansetron 11.2 1.000 41.6 72.0 
8-OH ondansetron 13.2 1.179 47.6 77.6 
6-OH, N-desmethyl ondansetron 12.8 1.143 45.6 75.6 
7-OH, N-desmethyl ondansetron 13.2 1.179 44.4 71.6 
Ranitidine 5.6 - - 46.0 
N-desmethyl ranitidine 4.0 0.714 - 20.8 
Ranitidine N-oxide 2.8 0.500 - 16.4 
Ranitidine S-oxide 2.8 0.500 - 22.8 
Loxtidine 5.2 - - - 
AH25227 15.2 2.923 - - 
GR30450 6.0 1.154 - - 
AH24610 3.2 0.615 - - 
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Table 2.7 
Elution distances of ondansetron, ranitidine, and metabolites following manual 
multiple development on silica gel 60 HPTLC plates using MMD Schemes 3 and 7 
with 1% ammonia solution 
Scheme 3 Scheme 3 Scheme 7 Scheme 7 
with NH3 with NH3 
Compound ED(mm) ED(mm) ED(mm) ED(mm) 
Ondansetron 11.2 13.2 44.0 43.6 
N-desmethyl ondansetron 13.6 15.2 48.4 46.4 
5-OH ondansetron 12.8 14.0 47.2 45.2 
6-OH ondansetron 11.2 12.0 42.4 42.0 
7-OH ondansetron 11.2 12.0 41.6 42.0 
8-OH ondansetron 13.2 14.8 47.6 45.6 
6-OH, N-desmethyl ondansetron 12.8 14.0 45.6 44.0 
7-OH, N-desmethyl ondansetron 13.2 13.6 44.4 43.2 
Ranitidine 5.6 6.4 - 21.2 
N-desmethyl ranitidine 4.0 4.8 - 11.6 
Ranitidine N-oxide 2.8 3.2 - 12.8 
Ranitidine S-oxide 2.8 ND - 6.4 
ND: Not detected 
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Table 2.8 
Elution distances of ondansetron, loxtidine and metabolites following manual 
multiple development on silica gel 60 HPTLC plates using MMD Schemes with 1% 
TEA 
Compound 
Ondansetron (ond) 
N-desmethyl and 
6-OH ondansetron 
7-OH ondansetron 
8-OH ondansetron 
6-OH, N-desmethyl and 
7-OH, N-desmethyl and 
Ranitidine 
N-desmethyl ranitidine 
Ranitidine N-oxide 
Ranitidine S-oxide 
Loxtidine 
AH25227 
GR30450 
AH24610 
Scheme 3 Scheme 9 Scheme 10 Scheme 11 Scheme 12 
ED(mm) ED(mm) ED(mm) ED(mm) ED(mm) 
21.2 
17.6 
17.2 
14.8 
18.0 
15.6 
14.0 
51.6 
44.8 
47.2 
42.0 
40.4 
41.6 
36.8 
40.8 
27.2 
6.0 
24.8 
42.0 
76.0 
16.8 
10.4 
51.2 59.2 63.6 
50.0 56.8 59.2 
49.2 55.6 59.6 
46.4 50.8 55.6 
50.0 56.4 61.6 
46.4 52.0 55.2 
42.8 44,4 50.0 
20.0 
31.6 
7.6 
5.2 
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metabolites was unsuccessful; increased focusing of the gradient did not increase 
separation. The presence of TEA as the strongest component in these systems may have 
reduced the effect of small changes in the other solvents. 
Isocratic development of ondansetron and its metabolites was carried out to determine 
whether multiple development could be avoided. Under these conditions, separation of 
some components was increased, but the peaks obtained were much broader than after 
multiple development so the potential increased resolution was lost, Table 2.9. This 
demonstrated the advantage of multiple development in focusing sample bands on the 
chromatograms. 
2.4.1.3 Compounds to model Phase II transformations 
The EDs obtained from model compounds and their glucuronide and sulphate conjugates 
after development with the full linear gradient (MMD Scheme 3) are presented in Tables 
2.10 and 2.11. The relative elution distances of the conjugates (relative to the EDs of the 
parent compounds) are summarised in Table 2.12 and presented graphically in Figure 
2.22. In general the mean REDs of the glucuronides were <0.3 (range 0.127 to 0.275), 
whereas those of the sulphates were >0.3 (range 0.326 to 0.354) with the exception of 
epiandrosterone sulphate (0.225). Phenolphthalein disulphate had a mean RED value 
more typical of a glucuronide (0.263), however a disulphate might be expected to behave 
in a different manner chromatographically to a mono-sulphate. 
Analysis of variance was applied to the conjugate RED data to test the null hypothesis 
that the samples (compounds) came from populations with equal means. The hypothesis 
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Table 2.9 
Elution distances of ondansetron and metabolites on silica gel 60 HPTLC plates 
using isocratic development for 9.0cm 
System 1: Methanol (1.8) + Ethyl Acetate (8.2) + 1% TEA 
System 2: Methanol (2.55) + Ethyl Acetate (7.45) + 1% TEA 
Compound System 1 System 2 
ED(mm) ED(mm) 
GR38032 49.6 74.0 
GR41352 : N-desmethyl 42.4 72.0 
GR60661 : 6-OH 42.4 66.8 
GR63418 : 7-OH 35.2 58.8 
GR60317 : 6-OH, N-desmethyl 35.6 62.4 
GR65826 : 7-OH, N-desmethyl 26.8 49.6 
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Table 2.10 
Elution distances of conjugated glucuronide and sulphate metabolites following 
manual multiple development on silica gel 60 HPTLC plates using MMD Scheme 3 
PLATE 1 PLATE 2 
Compound ED(mm) RED ED(mm) RED 
Naphthol 70.0 - 64.4 - 
N. glucuronide 14.0 0.200 13.6 0.211 
N. sulphate 21.2 0.303 22.0 0.342 
Paracetamol 45.6 - 44.0 - 
Pa. glucuronide 9.6 0.211 10.4 0.236 
Pa. sulphate 15.6 0.342 16.4 0.373 
Phenol 67.2 - 62.8 - 
Ph. glucuronide 10.8 0.161 11.6 0.185 
Phenolphthalein 55.2 - 54.8 - 
Pp. glucuronide 12.8 0.232 14.4 0.263 
Pp. disulphate 13.6 0.246 15.2 0.277 
4-MeU 58.8 - 62.0 - 
4-MeU glucuronide 9.6 0.163 9.6 0.155 
4-MeU sulphate 22.8 0.388 20.0 0.323 
Epiandrosterone 66.0 - 68.5 - 
Ep. glucuronide 8.0 0.121 8.0 0.117 
Ep. sulphate 14.0 0.212 15.0 0.219 
Chloramphenicol 47.6 - 47.2 - 
Chl. glucuronide 11.6 0.244 12.4 0.263 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Table 2.11 
Elution distances of conjugated glucuronide and sulphate metabolites following 
manual multiple development on silica gel 60 HPTLC plates using MMD Scheme 3 
PLATE 3 PLATE 4 
Compound ED(mm) RED ED(mm) RED 
Naphthol 65.6 - 65.6 - 
N-glucuronide 14.4 0.220 10.4 0.159 
N-sulphate 22.0 0.335 21.2 0.323 
Paracetamol 45.6 - 44.4 - 
Pa-glucuronide 13.6 0.298 8.2 0.185 
Pa-sulphate 16.4 0.360 15.2 0.342 
Phenol 64.8 - 64.0 - 
Ph-glucuronide 13.2 0.204 10.0 0.156 
Phenolphthalein 56.0 - 55.6 - 
Pp-glucuronide 14.4 0.257 11.2 0.201 
Pp-disulphate 15.2 0.271 14.4 0.259 
4-MeU 58.4 - 54.0 - 
4-MeU glucuronide 9.6 0.164 10.4 0.193 
4-MeU sulphate 19.2 0.329 20.0 0.370 
Epiandrosterone 64.5 - 59.0 - 
Ep. glucuronide 8.0 0.124 8.5 0.144 
Ep. sulphate 15.0 0.233 14.0 0.237 
Chloramphenicol 43.2 - 42.0 - 
Chl. glucuronide 12.0 0.278 13.2 0.314 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Table 2.12 
Relative elution distances of conjugated glucuronide and sulphate metabolites 
following manual multiple development on silica gel 60 HPTLC plates using MMD 
Scheme 3 
Compound Plate 1 Plate 2 Plate 3 Plate 4 Mean S. D. C of V 
N gluc. 0.200 0.211 0.220 0.159 0.198 0.027 13.6% 
Pa gluc. 0.211 0.236 0.298 0.185 0.233 0.048 20.8% 
Ph gluc. 0.161 0.185 0.204 0.156 0.177 0.022 12.6% 
Pp gluc. 0.232 0.263 0.257 0.201 0.238 0.028 11.8% 
4-MeU gluc. 0.163 0.155 0.164 0.193 0.169 0.017 9.9% 
Ep gluc. 0.121 0.117 0.124 0.144 0.127 0.012 9.5% 
Chl gluc. 0.244 0.263 0.278 0.314 0.275 0.030 10.8% 
N sulph. 0.303 0.342 0.335 0.323 0.326 0.017 5.2% 
Pa sulph. 0.342 0.373 0.360 0.342 0.354 0.015 4.3% 
4-MeU sulph. 0.388 0.323 0.329 0.370 0.353 0.032 9.0% 
Ep sulph. 0.212 0.219 0.233 0.237 0.225 0.012 5.2% 
Pp disulph. 0.246 0.277 0.271 0.259 0.263 0.014 5.2% 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Figure 2.22 
Relative elution distances (RED) of glucuronide and sulphate conjugates after MMD 
on silica gel 60 HPTLC plates using MMD Scheme 3 
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was shown to be incorrect (p=0) indicating that the mean RED values came from 
different populations. A simultaneous group comparison test was carried out and the 
results are shown in Figure 2.23. The error bars from four out of the seven glucuronides 
tested did not overlap with the grand average error bounds indicating that their means 
were significantly below the average. Three out of the four mono-sulphates had means 
significantly above the average. This demonstrated that there were essentially two 
populations of RED values, one corresponding to the glucuronides and the other 
corresponding to the sulphates. There was however some overlap with a few compounds 
having values either higher (e. g., chloramphenicol glucuronide) or lower (e. g., 
epiandrosterone sulphate) than the others in their class. 
The existence of two populations of RED values was confirmed by use of Duncan's 
multiple comparison test. Observations were ranked in ascending order of mean values 
and put into groups within which no significant difference was observed at the 5% level. 
The groups formed are shown below, and with the exception of epiandrosterone sulphate 
there was a clear difference between the group containing the mono-sulphates and the 
remaining overlapping groups containing the glucuronides. Epiandrosterone glucuronide 
also had a low RED value, and there was a significant difference between the RED values 
of the two epiandrosterone conjugates. 
Groups of mean RED values with no significant differences at the S% level 
(Duncan's Test) 
Ep-g 4MeU-g Ph-g N-g Ep-s Pa-g Pp-g Pp-ds Ch-g N-s 4MeU-s Pa-s 
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Figure 2.23 
Simultaneous comparisons between groups of RED values following MMD of 
conjugated metabolites on silica gel 60 HPTLC plates using MMD Scheme 3 
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line, the group mean is not significantly different from the grand average. 
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The data obtained to determine the intra-plate variation in retention are shown in Table 
2.13. Excellent reproducibility was obtained for the REDS (0.89 and 1.65%) indicating 
that it is valid to compare EDs of different compounds when chromatographed on the 
same plate, but on different tracks. The inter-plate variation, shown in Table 2.12, was 
considerably greater than the infra-plate variation. In general, the variation in the REDs 
of the glucuronides was greater than that of the sulphate REDs. This can be explained 
because migration of the glucuronides took place primarily in the first two or three steps 
of the MMD procedure, and the extent of migration was therefore controlled largely by 
the accuracy to which the first step was developed to 4mm beyond the origin. The 
sulphates migrated further, and therefore their migration and that of parent compounds 
was controlled by subsequent elution steps. 
The full linear gradient provided excellent separation between parent compounds and the 
glucuronide and sulphate conjugates. However although the conjugates were resolved 
from each other, resolution was not complete in all cases. In biological matrices where 
endogenous conjugated material is present, additional separation might be required in 
order to separate drug-related material from endogenous components. The EDs obtained 
from the glucuronide and sulphate conjugates after development on expanded linear 
gradients (MMD Schemes 7 and 9) are presented in Table 2.14. Greater separation of the 
conjugated metabolites was achieved with both systems, however the parent compounds 
migrated with the solvent front so RED values could not be obtained. 
The EDs obtained after development of the conjugates with full linear gradients 
containing either glacial acetic acid (1% v/v) or TEA (1% v/v) are presented in Table 
2.15 and are compared with the data obtained without modifier. In all cases the REDS of 
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Table 2.13 
Intra-plate variation in relative elution distances following manual multiple 
development on silica gel 60 HPTLC plates using MMD Scheme 3 
Track No. Paracetamol Paracetamol 
Glucuronide Sulphate 
1 0.212 0.363 
2 0.212 0.354 
3 0.212 0.363 
4 0.212 0.363 
5 0.211 0.360 
6 0.219 0.360 
7 0.219 0.360 
Mean 0.214 0.360 
S. D. 0.004 0.003 
C of V 1.65% 0.89% 
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Table 2.14 
Elution distances of conjugated glucuronide and sulphate metabolites following 
manual multiple development on silica gel 60 HPTLC plates using expanded linear 
MMD Schemes 7 and 9 
Compound MMD Scheme 7 MMD Scheme 9 
ED(mm) ED(mm) 
Naphthol ND ND 
N. glucuronide 30.8 18.8 
N. sulphate 64.4 55.2 
Paracetamol ND ND 
Pa. glucuronide 24.0 15.6 
Pa. sulphate 52.0 35.6 
Phenolphthalein ND ND 
Pp. glucuronide 30.0 18.8 
Pp. sulphate 44.0 55.2 
4-MeU ND ND 
4-MeU glucuronide 26.4 17.2 
4-MeU sulphate 61.6 51.6 
Epiandrosterone ND ND 
Ep. glucuronide 26.0 15.5 
Ep. sulphate 50.0 34.5 
Chloramphenicol ND ND 
Chl. glucuronide 34.8 22.0 
ND Not detected - migrated with solvent front. 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Table 2.15 
Effect of modifiers on the elution distances of conjugated glucuronide and sulphate 
metabolites following manual multiple development on silica gel 60 HPTLC plates 
using MMD Scheme 3 
NORMAL TEA ACETIC ACID 
ED(mm) RED ED(mm) RED ED(mm) RED 
Naphthol 66.4 - 66.8 - 70.4 - 
Na glucuronide 13.1 0.198 16.8 0.251 14.4 0.205 
Na sulphate 21.6 0.326 24.0 0.359 28.8 0.409 
Phenolphthalein 55.4 - 61.6 - 61.6 - 
Pp glucuronide 13.2 0.238 16.8 0.273 -15.6 0.253 
4-Me Umbelliferone 58.3 - 60.8 - 61.6 
4-Me U glucuronide 9.8 0.169 16.4 0.270 13.2 0.214 
4-Me U sulphate 20.5 0.353 23.6 0.388 25.2 0.409 
Paracetamol 44.9 - 52.0 - 52.8 
Pa glucuronide 10.5 0.233 16.4 0.315 12.4 0.235 
Pa sulphate 15.9 0.354 20.4 0.392 18.0 0.341 
Chloramphenicol 45.0 - 49.2 - 51.6 
Chl glucuronide 12.3 0.275 18.8 0.382 15.2 0.295 
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the glucuronides were increased more with acetic acid as the modifier than with TEA, and 
conversely in all cases except one (paracetamol sulphate) the sulphate REDs were 
increased more with TEA than with acetic acid in the solvent mixtures. This could 
provide an additional means of conjugate identification in conjunction with the RED data. 
2.4.3 Automated Multiple Development (AMD) 
The EDs obtained after developing the conjugated metabolites and their parent 
compounds using AMD are presented in Tables 2.16 and 2.17. The RED values are 
summarised in Table 2.18 and presented graphically in Figure 2.24. The AMD inter- 
plate data were more reproducible than those obtained using the MMD procedure, and the 
difference in RED values between the glucuronide. and sulphate conjugates was more 
pronounced. Using AMD, all the glucuronide RED values were <0.2 with the exception 
of chloramphenicol glucuronide (0.268), and the sulphate RED values were all >0.25. 
The disulphate had a lower RED value than the mono-sulphates (0.226) as was found 
with MMD. These data showed the benefit of automation with this complex 
development procedure. 
2.4.4 Detection Limits 
2.4.4.1 Analyte against plate background 
The detection limits for paracetamol and its conjugates applied as pure solutions to a 
HPTLC plate were determined. The ultraviolet absorbance maxima of the compounds on 
a silica HPTLC plate were measured by scanning spots of the compounds in situ with a 
Camag TLC scanner II. 
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Table 2.16 
Elution distances of conjugated glucuronide and sulphate metabolites following 
automated multiple development on silica gel 60 HPTLC plates using AMD 
Scheme 1 
PLATE 1 PLATE 2 
Compound ED(mm) RED ED(mm) RED 
Naphthol 58.8 - 58.4 - 
N. glucuronide 8.4 0.143 9.2 0.158 
N. sulphate 19.6 0.333 19.2 0.329 
Paracetamol 44.4 - 43.2 - 
Pa. glucuronide 6.8 0.153 8.4 0.194 
Pa. sulphate 12.4 0.279 12.8 0.296 
Phenol 57.2 - 57.2 - 
Ph. glucuronide 3.6 0.063* 7.2 0.126 
Phenolphthalein 54.0 - 53.6 - 
Pp. glucuronide 8.4 0.153 9.2 0.172 
Pp. disulphate 11.6 0.215 11.6 0.216 
4-MeU 53.2 - 53.2 - 
4-MeU glucuronide 6.4 0.120 7.6 0.143 
4-MeU sulphate 19.6 0.368 19.2 0.361 
Epiandrosterone 58.0 - 59.0 - 
Ep. glucuronide 8.0 0.138 9.0 0.153 
Ep. sulphate 14.5 0.250 14.5 0.246 
Chloramphenicol 45.2 - 42.4 - Chl. glucuronide 10.4 0.230 10.8 0.255 
* Not used in the calculation of means and standard deviations (Table 29) because this 
data point is inconsistent with the remaining data. 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Table 2.17 
Elution distances of conjugated glucuronide and sulphate metabolites following 
automated multiple development on silica gel 60 HPTLC plates using AMD 
Scheme 1 
I PLATE 3 PLATE C 
Compound ED(mm) RED ED(mm) RED 
Naphthol 57.2 - 57.2 - 
N. glucuronide 9.2 0.161 9.2 0.161 
N. sulphate 17.6 0.308 17.2 0.301 
Paracetamol 42.0 - 42.4 - 
Pa. glucuronide 8.0 0.190 8.0 0.189 
Pa. sulphate 12.4 0.295 12.8 0.302 
Phenol 56.0 - 56.4 - 
Ph. glucuronide 6.8 0.121 7.6 0.135 
Phenolphthalein 52.0 - 51.6 - 
Pp. glucuronide 9.2 0.177 8.8 0.171 
Pp. disulphate 12.0 0.231 12.4 0.240 
4-MeU 51.6 - 51.2 - 
4-MeU glucuronide 8.0 0.155. 8.0 0.156 
4-MeU sulphate 17.2 0.333 17.2 0.336 
Epiandrosterone 59.0 - 58.0 - 
Ep. glucuronide 9.5 0.161 9.5 0.164 
Ep. sulphate 15.5 0.263 15.0 0.259 
Chloramphenicol 38.8 - 37.6 - 
Chl. glucuronide 11.2 0.289 11.2 0.298 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp . Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Table 2.18 
Relative elution distances of conjugated glucuronide and sulphate metabolites 
following automated multiple development on silica gel 60 HPTLC plates using 
AMD Scheme 1 
Compound Plate 1 Plate 2 Plate 3 Plate 4 Mean S. D. C of V 
N gluc. 0.143 0.158 0.161 0.161 0.156 0.009 5.5% 
Pa gluc. 0.153 0.194 0.190 0.189 0.182 0.019 10.5% 
Ph gluc. 0.063* 0.126 0.121 0.135 0.127 0.007 5.6% 
Pp gluc. 0.153 0.172 0.177 0.171 0.168 0.011 6.2% 
4-MeU gluc. 0.120 0.143 0.155 0.156 0.144 0.017 11.7% 
Ep gluc. 0.138 0.153 0.161 0.164 0.154 0.012 7.6% 
Chl gluc. 0.230 0.255 0.289 0.298 0.268 0.031 11.7% 
N sulph. 0.333 0.329 0.308 0.301 0.318 0.016 4.9% 
Pa sulph. 0.279 0.296 0.295 0.302 0.293 0.010 3.4% 
4-MeU sulph. 0.368 0.361 0.333 0.336 0.350 0.018 5.0% 
Ep sulph. 0.250 0.246 0.263 0.259 0.255 0.008 3.1% 
Pp disulph. 0.215 0.216 0.231 0.240 0.226 0.012 5.4% 
* Not used in the calculation of means and standard deviations because this data point is 
inconsistent with the remaining data. 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Figure 2.24 
Relative elution distances (RED) of glucuronide and sulphate conjugates after AMD 
on silica gel 60 HPTLC plates using AMD Scheme 1 
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The UV maxima were : 
Paracetamol: 251nm 
Paracetamol glucuronide 247nm 
Paracetamol sulphate 245nm 
The detection limit for paracetamol and its conjugates against the plate background was 
determined by scanning at 250nm. Chromatograms obtained following MMD of the 
standards on silica HPTLC plates using MMD Scheme 3 are shown in Figure 2.25. In 
each case, lOng was detected easily, but ing was below the limit of detection. The 
chromatograms indicated that 5ng of each compound would be detected against the plate 
background. Thus if a 51AI sample of a biological fluid was applied to a plate, the limit of 
detection would be 1µg/ml assuming that it was not compromised by endogenous 
material in the sample. 
2.4.4.2 Analyte against control urine and plasma 
Chromatograms from control rat and dog urine following MMD on silica HPTLC plates 
using MMD Scheme 3, obtained by scanning at various wavelengths are shown in Figure 
2.26. At the lower wavelengths, a large amount of material was detected on the plate, 
particularly in the region to which the conjugated metabolites elute. The material 
detected at 320nm was reduced considerably. Paracetamol and its conjugated metabolites 
were not detected on the plate against the endogenous background at concentrations of 
either 1 or 10µg/ml in urine. 
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Figure 2.25 
HPTLC chromatograms of paracetamol and its glucuronide and sulphate 
conjugates following manual multiple development on silica gel 60 HPTLC plates 
using MMD Scheme 3 
Plate background 
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Chromatograms from control rat and dog plasma following MMD on silica HPTLC 
plates using MMD Scheme 3, obtained by scanning at various wavelengths are shown in 
Figure 2.27. There was much less material detected on the plate than was found with 
urine, and at 320nm the material detected was reduced considerably. Chromatograms 
from plasma spiked with paracetamol and its conjugated metabolites at 1 and 10µg/ml 
after MMD on silica HPTLC plates using MMD Scheme 3 are shown in Figure 2.28. 
Paracetamol and its conjugated metabolites were not detected on the plate against the 
endogenous background at a concentration of 1 µg/ml, but at 10µg/ml there was evidence 
of paracetamol and the sulphate metabolite. The glucuronide was not detected. 
2.5. Discussion 
The main aim of the studies described in this chapter was to assess the usefulness of 
multiple development techniques on normal-phase HPTLC for the separation of drugs 
and metabolites with a view to developing a generally applicable gradient. Further aims 
were to assess the sensitivity of HPTLC for detecting drugs and metabolites in biological 
fluids. 
High-performance thin-layer chromatography with multiple development has been shown 
to be useful for the separation of a wide range of compounds with large differences in 
polarity. The elution distances (EDs) obtained from a multiple development gradient 
comprising solvent mixtures having a linear decrease in elutropic strengths from 
methanol (0.73) to hexane (0.0) are summarised in Figure 2.29. The compounds were 
separated over most of the HPTLC plate and only a few compounds failed to elute more 
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Figure 2.28 
Detection of paracetamol and conjugated metabolites in plasma after direct spotting 
of plasma and manual multiple development on silica gel 60 HPTLC plates using 
MMD Scheme 3 
Control rat plasma 
Rat plasma spiked at lµg/ml 
Rat plasma spiked at 10µg/ml 
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than 10mm using-this gradient. The linear gradient thus had an advantage over 
previously used universal gradients which tended to include abrupt changes in elutropic 
strength which were likely to cause clustering of compounds at the point where the 
change occurred. 
Most of the compounds selected as model Phase I metabolites had smaller EDs than the 
"parent" compounds as would be predicted. The exceptions were indole when compared 
with N-methyl indole, some metabolites of ondansetron when developed with gradients 
not containing TEA, and the relatively non-polar metabolite of loxtidine formed after N- 
and O-dealkylation. The loxtidine metabolite is formed through loss of the relatively 
polar triazole and carboxylic acid groups, so an increase in retention would be expected in 
this case. The separation between "parent compound" and "metabolite" on the full linear 
gradient was small in a large number of cases with RED values being greater than 0.9 
particularly after aromatic hydroxylation and O-dealkylation to form aromatic 
hydroxylated compounds. In contrast, aliphatic hydroxylation resulted in greater 
separation with a mean RED value of about 0.8. This can be explained because a 
hydroxyl group has a high electron density, tending to release electrons, and by this 
means interacts with the silica surface. The electron density remains with the hydroxyl 
group on aliphatic alcohols which thus interact strongly with the silica surface. However, 
an aromatic system is unsaturated electronically, so a hydroxyl group attached to an 
aromatic ring is able to share its electron density with that system. There is therefore a 
reduced electron density on an aromatic hydroxyl group compared with an aliphatic 
hydroxyl, and its interaction with the silica surface is accordingly weaker. The three 
phenolic compounds which had lower RED values (2,3-dihydroxybenzoic acid, 
resorcinol and hydroquinone) also had other electron releasing hydroxyl groups on the 
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ring which may have reduced the extent to which delocalisation could occur when a 
second hydroxyl group was added. 
Oxidation to form carboxylic acids resulted in retention changes similar to aliphatic 
hydroxylation, and the accompanying characteristic broad peaks obtained with these 
compounds were indicative of their presence. The presence of acidic groups may be 
confirmed further by development with a gradient containing acetic acid. The acetic acid 
suppresses the ionisation of acidic compounds, causing increased migration of some 
acidic compounds with an improved peak shape in all cases. Insufficient examples of 
compounds formed by N-demethylation were obtained for this transformation to be 
examined adequately with compounds which migrated on the full gradient system. 
Ondansetron, ranitidine, loxtidine and their metabolites were retained very strongly using 
MMD Scheme 3. These compounds are able to interact with silica by a cation-exchange 
mechanism, hence they were only eluted reasonable distances with solvent mixtures 
containing high proportions of methanol, or with a modifier such as TEA which competes 
for the sites on the silica surface which are able to partake in cation-exchange. 
Ondansetron, ranitidine and loxtidine all required separation on gradients over a narrow 
elutropic strength range because of their strong interactions with silica, and although 
separation was achieved, the RED values obtained could not be compared directly with 
the values obtained from the other compounds using the full gradient. 
Separation of Phase I model compounds was increased when gradients covering reduced 
elutropic strength ranges were used. Use of these shallow gradients may be considered as 
being analogous to increasing the magnification of a microscope when studying a 
specimen. As more detail is observed with greater magnification under a microscope, so 
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a more shallow gradient increases the resolution on the HPTLC plate. The RED values 
increased accordingly as the "magnification" was increased, but could not be compared 
with the values obtained using the full gradient. 
The full linear gradient gave excellent separation of conjugated metabolites from their 
parent compounds, and the RED values obtained for the conjugated metabolites were 
generally within two ranges which were significantly different for glucuronides and 
sulphates. This gave a means for the tentative characterisation of conjugated metabolites, 
which may be strengthened by investigation of the behaviour of the component of interest 
with the addition of acetic acid (greater increase in RED of a glucuronide) and TEA 
(greater increase in RED of a sulphate). The full gradient separated the glucuronides 
from the sulphates, but increased separation was obtained when gradients covering 
reduced elutropic strength ranges were used. However, this again posed the problem of 
comparing retention with that of parent compound on the full gradient. 
The previous discussion has indicated the difficulty that exists in obtaining RED values 
when comparing elution distances of two compounds on different gradients. In the 
following sections, a method to overcome this problem is proposed. 
A more appropriate parameter than elution distances for comparing retention between 
different linear gradients may be obtained by calculating "elution indices". If elutropic 
strength is plotted against the mid-point of the difference in distance between adjacent 
developments on linear MMD gradients, linear plots are obtained, and equations for these 
lines can be calculated by linear regression analysis. An "elution index" can be 
interpolated from the regression equation for each distance from the origin to which a 
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substance might elute, as shown in Figure 2.30. The equations for the full linear gradient 
(MMD Scheme 3), and expanded gradients (MMD Schemes 7 and 9) are shown in Table 
2.19. The elution distances obtained for the compounds developed using each system can 
be interpolated from the equation for the system concerned and the values calculated for 
the glucuronide and sulphate conjugates are shown in Table 2.19. 
The elution indices calculated from the expanded gradients (MMD Schemes 7 and 9) 
were in very good agreement with each other and with the values from the full gradient. 
If the elution indices from the expanded systems are then substituted into the equation for 
the full gradient, the elution distances to which the compounds would have run on that 
system can be obtained. These values are shown in parentheses in Table 2.19 and are 
also in good agreement with the actual distances to which the compounds eluted with the r 
full gradient. Relative elution distances can then be computed using the elution distances 
calculated from the elution indices obtained on the expanded gradients and the elution 
distance of the parent compound from the full gradient. The values obtained are shown in 
Table 2.20. 
Very good agreement was found between the estimated RED values and those obtained 
experimentally on the full gradient. These data show that expanded gradients can be used 
to increase resolution, and also that the elution data can be related back to the full 
gradient by use of elution indices. Meaningful RED values can thus be calculated. This 
method can be applied to the linear gradients because the linearity provides a function to 
relate different gradients to each other. This would be much more difficult to achieve on 
universal gradients and thus gives another advantage to the linear gradients. 
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Figure 2.30 
Interpolation of elution indices from graphs of elutropic strength against 
development distance for three linear MMD gradients 
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Table 2.19 
Elution indices calculated from linear MMD gradients for glucuronide and sulphate 
metabolites 
Gradient Linear Regression Equation 
MMD Scheme 3 Y= -0.00873X + 0.780510 
MMD Scheme 7 Y= -0.00152X + 0.731717 
MMD Scheme 9 Y= -0.00254X + 0.732861 
Y= Elution Index 
X= Distance (mm) 
Elution Index (Predicted Distance (mm) on MMD Scheme 3) 
Compound 
N glucuronide 
N sulphate 
Pa glucuronide 
Pa sulphate 
pp glucuronide 
pp disulphate 
4-MeU glucuronide 
4-MeU sulphate 
Ep glucuronide 
Ep sulphate 
MMD Scheme 3 MMD Scheme 7 MMD Scheme 9 
0.666 (13.1) 
0.592 (21.6) 
0.685 (10.9) 
0.633 (16.9) 
0.685 (10.9) 
0.592 (21.6) 
0.689 (10.5) 
0.642 (15.9) 
0.670 (12.7) 
0.653 (14.6) 
0.697 (9.6) 
0.606 (20.0) 
0.710 (8.1) 
0.654 (14.5) 
Chl glucuronide 0.672 (12.4) 
N: Naphthol 
Pa : Paracetamol 
Ph : Phenol 
Pp : Phenolphthalein 
0.695 (9.8) 
0.652 (14.7) 
0.686 (10.8) 
0.665 (13.2) 
0.691 (10.2) 
0.638 (16.3) 
0.679 (10.1) 
0.655 (14.4) 
0.679 (11.6) 
0.693 (10.0) 
0.642 (15.9) 
0.685 (10.9) 
0.662 (13.6) 
0.689 (10.5) 
0.602 (20.2) 
0.677 (10.0) 
0.645 (15.5) 
0.677 (11.9) 
4-MeU: 4-Methylumbelliferone 
Ep : Epiandrosterone 
Chl : Chloramphenicol 
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Table 2.20 
RED values for conjugated metabolites estimated from elution indices on expanded 
linear MMD gradients compared with full gradient values 
RED Values 
Compound MMD Scheme 3 MMD Scheme 7 MMD Scheme 9 
N glucuronide 0.197 0.164 0.164 
N sulphate 0.325 0.255 0.325 
Pa glucuronide 0.234 0.218 0.223 
Pa sulphate 0.354 0.327 0.354 
Pp glucuronide 0.229 0.195 0.197 
Pp disulphate 0.264 0.238 0.245 
4-MeU glucuronide 0.163 0.173 0.179 
4-MeU sulphate 0.340 0.297 0.340 
Ep glucuronide 0.126 0.157 0.155 
Ep sulphate 0.225 0.223 0.240 
Chl glucuronide 0.261 0.244 0.250 
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The elution distances from indoles, coumarins and biphenyls obtained using expanded 
gradients, and the data from ondansetron and its metabolites on an expanded gradient 
with TEA were treated in the same way as the conjugate data, and predicted elution 
distances were computed. These are compared with the measured values in Table 2.21. 
The data from the expanded gradients for the indoles, coumarins and biphenyls were in 
good agreement with each other, but tended to predict smaller elution distances than were 
obtained in practice. The reason for this might be that for these analyses the HPTLC 
plates could not be placed in a vacuum to remove the solvent after each step because 
some of the compounds under examination would have evaporated under those 
conditions. This would have meant that traces of the more polar solvents (in particular 
methanol) would still have been present on the plate and might have caused an increase in 
migration of the compounds. The expanded gradients only used a single step containing 
methanol to concentrate the sample spots initially, thus on these systems limited 
contamination with methanol would have occurred, whereas MMD Scheme 3 used 
methanol for six steps. 
The predicted elution distances for ondansetron and its metabolites were in broad 
agreement with those obtained experimentally. The data therefore support the use of 
elution indices to predict elution distances on the full gradient particularly for compounds 
that are retained strongly. The use of expanded gradients for the less polar compounds 
may be limited to obtaining increased resolution in order to determine the number of 
components present in areas of the chromatogram where a number of peaks elute close to 
each other. 
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Table 2.21 
Elution distances calculated from elution indices compared with measured elution 
distances for indoles, coumarins, biphenyls and ondansetron metabolites 
Gradient 
MMD Scheme 5 
MMD Scheme 6 
Y= Elution Index 
Linear Regression Equation 
Y= -0.00612X + 0.539 
Y= -0.00312X + 0.373 
X= Distance (mm) 
Compound MMD Scheme 3 MMD Scheme 5 MMD Scheme 6 
1-Methylindole 69.2 62.7 74.4 
Indole 75.2 69.7 66.8 
5-Hydroxyindole 68.8 61.1 58.2 
5-Methoxyindole 74.0 65.8 67.4 
6-Methylindole 76.0 70.6 67.4 
Indole-6-carboxylic acid 61.2 55.1 53.2 
3-Methylindole 76.8 71.7 68.3 
Indole-3-carboxylic acid 63.2 56.5 53.4 
3-Indolemethanol 61.6 60.5 60.4 
Coumarin 72.0 65.0 62.6 
4-Hydroxycoumarin 50.0 48.2 51.8 
7-Hydroxycoumarin 67.2 59.4 56.9 
7-Methoxycoumarin 70.4 62.7 60.9 
Biphenyl 76.4 Not Detected 78.0 
2-Phenylphenol 78.0 69.4 67.2 
4-Phenylphenol 74.0 65.2 61.8 
4'4-Biphenol 76.4 59.6 56.3 
Compound 
Ondansetron 
N-desmethyl ondansetron 
6-OH ondansetron 
7-OH ondansetron 
8-OH ondansetron 
6-OH, N-desmethyl ondansetron 
7-OH, N-desmethyl ondansetron 
MMD Scheme 3 MMD Scheme 9 
with 1% TEA with 1% TEA 
21.2 20.4 
17.6 18.5 
17.2 19.2 
14.8 17.8 
18.0 17.8 
15.6 17.6 
14.0 16.2 
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The elution distances predicted for ondansetron, ranitidine and their metabolites were 
used to calculate RED values for the metabolites which are shown in Table 2.22. The 
data for the hydroxylated metabolites of ondansetron were in general agreement with the 
data obtained from the other compounds undergoing aromatic hydroxylation, however the 
data showed that the position of substitution relative to other groups within the ring 
system affects the magnitude of the RED value. When the hydroxyl group was in closer 
proximity to the indole nitrogen it appeared to cause a greater change in the retention 
relative to ondansetron. This may have been due to the electron donating properties of 
the basic indole nitrogen suppressing the delocalisation of the hydroxyl group electrons 
when the two groups were in close proximity as was the case for the 8-hydroxy 
metabolite. 
N-demethylation of ondansetron had little effect on the elution distance (RED=0.907), 
whereas the N-demethylated metabolite of ranitidine had a RED value of 0.67. This 
difference was due to the differing extents to which the molecular structures can 
accommodate the increase in basicity caused by N-demethylation. In the case of 
ondansetron, the electrons of the basic indole nitrogen are delocalised within the aromatic 
ring structure, whereas in ranitidine the amine is essentially aliphatic in nature and its 
electrons are therefore available for interaction with the silica surface. 
The data obtained in the present studies have shown that certain metabolic 
transformations caused characteristic changes in elution distance with linear MMD 
systems in the rank order aromatic hydroxylation and dealkylation < aliphatic 
hydroxylation and aromatic oxidation to carboxylic acids « sulphate conjugation < 
glucuronide conjugation. Manual multiple development proved reliable and fairly 
reproducible, however the technique is very time consuming and tedious for the operator. 
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Table 2.22 
RED values from predicted elution distances for metabolites of ondansetron and 
ranitidine 
Compound RED Value 
N-desmethyl ondansetron 0.907 
6-OH ondansetron 0.941 
7-OH ondansetron 0.872 
8-OH ondansetron 0.843 
6-OH, N-desmethyl ondansetron 0.862 
7-OH, N-desmethyl ondansetron 0.794 
N-desmethyl ranitidine 0.664 
Ranitidine N-oxide 0.718 
Ranitidine S-oxide 0.670 
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Automated multiple development was more reproducible because human error was 
removed, and was far less tedious to operate than MMD. The main disadvantage of the 
AMD system is its inability to mix solvents to order. The mode by which it operates 
makes it ideal for universal systems, however it is difficult to produce linear gradients, 
and the need to miss out steps which were not required made it cumbersome to use. A 
version of the instrument which mixes solvents to any specification would be most 
useful. 
H-iPTLC has been shown to have the sensitivity required to detect very small amounts of 
material, however the background from plasma, and urine especially, was high. The high 
background from the biological matrices coupled with the limited volumes of material 
which could be applied to the plate meant that paracetamol and its metabolites could not 
be detected in urine up to a concentration of 10µg/ml, and in plasma only two 
components were detected. Thus the ideal screening method comprising application of 
the biological fluid followed by chromatography and detection would be impractical for 
the majority of compounds. The exception to this may be compounds which have 
ultraviolet absorption at wavelengths in excess of 300nm or which are fluorescent. 
However, it would need to be assumed that these properties of parent compound were 
preserved in metabolites which may not be the case. Compounds present at higher 
concentrations may be detected after direct application of the biological matrix, but 
relatively large components may be missed, and the large salt deposit at the origin of the 
HPTLC plate is likely to affect the chromatography and possibly invalidate some of the 
elution distance data obtained. 
It is therefore necessary to produce a purer and more concentrated solution of drug and 
metabolites from the biological fluids which can be applied to the HPTLC plate. This 
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could take the form of an extract which might be prepared in a number of ways. 
However if the aims of this thesis are to be achieved it is necessary for the extraction to 
be of a- general nature so that all drug-related material is made available for subsequent 
HPTLC analysis. 
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CHAPTER THREE 
EXTRACTION OF DRUGS AND METABOLITES 
FROM BIOLOGICAL FLUIDS 
3.1 Introduction 
An ideal method for the detection of all drug-related material in biological fluids 
following administration of a drug to animals would require no sample pre-treatment or 
clean-up prior to the separation and detection of the compounds of interest. It has been 
found however, that a clean-up step is required in order to remove interfering endogenous 
material and to concentrate samples of plasma and urine before analysis by 
HPTLC/MMD (Chapter 2). There are a number of criteria required of a general clean-up 
procedure. These criteria are listed below. 
1. The clean-up procedure must be sufficiently general to provide recovery of all 
drug-related material. 
2. The procedure must be simple and robust. 
3. The procedure must not use conditions under which drug or metabolites might 
decompose. 
4. Proteins and low molecular weight components which may interfere with 
chromatography and with the detection of drug-related material must be 
removed. 
5. The sample must be collected in a form which facilitates concentration of the 
sample and application to a HPTLC plate for analysis. 
6. The procedure should provide some discrimination between classes of 
compound. 
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In designing a strategy for a general extraction procedure, the physical and chemical 
properties of drugs and their metabolites must be considered alongside the extraction 
techniques available. 
In this chapter, a strategy for the development of a general extraction procedure is 
proposed, and the various options are assessed to determine whether they fulfil the 
requirements for a general extraction procedure. Paracetamol and its glucuronide and 
sulphate conjugates are used as model compounds to carry out the assessment. The 
extraction scheme selected is examined for its general applicability by extracting a range 
of model compounds from plasma, and estimates of detection limits are made by 
comparing chromatograms of extracts from spiked samples with chromatograms from 
controls. Finally, the extraction procedure is assessed for its likely applicability to 
metabolism studies. 
3.1.1 Sample Preparation Methods Used in Metabolism Studies 
It has been suggested that sample preparation-strategy and tactics have to be learned 
largely by experience and "lore" (Martin and Reid, 1981). There has, however, been 
significant development in sample preparation technology in the last decade. With this 
development, the view that robust procedures to isolate components of interest from 
complex matrices can be devised successfully by considering the chemistry of the 
interactions involved has gained greater acceptance (McDowall, 1989). Various reviews 
on sample preparation techniques for biomedical analysis or metabolite isolation have 
been published (Reid, 1976; Martin and Reid, 1981; Lim, 1988; McDowall, 1989): 
nevertheless, in considering a strategy for the development of a general extraction 
procedure it is pertinent to review the sample preparation techniques that have been used 
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previously in drug metabolism studies and biomedical analysis, and to assess them 
against the criteria for the general procedure. The methods available can be classed 
generally as protein precipitation, liquid-liquid extraction and liquid-solid extraction. 
The suitability of these methods are considered in the following sections. 
3.1.1.1 Protein Precipitation 
The most simple approach to sample preparation is protein precipitation, and this may be 
applicable to the analysis of plasma. Proteinacious material can be precipitated from 
plasma by the addition of water miscible solvents such as methanol, acetonitrile, and 
acetone (Woollard, 1984). Acids such as perchloric acid, trichloroacetic acid and tungstic 
acid form insoluble protein salts with proteins at low pH, and proteins may also be 
precipitated by forming insoluble salts with cations such as Cu2+ and Zn2+ in alkaline 
solutions. The benefits and problems which might be associated with these methods are 
considered below. 
The use of acids might result in hydrolysis of labile metabolites, and addition of inorganic 
salts would increase the salt concentration of the samples and might further exacerbate 
interference with the solvent front found during chromatography of untreated plasma and 
urine samples (Chapter 2). These methods are therefore considered to be inappropriate. 
The use of organic solvents might provide a simple approach to sample preparation (i. e. 
the removal of proteins may be sufficient to overcome the problems encountered with 
I-IPTLC/MMD of untreated plasma). In this case however, low molecular weight 
compounds such as salts would not be removed, and the process would result in dilution 
rather than concentration of the sample unless the organic solvent was subsequently 
removed by evaporation. It has also been found that some compounds adsorb onto or 
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co-precipitate with the protein precipitate causing a reduction in recovery. The technique, 
although simple, would not provide discrimination between classes of compound, and 
would not assist in the analysis of urine. In view of the problems perceived, protein 
precipitation is not considered to be an appropriate method of sample preparation to 
pursue for the present studies. 
3.1.1.2 Liquid-liquid Extraction 
Liquid-liquid extraction (LLE) has been the method used most widely for extracting 
drugs and metabolites from biological fluids for many years, and it is only in the last 
decade that its dominance has been challenged. In LLE, the biological fluid is mixed 
with an immiscible organic solvent, and drug-related material is concentrated in either the 
aqueous or organic layer by partition. Ionised molecules tend to remain in the aqueous 
layer whereas non-ionised molecules partition into the organic solvent. The distribution 
of molecules between the aqueous and organic layers is influenced strongly by the pH at 
which the extraction is carried out and the pka of ionisable groups on the molecules. 
Acids are non-ionised (i. e. protonated) at pH values below their pka and are present as 
anions at pH values above their pka. Conversely, bases are present as cations below their 
pka and are non-ionised above their pka. Thus, at low pH, acidic compounds tend not to 
be ionised and would therefore be concentrated in the organic layer, whereas bases which 
would be ionised at low pH would remain in the aqueous layer. The converse would be 
true at high pH. 
Use of LLE as a general procedure for the isolation of drugs and unknown metabolites 
from biological fluids is complicated by wide polarity differences between parent drugs, 
which may be lipophilic in nature, and conjugated metabolites which are usually 
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hydrophilic. Often, drug and its Phase I metabolites can be extracted into a fairly non- 
polar solvent, assuming that the pH conditions are correct,, but this may be complicated if 
an ionisable group is added to the molecule during Phase I metabolism. As discussed in 
Chapter 1 (Section 1.2), the groups which are added during drug metabolism are 
generally anionic, so extraction of samples containing acidic drugs and their metabolites 
is generally straight forward. The complications arise with basic drugs because addition 
of anionic groups leads to the formation of zwitterions. Zwitterions are molecules 
containing an acidic and a basic group which cannot exist in a completely non-ionised 
form at any pH. Thus, a basic molecule which would be extracted into a non-polar 
solvent at high pH, might be oxidised during metabolism to form a carboxylic acid which 
would require a low pH for extraction. An example of this is the metabolite formed by 
oxidation of loxtidine in the rat (Bell, Bradbury, Jenner, Manchee and Martin, 1983). 
Similarly, oxidative deamination of a basic drug can give rise to an acidic metabolite as is 
the case with mescaline in the rat and man (Schreiber, 1970). 
A molecule in its ionised form, despite its high polarity, would not necessarily remain in 
the aqueous layer, but may be sufficiently lipophilic to extract into an organic layer. 
Some sulphate metabolites, although highly polar, are fairly lipophilic and can be 
extracted by LLE (Martin and Reid, 1981). 
Although many schemes have been devised in which drugs and metabolites have been 
extracted from biological fluids using LLE, these have often been specific for the 
particular drug and metabolites under investigation. In most cases conjugated metabolites 
have been identified by the increases in Phase I metabolites observed following enzyme 
or acid hydrolysis of the samples rather than by isolation of the intact conjugated 
metabolites. Thus Kumbs, Genin-Ramakers and 'Mardens-ý (1985) extracted 
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anticonvulsant drugs and their Phase I hydroxylated and epoxide metabolites from plasma 
into ethyl acetate at pH 6.7, Covey, Crowther, Dewey and Henion (1985) isolated 
desmethyl imipramine, imipramine N-oxide, promazine N-oxide, and promazine N-oxide 
sulphoxide by LLE from horse urine into dichloromethane/2-propanol (3/1 v/v) under 
basic conditions and Sistovaris (1983) extracted nomifensine and its Phase I metabolites 
from urine into ethyl acetate at pH 10 after enzyme hydrolysis of the N-glucuronides 
present. Covey et at. (1985) also extracted hydroxy metabolites using the procedure 
described above after enzyme hydrolysis of the glucuronide conjugates. 
If a drug and its Phase I metabolites are extracted successfully, conjugated metabolites 
can often be extracted into less polar solvents such as 1-butanol, ethyl acetate or ethanol- 
ether after acidification of the aqueous layer and addition of inorganic salts such as 
ammonium sulphate. Thus Becket, Beaven and Robinson (1963) used n-butanol to 
isolate N-dedimethylchlorpromazine glucuronide from urine and Irving, Wiseman and 
Hill (1967) used ether-ethanol to extract the 0-glucuronide of N-hydroxy-2- 
acetylaminofluorene from bile. 
LLE is a versatile technique with an extensive range of pH conditions and solvents 
available, giving a large number of possible conditions for extracting drugs and 
metabolites from biological fluids. In seeking a general extraction procedure however, 
the diversity of schemes possible becomes a limitation because for each class of 
compound the choice of solvent is important. Furthermore, LLE does not always provide 
good recoveries, particularly for conjugated metabolites (Tomasic, 1978). 
Although specific LLE techniques used in drug metabolism studies do not lead towards a 
general extraction procedure, the field of toxicological and clinical drug screening may 
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provide schemes which would be of use for drug and metabolite screening. Horning, 
Gregory, Nowlin, Stafford, Lertratanangkoon, Butler, Stillwell and Hill (1974) described 
an isolation procedure, which was a modification of alcohol-potassium carbonate salting 
out procedures developed by Bastos, Kananen, Young, Monforte and Sunshine (1970), in 
which a range of basic and neutral drugs was extracted into ethyl acetate with recoveries 
in the range 84-104% from plasma and urine saturated with ammonium carbonate. 
Ammonium carbonate was used instead of potassium carbonate because it dissolves 
endothermically causing the solution to cool, whereas the potassium salt dissolves 
exothermically producing heat which could cause breakdown of labile metabolites. 
Acidic drugs and metabolites, including glucuronides, were extracted into ethyl acetate or 
chloroform from urine acidified with sulphuric acid to pH 1. This method provided good 
recoveries and some discrimination between classes of compound. It may therefore fulfil 
most of the criteria for a general extraction procedure. 
3.1.1.3 Liquid-Solid Extractions 
Liquid-solid extractions (LSE) can be carried out with a wide range of different materials. 
In LSE, biological fluid samples are passed through a solid matrix onto which molecules 
in solution adsorb, and are thus extracted. The main interactions which occur depend 
upon the nature of the solid matrix, and range from non-polar Van der Waals forces to 
electrostatic interactions. The principles of method development using LSE have been 
documented clearly by Van Home (1985), and the use of these materials in biomedical 
analysis has been reviewed recently by McDowall (1989). 
A wide range of different solid support materials has been used to isolate drugs and 
metabolites from biological fluids either for quantitative analysis by chromatographic or 
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other techniques, or for the purpose of identification. Classical adsorbents such as carbon 
and alumina have been used for many years and have had wide application. Jack, Dean, 
Kendall and Laugher (1980) extracted antihypertensive drugs and their metabolites from 
urine under basic conditions onto a charcoal slurry which was subsequently washed with 
water and then mixed with methanol. The methanol supernatant was analysed by TLC. 
Activated charcoal was also used by Fujimoto and Way (1957) to isolate morphine 
glucuronide from human urine and by Arcos and Lieberman (1965) to extract glucuronide 
conjugates of steroids from urine. Alumina has been used traditionally for the isolation 
of catecholamines because of its selectivity for analytes with vicinal hydroxyl groups 
(Anton and Sayre, 1962). Alumina therefore has specialised uses, and neither alumina or 
charcoal are available currently in a form convenient for routine use in a manner which 
would ensure reproducibility from one extraction to the next. They are not therefore 
considered as possible materials upon which to base a general extraction strategy. 
Non-ionic resins made from high surface area styrene-divinylbenzene copolymers, have 
been found to be useful for the adsorption of organic compounds. The materials have a 
large surface area and seem to be generally applicable as adsorbents for moderately 
hydrophilic organic compounds. One of the earliest uses of this material to isolate 
metabolites was by Fujimoto and Haarstad (1969) when they isolated morphine ethereal 
sulphate from the urine of the chicken and cat, and morphine-3-glucuronide from the 
urine of the rabbit. Fujimoto and Wang (1970) showed that Amberlite XAD-2 resin was 
useful for the extraction of a range of narcotic analgesics from human urine, and 
Weissman, Lowe, Beattie and Demetriou (1971) showed that metabolites of narcotics, 
analgesics, symphatomimetics, hypnotics and sedatives can be isolated using XAD-2 
resin. Recently, Szumilo and Dzido (1992) used XAD-2 resin to isolate tryptamide (a 
compound with potent anti-inflammatory and analgesic activity) and its metabolites, 
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including conjugates, from rat urine. However, the conjugates were identified by 
comparing TLC profiles of extracts before and after enzyme hydrolysis. Non-ionic resins 
have been used extensively to isolate a wide range of drugs and metabolites, particularly 
from urine. The advantage is almost quantitative recovery of organic material, however 
its lack of selectivity makes it essentially a procedure to remove salt and concentrate the 
sample. Thus most of the criteria specified for a general extraction procedure would be 
fulfilled by a non-ionic resin, but there would be no easy discrimination between classes 
of compound. 
Some of the non-specificity of the non-ionic resins could be overcome by use of ion- 
exchange resins, particularly the basic resins, which would preferentially retain 
conjugated metabolites by an anion-exchange mechanism (Tomasic, 1978). The trend 
over the last decade, however, has been towards the use of chemically modified silicas for 
LSE, such as are used for high-performance liquid chromatography (HPLC). These 
materials have the advantage that they are readily available commercially from a number 
of suppliers packed in a form convenient for routine use. The bonded phases available 
have a range of chemical properties which can be utilised to obtain either specific or 
general extractions, and the quality control of the material is such that reproducibility 
from one batch of material to another is obtained. 
The bonded silica material used for sample preparation by LSE is generally based upon 
silica particles with a mean diameter of 40µm compared with 3 or 5µm material that is 
used for packing HPLC columns. The material, 50-500mg, is dry packed into Luer 
tipped polypropylene reservoirs to form a sorbent bed, and held in place between two frits 
as shown in Figure 3.1. For use, the LSE cartridges are mounted on a vacuum manifold 
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Figure 3.1 
Liquid-solid extraction cartridge 
Sample and solvents applied to reservoir 
Sorbent bed 
(50-500mg) 
Luer tipped polypropylene 
reservoir 
Frits 
Eluents passed through sorbent 
bed with the assistance of vacuum. 
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which can hold up to 50 cartridges (Bland, Harrison, Martin and Tanner, 1984). Solvent 
and sample are passed through the sorbent bed by use of the vacuum. The equipment 
used is described more fully in Section 3.2.2. 
The sorbents available for LSE and their properties are summarised in Figure 3.2. These 
range from non-polar octadecyl (C18), which exhibits primarily Van der Waals 
interactions and behaves similarly to the organic layer in liquid-liquid extractions, to 
polar diol or unmodified silica. Sorbents capable of anion- or cation-exchange 
interactions are also available, and most of the sorbents exhibit more than one type of 
interaction. The physical and chemical properties of these sorbents can be used to design 
an appropriate extraction procedure based upon the physical and chemical properties of 
the analytes which are to be isolated, and upon the properties of the matrix from which 
they need to be separated. 
The use of LSE techniques in metabolism studies has been more limited than in routine 
biomedical analysis, possibly because of the variety of traditional methods available, and 
perhaps reflecting the small numbers of samples prepared in metabolism studies 
compared with the high throughput required in routine assays for which LSE cartridges 
are ideally suited (McDowall, 1989). 
Two recent LSE approaches for isolating drugs and metabolites may be applicable to a 
general extraction. These are based upon; (i) use of ion-pairing to retain anionic 
metabolites on a non-polar sorbent followed by sequential elution via an anion-exchange 
material to obtain separate elution of anions of different strength and (ii) use of ion- 
suppression by acidifying the sample to retain anionic components on a non-polar sorbent 
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Figure 3.2 
Physical and chemical properties of commercially available sorbents 
Interactions 
NON-POLAR Primary Secondary 
CIS Octadecyl -Si-C1sH37 Non-polar Polar/CE 
Cs Octyl -Si-CgH17 Non-polar Polar/CE 
C2 Ethyl -Si- C2H5 Non-polar/Polar CE 
CH Cyclohexyl -Si-c Non-polar Polar/CE 
PH Phenyl -Si-O Non-polar Polar/CE 
POLAR 
CN Cyanopropyl -Si- CH2CH2CH2CN Non-polar/Polar CE 
20H Diol -Si- (CH2)3OCH2CH- CH2 Non-polar/Polar CE 
OH OH 
Si Silica -Si- OH Non-polar/Polar CE 
ION-EXCHANGE 
CBA Carboxymethyl -Si- CH2000 - CE Non-polar/Polar 
PRS Sulphonylpropyl -Si- (CH2)3SO3 CE Non-polar/Polar 
5CX Benzenesulphonylpropyl -Si-(CH2)3-0-SO3 CE/Non-polar Polar 
NH2 Aminopropyl -Si-(CH2)3NH2 Polar/AE Non-polar/CE 
PSA N-propylethylenediamine -Si-(CH2)3NH(CH2)2NH2 Polar/AE Non-polar/CE 
DEA Diethylaminopropyl -Si- (CH2)3NH(C2H5)2 Polar/AE Non-polar/CE 
SAX Trimethylaminopropyl -Si- (CH2)3N(CH3)3 AE Polar/Non-polar/CE 
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followed by sequential elution with varying proportions of methanol-water to elute 
components in groups based upon their lipophilicity. These are discussed in more detail 
below. 
Vanluchene and Vandekerckhove (1983) developed a method to isolate free and 
conjugated steroids from serum, tissues, and peritoneal fluids. The fluids were buffered 
to pH 5, and triethylammonium sulphate (TEAS) was added to form ion-pairs with the 
anionic glucuronide and sulphate metabolites. The mixture was then extracted using Sep- 
PakTM C18 cartridges which were washed with buffer prior to eluting the steroids and 
conjugates with methanol. The free and conjugated steroids were then separated from 
each other by a variety of fairly complex liquid-liquid extraction procedures. Thus this 
method provided recovery of all material, but no discrimination between classes of 
compound. In 1988, the same workers used an approach to isolate free and conjugated 
steroids using a combination of C18 and SAX (strong anion-exchange) cartridges 
(Vanluchene and Vandekerckhove, 1988) which is summarised in Figure 3.3. This 
approach afforded recovery of all compounds from the biological fluids, but had the 
additional advantage that the free and conjugated steroids were eluted separately. 
Furthermore the difference in strength of the glucuronide and sulphate anions was 
exploited to elute these two classes of compound separately. Thus discrimination 
between classes of compound was achieved. 
The second approach was used by Wilson and Nicholson (1987). Urine containing 
ibuprofen and its metabolites was acidified with formic acid prior to extraction on a C18 
cartridge. Acidification of the sample suppressed the ionisation of ibuprofen, its acidic 
Phase I metabolites and glucuronide conjugates, making them more lipophilic and able to 
-142- 
Figure 3.3 
Schematic representation of C18/SAX extraction procedure (Vanluchene and 
Vandekerckhove, 1988) 
Methanol (5m1) Water (10m1) 
Sample 0.15M potassium 
(see below) acetate, pH5 (7.5m1) 
Methanol (4m1) Water (5ml 
O. S( ac 
5m1) 
acid Methanol (4m1 ) (2 2x 25m ) 
........... . .......... ............ .......... ......... ............ 
0.25M TEAS (8.4m1) 
0.2M formic acid it 
methanol/water 1: 1 (8., 
1r 
Methanol (4ml) 
l 
1 
1 Free steroids 
Sample: 
Urine (I ml) 
0.5M triethylammonium sulphate (TEAS, 250µl) 
1.5M potassium acetate (100µl) 
Adjusted to pH 5.0 
Steroid glucuronides Steroid sulphates 
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interact non-ionically with the octadecyl groups on the sorbent. The metabolites were 
then recovered from the cartridge in fractions by eluting sequentially with methanol-water 
mixtures containing increasing proportions of methanol. This approach separated 
metabolites into groups based upon their lipophilicity rather than by chemical class as 
was achieved by Vanluchene and Vandekerckhove (1988). Use of ion-suppression may 
however provide a useful alternative to ion-pairing for the initial extraction of drug- 
related material from biological fluids. 
3.1.2 General Extraction Strategy 
In designing a strategy for a general extraction procedure, the physical and chemical 
properties of drugs and their metabolites must be considered alongside the extraction 
techniques available. An evaluation of the methods of sample preparation available, and 
consideration of these against the criteria set out for a general procedure has identified 
three main strategies which would seem appropriate; liquid-liquid extraction using the 
salting out procedure of Horning et al. (1974), and two liquid-solid methods based on the 
work of Vanluchene and Vandekerckhove (1988) and Wilson and Nicholson (1987). 
These are summarised in Figures 3.4-3.6, and the rationale for their selection is discussed 
in the following paragraphs. 
The liquid-liquid salting out procedure is shown in Figure 3.4. The procedure comprises 
two simple extractions designed to isolate basic, neutral and non-polar acidic molecules 
in Extract A and polar acidic molecules in Extract B. Addition of a large concentration of 
salt (ammonium carbonate) to the aqueous phase increases its ionic strength and hence its 
polarity. This tends to decrease the affinity of polar organic compounds for the aqueous 
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Figure 3.4 
Liquid-liquid salting out procedure 
Saturate with ammonium carbonate 
Extract with propan-2-ol 
Centrifuge 
Plasma or urine containing 
salts, proteins and other 
endogenous molecules, drugs 
and metabolites, possibly acidic 
basic and neutral. 
Acidify with HCl 
Extract with ethyl acetate 
Centrifuge 
Organic phase containing 
polar acidic metabolites 
and other acidic compounds 
Remove organic layer (Extract B) 
Dry to residue 
Organic phase containing 
basic, neutral and non-polar 
acidic drugs and metabolites 
plus endogenous components 9 
Remove organic layer (Extract A) 
Dry to residue 
Aqueous phase containing 
salts, denatured protein, 
polar acidic compounds 
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phase and thus allows them to be extracted into the organic phase. All except the most 
polar metabolites are extracted under these conditions. After the initial extraction, 
acidification of the sample suppresses the ionisation of any acidic compounds or 
conjugated metabolites present, increasing their lipophilicity and allowing them to be 
extracted into the organic phase. Thus two extracts are obtained with some 
discrimination between classes of compound by use of a very simple procedure. 
The LSE strategy using ion-pairing, shown in Figure 3.5, employs an initial extraction on 
C18 material followed by a second extraction on an anion-exchange cartridge. The 
anions (acidic, compounds and conjugated metabolites) are made lipophilic by means of 
ion-pairing with TEAS at pH5. These and neutral compounds are retained on the C18 
sorbent by Van der Waals interactions, with basic compounds being retained by a 
combination of Van der Waals and weak cationic interaction with residual silanol groups 
present on the bonded phase (Van Home, 1985). Washing with water elutes salts, other 
polar material and proteins. Elution with methanol from the C18 cartridge onto the 
anion-exchange cartridge elutes all except extremely non-polar material, and disrupts the 
ion-pairs. The resulting anionic components (acidic compounds and conjugated 
metabolites) retain on the anion-exchange cartridge, while the basic and neutral 
molecules pass though to be collected. Elution with methanol and formic acid elutes the 
weak anions (acidic drugs and Phase I metabolites and glucuronides), and subsequent 
elution with methanol containing a high concentration of ammonium acetate elutes any 
remaining material, including sulphates, by competitive displacement from the cationic 
sites on the sorbent by the high concentration of anions present. 
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Figure 3.5 
Liquid-solid extraction procedure using ion-pairing 
(Column conditioning) 
Methanol Water 
(Column conditioning) 
Methanol Water 
,ý -' SAX 
Sample (lml) (Wash) (Elute) 
+TEAS 
+Buffer Water Methanol 
. vvt.. 
ý`. h .. 
11 11 
Retain basic and neutral 
compounds 
Acids retained as ion-pairs 
Salts, proteins, 
small polar 
molecules 
(Elution Steps) 
Methanol/ammonium acetate Methanol/formic acid 
1Il[ .e 
Strong anions: Weak anions: 
Sulphates Carboxylic acids 
Urinary pigments Glucuronides 
Non-anionic compounds 
Basic and neutral drugs 
and metabolites plus 
endogenous compounds 
TEAS = Tricthylammonium sulphate 
- 147 - 
The second liquid-solid strategy using ion-suppression, shown in Figure 3.6, employs an 
initial extraction on C18 material at a low pH, followed by further extraction on an anion- 
exchange cartridge. Addition of formic acid to the biological fluid reduces the pH and 
suppresses the ionisation of the acidic components, including glucuronide and sulphate 
conjugates. These conditions should not be sufficiently harsh to risk breakdown of labile 
conjugates which usually require treatment with strong mineral acids to undergo 
hydrolysis (Tomasic, 1978). Basic compounds will be ionised at the low pH and will 
therefore interact strongly with residual silanol groups on the sorbent by a cation- 
exchange mechanism. These secondary cation-exchange interactions are readily 
disrupted with methanol. Following extraction of all components from the matrix, the 
components are eluted using the same procedure described in the previous strategy. 
3.1.3 Aims of the Present Studies ,. 
The aims of the studies described in this chapter are to assess the strategies for a general 
extraction procedure which have been discussed in the previous sections, to select a 
procedure which fulfils the criteria which have been set out and to examine its general 
applicability to the extraction of a range of model compounds. 
3.2 Experimental 
paracetamol, paracetamol glucuronide and paracetamol sulphate were used as model 
compounds for initial testing of the proposed extraction strategies. These compounds 
were selected because they provided typical examples of a non-acidic drug and two 
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Figure 3.6 
Liquid-solid extraction procedure using ion-suppression 
(Column conditioning) 
Methanol Water 
(Column conditioning) 
Methanol Water 
SAX -ý ý- --l F 
Sample (Iml) (Wash) (Elute) 
+ Formic acid Water Methanol 
11 
Retain acidic and 
II If 
neutral compounds 
Bases retained by cation- 
Salts, proteins, 
exchange on silanols small polar 
molecules 
(Elution Steps) 
Methanolammonium acetate Methanol/formic acid 
Strong anions: Weak anions: 
Sulphates Carboxylic acids 
Urinary pigments Glucuronides 
V 
Methanol cluent: 
Non-anionic compounds 
Basic and neutral drugs 
and metabolites plus 
endogenous compounds 
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anionic conjugated metabolites. This combination was chosen to determine whether the 
extraction strategies would discriminate between classes of compound, and in addition, 
indicate whether drugs and metabolites would be detected against the endogenous 
background in the extracts. 
The MMD Schemes used to develop HPTLC plates which are referred to in this section 
are detailed in Appendix I. 
3.2.1 Liquid-Liquid Extractions 
Liquid-liquid extractions were carried out in accordance with the procedure shown in 
Figure 3.4. Paracetamol and its glucuronide and sulphate conjugates were extracted from 
plasma and urine after a two stage extraction; one saturated with ammonium carbonate, 
and the second after acidification with hydrochloric acid. Ammonium carbonate (200mg) 
was added to a lml sample of plasma or urine and as much as possible was dissolved. 
The saturated biological fluid sample was then extracted with propan-2-ol (2m1) by 
vortex mixing for 2 minutes. After centrifugation, the boundary between the aqueous and 
organic layers was difficult to discern. After removal of the organic layer, the aqueous 
phase was acidified by addition of 300µl concentrated hydrochloric acid, gradually so 
that the evolution of carbon dioxide from the sample was not too vigorous, and the 
acidified sample was then extracted with ethyl acetate (2m1). The extracts were 
evaporated to residue in a Savant Speed Vac concentrator (Stratech Scientific, London, 
UK), the residues were taken up in acetonitrile (l00µ1), and 10µl spots were applied to 
Merck silica gel HPTLC plates (Merck, Poole, UK). The remaining acetonitrile in which 
the extracts had been reconstituted was dried to residue, the residues were taken up in 
methanol (100µl) and l0µl was applied to a HPTLC plate. This was done to investigate 
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whether use of acetonitrile instead of methanol to reconstitute the residues would reduce 
the amount of interfering material taken up without reducing the recovery of drug-related 
material. The extracts were analysed by HPTLC using a reduced MMD procedure which 
had been shown to separate paracetamol and its glucuronide and sulphate conjugates. 
The development steps used are shown below: 
1. Methanol for 1cm 
2. Methanol (4.5) + Ethyl acetate (5.5) for 2.5cm 
3. Methanol (1.4) + Ethyl acetate (8.6) for 4cm 
4. Ethyl acetate (7) + Chloroform (3) for 5.5cm 
After development, the HPTLC plates were scanned from origin to solvent front using a 
Camag TLC Scanner II (BDH, Poole, UK), and material on the plate was detected by 
ultraviolet absorbance at 254nm. The signal output was recorded on a Triläb 2000 
Chromatography Data System (Trivector, Sandy, UK). 
3.2.2 Liquid-Solid Extractions 
Liquid-solid extractions were carried out using Bond ElutTM extraction cartridges (Jones 
Chromatography, Hengoed, UK). Conditioning, washing and eluting solvents, and 
samples, were passed through the sorbent material by use of a vacuum manifold 
underneath which was placed either a waste tray to collect unwanted eluent, or sample 
tubes in which to collect eluents that were required for analysis. The equipment used was 
described by Bland et al. (1984) and is shown schematically in Figure 3.7. 
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3.2.2.1 Reversed-phaseron-exchange combinations 
Initially, paracetamol and its glucuronide and sulphate conjugates were extracted from 
solutions using reversed-phase (C18) and various anion-exchange cartridges (NH2, PSA 
and SAX). Solutions of paracetamol and its glucuronide and sulphate conjugates 
(10µg/ml) were prepared in 10mM sodium acetate buffer (pH6), and Iml aliquots were 
extracted using Extraction Scheme 1, Table 3.1. 
The eluents from sample application and the aqueous wash were collected, and the 
ultraviolet absorption was measured at 254nm to determine whether the analytes were 
present in these solutions. The organic washes and eluents were collected, dried to 
residue, reconstituted in 541 methanol and analysed by HPTLC as described previously. 
A number of molecules which might interfere in a screening method for drugs and 
metabolites are present as endogenous components of plasma or urine (Altman and 
Dittmer, 1974). Some components such as creatinine, hippuric acid, uric acid, urea and 
allantoin may be present in urine at concentrations greater than 10mg/ml and could 
therefore represent major interferences. The fate of these endogenous components during 
extraction on C18 and PSA cartridges placed in tandem using Extraction Scheme 2 
(Table 3.1) was investigated. A solution of each compound (lmg/ml) was made up in 
10mM sodium acetate buffer (pH6), the solutions were extracted, and the concentrations 
of each compound in washes and eluents were measured by ultraviolet absorption at 
220nm against control washes and eluents. 
Control human plasma and control dog urine samples, and samples of the same matrices 
-153- 
Table 3.1 
Extraction Schemes 1 and 2 
Extraction Scheme 1 
100mg Bond E1utTM Extraction Cartridges (C18, NH2, PSA or SAX) 
Wet Methanol (2m1) 
Wet 10mM sodium acetate buffer, pH6 (2m1) 
Apply Sample in buffer (lml) 
Wash 10mM buffer (2m1) 
Wash Hexane (1 ml) 
Elute 3% ammonium acetate in methanol (2m1) 
Extraction Scheme 2 
100mg Bond E1utTM C18 and PSA cartridges placed in tandem 
Wet Independently Methanol (2m1) 
Wet Independently Water (2m1) 
Wet Independently 10mM sodium acetate buffer, pH6 (2m1) 
Place cartridges in tandem (C18 on PSA) 
Apply Sample (lml + 5m1 buffer) 
Wash Buffer (2m1) 
Wash Hexane (2m1) 
Elute Methanol (2m1) 
Elute 3% ammonium acetate in methanol (2m1) 
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spiked with paracetamol and paracetamol conjugates (1,10 and 100µg/ml) were extracted 
on C18/PSA cartridges using Extraction Scheme 2. Similar samples were also extracted 
on C18 cartridges using an ion-pair extraction based on the work of Vanluchene and 
Vandekerckhove (1988) (Extraction Scheme 3, Table 3.2). Eluents were analysed by 
HPTLC/MMD using MMD Scheme 3. Samples of hippuric acid and urea were also 
applied to the plate to examine whether they would be likely to interfere with the 
detection of drugs and metabolites. 
3.2.2.2 Development of a solid-phase extraction scheme 
It was envisaged that analysis of relatively large numbers of samples would be required in 
order to develop a robust general extraction procedure, therefore a HPLC system, specific 
for paracetamol and its conjugated metabolites, was used to analyse extracts prepared 
from plasma and urine. HPLC was chosen for this work because samples could be 
analysed automatically, whereas HPTLC/MMD required manual operation. An HPLC 
system to separate paracetamol, its glucuronide and sulphate was developed based on a 
method used by Wilson, Slattery, Forte and Nelson (1982). Chromatography was carried 
out at 40' C, using a 5µm UltrasphereTM ODS column (150 x 4.6mm) and a mobile phase 
of 0.1M potassium dihydrogen phosphate containing methanol (4%) and glacial acetic 
acid (0.75%) at a flow rate of lml/min. The compounds were detected by ultraviolet 
absorbance at 248nm. Baseline resolution of the three components was achieved with 
retention times of 222,342, and 549 seconds for the glucuronide, sulphate and 
paracetamol respectively. 
Initially, the extracts which had been prepared and analysed previously by HPTLC 
(Sections 3.2.1 and 3.2.2.1) were re-assayed using HPLC. 
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Table 3.2 
Extraction Schemes 3 and 4 
Extraction Scheme 3 
100mg Bond E1utTM C18 Cartridges 
Wet Methanol (5m1) 
Wet Water (10ml) 
Wet 0.15M potassium acetate buffer, pH5.0 (7.5m1) 
Apply Sample (1m1) + 0.5M triethylammonium sulphate (250µl) 
+ 1.5M potassium acetate (100µd) 
Wash 0.15M potassium acetate buffer, pH5.0 (7.5m1) 
Elute Methanol (4m1) 
Extraction Scheme 4 
100mg Bond ElutTM C18 and SAX cartridges 
Wet Independently Methanol (2m1) 
Wet Independently Water (2m1) 
Wet Independently 10mM sodium acetate buffer, pH6 (2m1) 
Place cartridges in tandem (C18 on SAX) 
Apply Sample (lml + 5m1 buffer) 
Wash Buffer (2m1) 
Wash Hexane (2m1) 
Elute Methanol (2m1) 
Elute 3% ammonium acetate in methanol (2m1) 
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Samples of plasma and urine spiked with paracetamol and conjugates at 10 and 100µg/ml 
were extracted using tandem C18/PSA and C18/SAX cartridges (Extraction Schemes 2 
and 4). The extracts were analysed by HPLC. 
The effect of sample dilution on the extraction efficiency was investigated. Plasma and 
urine samples spiked with paracetamol and conjugates at 10µg/ml, and control samples, 
undiluted and diluted 1: 1 or 1: 5 with buffer, were extracted using Extraction Scheme 2. 
The extracts were analysed by HPLC. 
One reason for the difficulty experienced with extracting glucuronides from biological 
matrices by ion-exchange methods may be the high concentrations of competitive strong 
anions in plasma and urine such as citrates, succinates, fumarates, and maleates. These 
strong anions can be precipitated from solution by the formation of insoluble lead salts 
when lead acetate is added, and thus be removed from solution. A solution of lead 
acetate (284mg/ml) was prepared based on estimates of the anion concentrations likely in 
plasma and urine respectively, and was added to plasma and urine in 10µ1 aliquots. The 
samples were mixed and centrifuged between addition of aliquots, the supernatant was 
removed and the process was repeated until no further precipitate was formed. Volumes 
required for complete precipitation of the anions were 70µl and 40µl for plasma and urine 
respectively. 
Plasma and urine samples spiked with paracetamol and metabolites at 10 and 100µg/ml 
were treated with lead acetate and extracted using Extraction Scheme 2. The extracts 
were assayed by HPLC. The urine extracts were re-analysed separately with 30 minute 
run times because of late eluting peaks. 
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Plasma and urine samples spiked with paracetamol and metabolites at 10 and 100µg/ml 
were extracted, with and without precipitation of the anions, on C18 cartridges using ion- 
suppression based upon the work of Wilson and Nicholson (1987) (Extraction Scheme 5, 
Table 3.3). The extracts were analysed by HPLC. 
Bond Elut CertifyTM II, a combined non-polar and anion-exchange phase, is a new mixed 
mode sorbent material recently introduced by Analytichem International (Harbor City, 
US), and has been used for the isolation of 1 1-nor-A-9-tetrahydrocannabinol-9-carboxylic 
acid from human urine (Dixit and Dixit, 1990). A series of extractions using ion- 
exchange and ion-suppression strategies were carried out on Bond Elut CertifyTM II 
cartridges using plasma and urine spiked with paracetamol and metabolites at 10µg/ml 
(Extraction Schemes 6-9, Tables 3.3-3.5). The extracts were analysed by HPLC. 
3.2.2.3 Analysis of extracts by HPTLC/MMD 
Bond Elut CertifyTM II extracts of plasma and urine were analysed using HPTLC/MMD. 
Spots (50,5% of the extract) were applied to the plate and development was carried out 
using MMD Scheme 3. Further analyses were carried out using MMD Scheme 9 (1µl, 
1% of the extract applied) and MMD Scheme 7 (0.5µl, 0.5% of the extract applied). 
Plasma spiked with paracetamol and metabolites at lOpg/ml was extracted and eluted 
with; (i) methanol (2ml), (ii) methanol containing 0.5% formic acid (2m1) and (iii) 5% 
ammonium acetate in methanol (2ml) (Extraction Scheme 10, Table 3.5). The extracts 
were analysed by HPTLGMMD using MMD Scheme 3 and were compared with extracts 
from control plasma prepared using the same conditions. 
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Table 3.3 
Extraction Schemes 5 and 6 
Extraction Scheme 5 
100mg Bond E1utTM C18 Cartridge 
Wet Methanol (2m1) 
Wet Water (2m1) 
Apply Sample + 10µl formic acid 
Wash Water (lml) 
Elute Methanol (2m1) 
Extraction Scheme 6 
130mg Bond Elut CertifyTM II Cartridge 
Wet Methanol (4m1) 
Wet Water (4m1) 
Wet 10mM sodium acetate buffer, pH 6 (2m1) 
Apply Sample (lml) 
Wash 10mM sodium acetate buffer, pH 6 (2m1) 
Elute Methanol (2m1) 
Elute 5% ammonium acetate in methanol (2m1) 
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Table 3.4 
Extraction Schemes 7 and 8 
Extraction Scheme 7 
130mg Bond Elut CertifyTM II Cartridge 
Wet Methanol (4m1) 
Wet Water (4m1) 
Wet 10mM sodium acetate buffer, pH 6 (2m1) 
Apply Sample (1m1) previously treated with lead acetate 
Wash 10mM sodium acetate buffer, pH 6 (2m1) 
Elute Methanol (2m1) 
Elute 5% ammonium acetate in methanol (2m1) 
Extraction Scheme 8 
130mg Bond Elut CertifyTM II Cartridge 
Wet Methanol (4m1) 
Wet Water (4m1) 
Apply Sample (lml) + lOµ1 formic acid 
Wash Water (2m1) 
Elute Methanol (2m1) 
Elute 5% ammonium acetate in methanol (2m1) 
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Table 3.5 
Extraction Schemes 9 and 10 
Extraction Scheme 9 
130mg Bond Elut CertifyTM II Cartridge 
Wet Methanol (4m1) 
Wet Water (4m1) 
Apply Sample (lml) + 10µl formic acid 
Wash 0.25M hydrochloric acid (2m1) 
Elute Methanol (2m1) 
Elute 5% ammonium acetate in methanol (2m1) 
Extraction Scheme 10 
130mg Bond Elut CertifyTM II Cartridge 
Wet Methanol (4m1) 
Wet Water (4m1) 
Apply Sample (lml) + formic acid (10µl for urine, 20µl for plasma) 
Wash Water (2m1) 
Elute Methanol (2m1) 
Elute " 0.5% formic acid in methanol (2m1) 
Elute 5% ammonium acetate in methanol (2m1) 
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Four control human plasma samples, a control dog plasma sample and a control rat 
plasma sample were extracted using Extraction Scheme 8 to check for interference from 
endogenous material. Samples of control urine were also extracted, with and without 
precipitation of anions with lead acetate. The extracts were analysed by HPTLC/MMD 
using MMD Scheme 3. 
Control urine was extracted using Extraction Scheme 10 and the methanol/formic acid 
and methanol/ammonium acetate extracts were analysed by HPTLC/MMD using MMD 
Scheme 9. The plate was scanned at different wavelengths to investigate the extent of 
endogenous interference. 
Model compounds, selected from those used in previous studies to investigate multiple 
development (Chapter 2), were spiked into control plasma (1 or 5 pg/ml) and extracted on 
Bond Elut CertifyTM II cartridges using Extraction Scheme 10. (Extracts were not carried 
out using compounds which were either volatile and would be lost during drying to 
residue, or were labile. ) Control plasma and urine samples were also extracted. The 
extracts were dried to residue and reconstituted in methanol (200µ1). Spots (lid) were 
applied to HPTLC plates for analysis, and development was carried out using MMD 
Scheme 3. 
3.3 Results 
During the present studies to investigate extraction strategies, and to develop a procedure 
for a general screening method, single experiments were carried out. Use of single 
experiments was considered appropriate for this work because each experiment was 
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designed to provide guidance for the next without definitive data being required. When a 
suitable system was developed, this would be tested for applicability and reproducibility. 
3.3.1 Liquid-Liquid Extractions 
The recoveries of paracetamol and its glucuronide and sulphate conjugates obtained from 
plasma and urine by liquid-liquid extractions, and analysed by HPTLC/MMD from 
acetonitrile and methanol solutions, are shown in Table 3.6. Recovery of paracetamol 
from plasma into propan-2-ol ranged from 45% at 1 µg/ml to 29% at lOpg/ml and 7% at 
100pg/ml on the acetonitrile plate. Some of the remainder was extracted into the ethyl 
acetate; 13% at 10µg/ml and 5% at 100µg/ml. Similar results were obtained on the 
methanol plate. No glucuronide was detected on the acetonitrile plate, but a small 
amount was detected on the methanol plate from the acid extract of the 100µg/ml plasma 
sample. No glucuronide was detected in any other extracts. The sulphate metabolite was 
extracted from plasma and detected on the acetonitrile plate, but was not detected on the 
methanol plate. Recovery of paracetamol sulphate ranged from 31% at 1 pg/ml to 18% at 
10µg/ml and 6% at 100µg/ml. Some of the remainder was extracted into the ethyl 
acetate; 5% at 10ug/ml and 1% at 100µg/ml. Most of the sulphate conjugate was 
extracted into propan-2-ol even though it would be ionised at the pH of the extraction. It 
is therefore possible that the sulphate was extracted by an ion-pair mechanism. Both 
paracetamol and paracetamol sulphate were present in both the propan-2-ol and ethyl 
acetate extracts, so the extraction provided no discrimination between compound classes. 
Recovery of all components from urine was poor. 
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Table 3.6 
Recoveries of paracetamol and conjugates from plasma and urine by liquid-liquid 
extraction 
Extracts reconstituted in acetonitrile 
Paracetamol Paracetamol Paracetamol 
Sulphate Glucuronide 
Plasma (lpg/ml, IPA) 45% 31% 0 
Plasma (10ug/ml, IPA) 29% 18% 0 
Plasma (100pg/ml, IPA) 7% 6% 0 
Plasma (1pg/ml, EtAc) 0 0 0 
Plasma (10pg/ml, EtAc) 13% 5% 0 
Plasma (100pg/ml, EtAc) 5% 1% 0 
Urine (lpg/ml, IPA) 0 0 0 
Urine (10pg/ml, IPA) 9% 0 0 
Urine (100pg/ml, IPA) 5% 0 0 
Urine (lpg/ml, EtAc) 0 0 0 
Urine (10pg/ml, EtAc) 13% 0 0 
Urine (100pg/ml, EtAc) 4% 0 0 
Extracts reconstituted in methanol 
Paracetamol Paracetamol Paracetamol 
Sulphate Glucuronide 
Plasma (lpg/ml, IPA) 40% 0 0 
Plasma (10pg/ml, IPA) 31% 0 0 
Plasma (100pg/ml, IPA) 7% 0 0 
Plasma (1pg/ml, EtAc) 0 0 0 
Plasma (10pg/ml, EtAc) 13% 4% 0 
Plasma (100)ig/ml, EtAc) 6% 2% 3% 
Urine (lpg/ml, IPA) 0 0 0 
Urine (l0pg/ml, IPA) 6% 0 0 
Urine (100pg/ml, IPA) 3% 0 0 
Urine (1}ig/ml, EtAc) 0 0 0 
Urine (10pg/ml, EtAc) 10% 0 0 
Urine (100pg/ml, EtAc) 1% 0 0 
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Chromatograms from liquid-liquid extracts of control plasma and urine samples 
following HPTLC/MMD after reconstitution in methanol or acetonitrile are shown in 
Figure 3.8. These show that use of acetonitrile instead of methanol to dissolve the 
residues and apply the samples to the HPTLC plate resulted in cleaner chromatograms. 
Thus detection of the sulphate was improved using acetonitrile, however in one extract on 
the methanol plate there was evidence of the glucuronide being present which did not 
appear on the acetonitrile plate. It was not clear therefore whether acetonitrile would 
dissolve all components of interest, particularly glucuronide conjugates. 
3.3.2 Liquid-Solid Extractions 
The data obtained from liquid-solid extractions are presented in the following sections. 
3.3.2.1 Reversed-phaseron-exchange combinations 
Recoveries of paracetamol and its glucuronide and sulphate conjugates obtained from 
buffer solutions on reversed-phase and anion-exchange Bond ElutTM cartridges using 
Extraction Scheme 1 are presented in Table 3.7. Paracetamol and its sulphate conjugate 
were retained on the C18 cartridge, but the glucuronide was not. The NH2 cartridge did 
not retain any drug-related material, however the other anion-exchange cartridges 
retained the conjugates but not paracetamol. Good recovery of all material retained on 
the cartridges, with the exception of paracetamol sulphate on the SAX cartridge, was 
obtained with 3% ammonium acetate in methanol. The data indicate that a combination 
of C18 and PSA cartridges would be suitable to provide an extraction of these 
compounds with discrimination between compound classes, this being possible if a 
methanol elution was added to remove paracetamol before eluting the conjugates. 
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Figure 3.8 
Chromatograms from liquid-liquid extracts of control plasma and urine samples 
following HPTLC/MMD after reconstitution in methanol or acetonitrile 
Acetonitrile 
Plasma (propan-2-ol) 
Plasma (ethyl acetate) 
Urine (propan-2-ol) 
Urine (ethyl acetate) 
Methanol 
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Table 3.7 
Recoveries of paracetamol and conjugates (10µg/ml) from buffer solutions (pH6) on 
reversed-phase and anion-exchange Bond EIutTM cartridges using Extraction 
Scheme 1 
C18 NH2 PSA SAX 
Paracetamol (apply)t 7 53 57 42 
Conjugates (apply)t 24 34 0 0 
Paracetamol (aq wash)t 0 2 0 0 
Conjugates (aq wash)t 0 0 0 0 
Paracetamol (hex wash 0 0 0 0 
Conjugates (hex wash) 0 0 0 0 
Paracetamol (elute)1 56% 0 5% 0 
Glucuronide (elute) t 0 89% 72% 
Sulphate (elute)1 48% 0 105% 0 
t Measurement by UV absorbance (arbitrary units) 
1 Measurement by HPTLC analysis 
Elution was carried out with 3% ammonium acetate in methanol 
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Ultraviolet absorbance measurements of eluents obtained following extraction of 
endogenous plasma and urine components from buffer solutions using Extraction Scheme 
2 are shown in Table 3.8. Creatinine, uric acid and allantoin were not retained on the 
cartridges because they were present in the sample breakthrough and washes. Small 
amounts of uric acid also appeared in the eluent. Urea could not be traced by use of 
ultraviolet absorption measurements because of its very poor ultraviolet absorbance. 
However, for the same reason, it would not interfere with detection on HPTLC/MMD, 
although its presence on the plate might affect the chromatography of other compounds. 
Hippuric acid was not detected in the sample breakthrough or washings, but about 20% of 
the amount applied was detected in the methanol/ammonium acetate eluent. Thus the 
endogenous compound most likely to be extracted from plasma and urine by this 
procedure is hippuric acid. 
Extracts from plasma and urine samples prepared using Extraction Schemes 2 and 3 were 
analysed by HPTLC/MMD, and although drug and conjugates were detected in the 
standards, no evidence of drug-related material was observed in the samples. 
Chromatograms from the control plasma and urine samples extracted using Extraction 
Schemes 2 and 3 are shown in Figure 3.9. There was very little interference on the 
chromatograms of the control plasma extracts from both extraction schemes. The 
chromatograms from the urine extracts had interfering material in the conjugate region of 
the chromatograms particularly, but there was more general interference from the Scheme 
3 extracts. 
Hippuric acid was detected by HPTLC/MMD using MMD Scheme 3 (ED=13.6mm), and 
would therefore interfere with conjugated metabolites. Urea was not detected, which was 
expected because of its poor ultraviolet absorbance. 
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Table 3.8 
Ultraviolet absorbance measurements of eluents from liquid-solid extraction of 
endogenous components from sodium acetate buffer (pH6) 
(Extraction Scheme 2) 
Creatinine Hippuric Urea Uric Allantoin 
Acid Acid 
Std (0.1mg/ml) 0.406a 0.515a 0.058b 0.492 0.632 
Sample + washes 0.403c 0.026 0.012 0.531 0.628 
Eluents 0.001 0.101 -0.008 0.020 -0.005 
a 0.01mg/ml 
b lmg/ml 
C 10-fold dilution 
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Figure 3.9 
HPTLC/MMD chromatograms from liquid-solid extractions of control plasma and 
urine using Extraction Schemes 2 and 3 
Control plasma (Extraction Scheme 2) 
Control plasma (Extraction Scheme 3) 
Control urine (Extraction Scheme 2) 
Control Urine (Extraction Scheme 3) 
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3.3.2.2 Development of a solid-phase extraction scheme 
A typical chromatogram recorded after HPLC analysis of paracetamol, paracetamol 
sulphate and paracetamol glucuronide standards is shown in Figure 3.10. Good 
resolution of the three components was obtained. The extracts previously analysed by 
HPTLC/MMD were re-analysed by HPLC and no drug-related material was detected. 
These results confirmed those obtained by HPTLC. 
The recoveries of paracetamol and its glucuronide and sulphate conjugates from plasma 
and urine following extraction on tandem C18/PSA and C18/SAX cartridges using 
Extraction Schemes 2 and 4 are shown in Table 3.9. The, recovery of paracetamol from 
plasma ranged from about 39% at 10µg/ml to about 28% at 100; cg/ml, and was 
independent of the matrix and the anion-exchange strength of the extraction cartridges. 
The recovery of paracetamol sulphate was variable, ranging between 39% at l0µg/ml and 
9% at 100pg/ml from plasma on PSA cartridges. Similar recoveries were obtained on 
SAX cartridges, therefore it was not clear whether either anion-exchange phase was 
preferable. The glucuronide was extracted poorly from plasma, recoveries ranging 
between 9% and 12%, and was not detected in the urine extracts. 
The data obtained from extractions on tandem C18/PSA cartridges to examine the effect 
of sample dilution on recoveries of paracetamol and its conjugated metabolites are shown 
in Table 3.10. Recoveries of paracetamol from plasma ranged between 71% when 
undiluted to 26% when diluted 1: 5 with buffer. Similar results were obtained from urine. 
Recoveries of the sulphate also decreased with dilution of the sample. Paracetamol 
glucuronide was not detected in any extracts. A reason for the failure of paracetamol 
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Figure 3.10 
HPLC chromatogram of paracetamol and its glucuronide and sulphate metabolites 
paracetamol glucuronide 222.0 
paracetamol sulphate 
342.0 
U 
paracetamol 
HPLC Conditions 
5µm Ultrasphere ODS Column (150 x 4.6mm) 
Mobile phase : 0.1M potassium dihydrogen phosphate containing methanol (4%) 
and glacial acetic acid (0.75%) 
Flow rate : lml/min 
Temperature 40°C 
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Table 3.9 
Recoveries of paracetamol and conjugates from plasma and urine by liquid-solid 
extraction on tandem C18/PSA and C18/SAX cartridges 
(Extraction Schemes 2 and 4) 
Sample Paracetamol Sulphate Glucuronide 
Plasma 10µg/ml (Scheme 2, PSA) 38% 39% 12% 
Plasma 100µg/ml (Scheme 2, PSA) 28% 9% 9% 
Plasma lOµg/ml (Scheme 4, SAX) 40% 16% 12% 
Plasma 100µg/ml (Scheme 4, SAX) 28% 20% 11% 
Urine 1Oµg/ml (Scheme 2, PSA) 38% 0 0 
Urine 100µg/ml (Scheme 2, PSA) 30% 8% 0 
Urine 10µg/ml (Scheme 4, SAX) 39% 0 0 
Urine 100µg/ml (Scheme 4, SAX) 27% 36% 0 
Table 3.10 
Effect of sample dilution on recoveries of paracetamol and conjugates from plasma 
and urine by liquid-solid extraction on tandem C18/PSA and C18/SAX cartridges 
(Extraction Scheme 2. Samples spiked at 10µg/ml) 
Sample Paracetamol Sulphate Glucuronide 
Plasma (undiluted) 71% 22% 0 
Plasma (diluted 1: 1) 50% 13% 0 
Plasma (diluted 1: 5) 26% 12% 0 
Urine (undiluted) 57% 15% 0 
Urine (diluted 1: 1) 44% 15% 0 
Urine (diluted 1: 5) 22% 10% 0 
Diluent was 10mM sodium acetate buffer, pH6. 
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glucuronide to extract, might have been the high concentrations of competitive strong 
anions present in plasma and urine. The anions present would include citrates, 
succinates, fumarates and maleates, and removal of these prior to extraction may be 
advantageous. 
The recoveries of paracetamol and its conjugated metabolites obtained from extractions 
on tandem C18/PSA cartridges following precipitation of the strong anions with lead 
acetate are presented in Table 3.11. Recoveries of paracetamol were similar to those 
obtained with no anion precipitation (Table 3.10). The recoveries of the glucuronide and 
sulphate were improved considerably by use of the precipitation step prior to extraction 
of the samples, and there was less difference in efficiencies between plasma and urine 
than had been observed previously. These data confirmed that extraction efficiencies 
were greater when plasma and urine were applied to the cartridges undiluted as was 
shown previously. 
The recoveries of paracetamol and its glucuronide and sulphate conjugates from plasma 
and urine following extraction with ion-suppression on C18 cartridges using Extraction 
Scheme 5 are shown in Table 3.12. Recoveries of paracetamol ranged from 63% to 87% 
at 10µg/ml and from 45% to 56% at 100µg/ml, and were not affected by anion 
precipitation. Very little conjugated material was retained on the C18 cartridges, with or 
without anion precipitation. It may be that the wash should have been carried out with 
acidified water to maintain the ion-suppression. The results from these and previous 
extractions have indicated that the 100mg Bond ElutTM cartridges did not have sufficient 
capacity for this application because recoveries from the samples with high 
concentrations were often less than those from the samples with low concentrations. 
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Table 3.11 
Effect of anion precipitation on recoveries of paracetamol and conjugates from 
plasma and urine by liquid-solid extraction on tandem C18/PSA cartridges 
(Extraction Scheme 2) 
Sample Paracetamol Sulphate Glucuronide 
Plasma lOµg/ml (undiluted) 73% 73% 56% 
Plasma 100µg/ml (undiluted) 54% -45% 31% 
Plasma lOug/ml (diluted 1: 5) 28% 27% 15% 
Plasma 100µg/ml (diluted 1: 5) 21% 26% 16% 
Urine lOµg/ml (undiluted) 85% 80% 102% 
Urine 100µg/ml (undiluted) 40% 45% 18% 
Urine lOug/ml (diluted 1: 5) 42% 33% 47% 
Urine 100µg/ml (diluted 1: 5) 21% 24% 11% 
Diluent was 10mM sodium acetate buffer, pH6. 
Table 3.12 
Recoveries of paracetamol and conjugates from plasma and urine by liquid-solid 
extraction on tandem C18/PSA cartridges 
(Extraction Scheme 5 with and without anion precipitation) 
Sample Paracetamol Sulphate Glucuronide 
Plasma 10µg/ml 87% 0 0 
Plasma 100µg/ml 56% 5% 0 
Plasma 10µg/ml (Ppt) 86% 0 0 
Plasma 100µg/ml (Ppt) 54% 4% 0 
Urine 10µglml 75% 0 0 
Urine 100µg/ml 51% 4% 0 
Urine 10µg/ml (Ppt) 63% 0 0 
Urine 100ug/ml (Ppt) 45% 0 0 
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The recoveries of paracetamol and its glucuronide and sulphate conjugates from plasma 
and urine following extractions on Bond Elut CertifyTM II cartridges are presented in 
Table 3.13. The ion-exchange mode gave some recovery of all components from plasma 
when the anion precipitation step had been carried out (Extraction Scheme 7), but no 
extraction of the glucuronide, and limited recovery of the sulphate occurred without prior 
anion precipitation (Extraction Scheme 6). The extraction efficiencies were similar from 
urine with the exception that glucuronide was not detected with or without anion 
precipitation. 
The ion-suppression mode gave good recovery of all components from both plasma and 
urine when the water wash was used (Extraction Scheme 8). The acid wash used in 
Extraction Scheme 9 reduced the recovery of the conjugated metabolites. Recoveries of 
paracetamol sulphate were greater from urine using ion-suppression, which may have 
been a function of the pH at which the extraction was carried out. Plasma may require 
addition of more formic acid to reach the same pH obtained by adding 10µi formic acid 
to urine. 
3.3.2.3 Analysis of extracts by HPTLC/AMD 
The recoveries of paracetamol and its conjugated metabolites from plasma and urine 
obtained by HPTLC/MMD analysis of Bond Elut CertifyTM II extracts using ion- 
exchange (Extraction Scheme 7) and ion-suppression (Extraction Scheme 8) are shown in 
Table 3.14. During the early MMD development steps using MMD Scheme 3, the 
extract material applied to the plate did not wet, leading to the formation of irregular 
solvent fronts. This was particularly severe with the methanol/ammonium acetate 
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Table 3.13 
Recoveries of paracetamol and conjugates from plasma and urine by liquid-solid 
extraction on Bond Elut CertifyTM II cartridges using Extraction Schemes 6 to 9 
(Samples spiked with paracetamol and conjugates at 10µg/ml) 
Analysis by HPLC 
Plasma 
Extraction Paracetamol Sulphate Glucuronide 
Scheme 
MeOH McOH/NH4Ac MeOH McOH/NH4Ac MeOH McOH/NH4Ac 
6 50% 0 4% 14% 0 0 
7 52% 0 0 45% 2% 19% 
8 53% 0 0 72% 0 52% 
9 49% 0 5% 19% 12% 0 
Urine 
Extraction Paracetamol Sulphate Glucuronide 
Scheme 
MeOH McOH/NH4Ac MeOH McOH/NH4Ac MeOH McOH/NH4Ac 
6 61% 0 5% 0 0 0 
7 56% 0 6% 75% 0 0 
8 56% 0 0 95% 0 53% 
9 33% 0 0 16% 3% 0 
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Table 3.14 
Recoveries of paracetamol and conjugates from plasma and urine by liquid-solid 
extraction on Bond Elut CertifyTM II cartridges using Extraction Schemes 6 to 9 
(Samples spiked with paracetamol and conjugates at 10µg/ml) 
Analysis by HPTLC/MMD 
Plasma 
Extraction Paracetamol Sulphate Glucuronide 
Scheme 
MeOH McOH/NH4Ac MeOH McOH/NH4Ac MeOH McOH/NH4Ac 
7 92% 00000 
8 94% 00 80% 0 58% 
Urine 
Extraction Paracetamol Sulphate Glucuronide 
Scheme 
MeOH MeOH/NH4Ac MeOH McOH/NH4Ac MeOH MeOH/NH4Ac 
7 105% 00 NQ 0 NQ 
8 NQ 00000 
NQ Evidence of material present, but not quantifiable because of interference. 
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extracts, and may have been due to local overloading of the silica layer. Nevertheless, 
paracetamol was detected at the concentrations expected from all extracts except the urine 
extract from the ion-suppression extraction (Extraction Scheme 8). The conjugates were 
detected in the ion-suppression extracts from plasma, but not in the ion-exchange 
extracts. No conjugates were detected in the urine extracts. The plasma control extracts 
contained little interfering material, but the urine extracts contained more endogenous 
material, especially the extracts obtained using the ion-suppression mode. 
The recoveries of paracetamol and its conjugated metabolites obtained from the same 
samples following HPTLC/MMD analysis using MMD Schemes 9 and 7 are shown in 
Table 3.15. There was little disturbance of the solvent front when 1% of the extract was 
applied, and no disturbance when 0.5% was applied. MMD Scheme 9 allowed 
paracetamol and paracetamol sulphate to be detected in all the extracts, and MMD 
Scheme 7 enabled paracetamol glucuronide to be detected in extracts obtained using the 
ion-suppression mode. These data demonstrated that further HPTLC/MMD analyses 
using shallow gradients may be required to detect drugs and metabolites in urine. 
Chromatograms from different eluents obtained following extraction of plasma spiked 
with paracetamol and its conjugated metabolites on Bond Elut CertifyTM II cartridges 
showed that paracetamol was eluted in the methanol eluent, paracetamol glucuronide was 
eluted in the formic acid/methanol eluent, and paracetamol sulphate was eluted in the 
ammonium acetate/methanol eluent. 
Examples of HPTLC/MMD chromatograms obtained from extracts of control human, 
dog and rat plasma on Bond Elut CertifyTM II cartridges are shown in Figure 3.11. 
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Table 3.15 
Recoveries of paracetamol and conjugates from plasma and urine by liquid-solid 
extraction on Bond Elut CertifyTM II cartridges 
(Samples spiked with paracetamol and conjugates at 10µg/ml) 
Analysis by HPTLC/MMD 
MMD Scheme 9 
Extraction Paracetamol Sulphate Glucuronide 
Scheme 
McOH McOH/NH4Ac MeOH McOH/NH4Ac MeOH McOH/NH4Ac 
Plasma (7) 74% 0 0 63% 0 0 
Plasma (8) 90% 0 0 109% 0 67% 
Urine (7) 47% 0 0 61% 0 0 
Urine (8) NQ 0 0 62% 0 0 
MMD Scheme 7 
Extraction Paracetamol Sulphate Glucuronide 
Scheme 
McOH McOH/NH4Ac McOH MeOH/NH4Ac MeOH McOH/NI14Ac 
Plasma (7) SF SF 0 61% 00 
Plasma (8) SF SF 0 111% 0 65% 
Urine (7) SF SF 0 NQ 00 
Urine (8) SF SF 000 65% 
NQ Evidence of material present, but not quantifiable because of interference. 
SF Material on solvent front. 
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Figure 3.11 
HPTLC/MMD chromatograms from Bond Elut CertifyTM II extracts of control 
plasma 
Methanol eluent 
Human plasma 1 
Human plasma 2 
Rat plasma 
Dog plasma ' 
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Methanollammonium acetate eluent 
The extracts of control plasma samples gave similar chromatograms with no species 
having endogenous components which were not present in the others except for one 
component in the dog plasma methanol/ am acetate eluent. Chromatograms from control 
urine are shown in Figure 3.12, and show that urine contained greater amounts of 
interfering material than plasma, however no advantage was obtained by precipitating the 
anions with lead acetate prior to extracting the samples. 
Chromatograms obtained after analysis of methanol/formic acid and 
methanoliammonium acetate eluents from Bond Elut CertifyTM II extracts of urine by 
HPMC/MMD using MMD Scheme 9 are shown in Figures 3.13 and 3.14. The majority 
of the interfering material was eluted in the methanol/formic acid and would therefore 
compromise the detection of glucuronide metabolites if they also eluted in the same 
eluent. Use of higher wavelengths, especially 280nm or above, reduced the amounts of 
interfering material detected, but whether these wavelengths could be used would depend 
upon the nature of the compounds being examined. 
The recoveries of model compounds from plasma obtained using Extraction Scheme 10 
on Bond Elut CertifyTM II cartridges are shown in Table 3.16, and chromatograms are 
presented in Figures 3.15-3.19. All compounds tested were extracted from plasma with 
recoveries of 45% or greater (except phenolphthalein disulphate which was not detected), 
and most compounds had recoveries in excess of 90%. Weakly acidic compounds 
containing carboxylic acid groups such as may be present on acidic drugs or Phase I 
metabolites, and glucuronide conjugates were eluted in methanol/formic acid with the 
exception of indole-3-carboxylic acid, and sulphates were eluted in methanol/ammonium 
acetate. This provided discrimination between classes of compound as required by the 
criteria for a general extraction procedure. 
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Figure 3.12 
HPTLC/MMD chromatograms from Bond Elut CertifyTM II extracts of control 
urine 
Methanol/ammonium acetate eluent (without anion precipitation) 
Methanol/ammonium acetate eluent (with anion precipitation) 
-183- 
Methanol eluent (without anion precipitation) 
Methanol eluent (with anion precipitation) 
Figure 3.13 
HPTLC/MMD chromatograms from Bond Elut CertifyTM II extracts of control dog 
urine 
Methanolformic acid eluent 
im 
32Qnm 
Methanol/ammonium acetate eluent 
m 
m 
Paracetamol glucuronide and 
sulphate E--- paracetamol glucuronide (1 µg), equivalent to 
200µg/m1 sample (230nm) 4--- paracetamol sulphate 
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Figure 3.14 
HPTLC/MMD chromatograms from Bond Elut CertifyTM II extracts of control rat 
urine 
Methanollformic acid eluent Methanol/ammonium acetate eluent 
ýn 
In 
VIII 
320nm 
Paracetamol glucuronide and 
sulphate (1µg), equivalent to 
200gg/ml sample (230nm) 
paracetamol glucuronide 
paracetamol sulphate 
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Table 3.16 
Recoveries of model compounds from plasma by liquid-solid extraction on Bond 
Elut CertifyTM II cartridges and analysis by HPTLC/MMD 
(Compounds above break were spiked at 50µg/ml, those below were spiked at 10µg/ml) 
Compound Methanol McOH/Formic Acid McOH/NH4Ac 
Elution Elution Elution 
4-Hydroxycoumarin - 119 - 
7 -Hydroxycoumarin 109 - - 
4 4-Biphenol 96 - - 
Aspirin - NQ - 
Salicylic Acid - 129 - 
Gentisic Acid - 45 - 
5-Hydroxyindole 72 - - 
Indole-3-carboxylic acid 95 - - 
3-Indolemethanol 87 - - 
Ondansetron 96 - - 
N-desmethyl ondansetron 62 - - 
7-Hydroxy-N-desmethyl ondansetron 128 - - 
4-Methylumbelliferone (4MeU) 109 - - 
4-MeU glucuronide - 74 - 
4-MeU sulphate - - 109 
Chloramphenicol 101 - - 
Chloramphenicol glucuronide - 101 - 
Naphthol 173 - - 
Naphthol glucuronide - 103 - 
Naphthol sulphate - - 68 
Paracetamol 66 - - 
Paracetamol glucuronide - 78 - 
Paracetamol sulphate - - 76 
Phenolphthalein 103 - - 
Phenolphthalein glucuronide - 97 - Phenolphthalein disulphate - - 
NQ: Not quantifiable because of interference in control plasma chromatogram. 
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Figure 3.15 
HPTLC/MMD chromatograms of methanol eluents from Bond Elut CertifyTM II 
extracts of model compounds from plasma 
7-hydroxycoumarin (50µg/m1) 
7-hydroxycoumarin 
4,4 "biphenol (50µg/m1) 
4,4 -biphenol 
5-hydroxyindole 
3-indole carboxylic acid (50µglm1) 
3-indole carboxylic acid 
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Control plasma 
5-hydroxyindole (50µg/ml) 
Figure 3.16 
HPTLC/MMD chromatograms of methanol eluents from Bond Elut CertifyTM II 
extracts of model compounds from plasma 
4-Methyl umbelliferone (IOpg/ml) 
< 4-methyl umbelliferone 
naphthol 
Control plasma Phenolphthalein (IOµg/ml) 
- phenolphthalein 
Chloramphenicol (l0µg/ml) 
chloramphenicol 
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Control plasma 
Paracetamol (10µg/ml) Naphthol (1Ogg/ml) 
Figure 3.17 
HPTLC/MMD chromatograms of methanol and methanol/formic acid eluents from 
Bond Elut CertifyTM II extracts of model compounds from plasma 
Control plasma (300nm) Ondansetron (IOµg/ml) 
N-desmethyl ondansetron (IOgg/m1) 7-Hydroxy-N-desmethyl ondansetron (1Oµg/m1) 
Methanolfonnic acid eluents 
Control plasma Aspirin (50µg/ml) 
Gentisic acid (50µg/ml) 
-A-----' 
4-Hydroxy coumarin (50µg/ml) 
f 
4 Peak due to model compound 
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Salicylic acid (50µg/m1) 
Figure 3.18 
HPTLC/MMD chromatograms of methanol/formic acid eluents from Bond Elut 
CertifyTM II extracts of model compounds from plasma 
Control plasma (human) 
4-Methylumbelliferone glucuronide (10µg/m1) 
Paracetamol glucuronide (10µghmml) 
Control plasma (rat) 
Naphthol glucuronide (lOµgfml) 
E rear. due to model compound 
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Chloramphenicol glucuronide (l0µg/ml) 
Control plasma (human) Control plasma (dog) 
Phenolphthalein glucuronide (10µg/m1) 
Figure 3.19 
HPTLC/MMD chromatograms of methanol/ammonium acetate eluents from Bond 
Elut CertifyTM II extracts of model compounds from plasma 
4-Methylumbelliferone sulphate (10µg/ml) Naphthol sulphate (1Ogg/ml) 
4- Peak due to model compound 
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Control plasma (rat) Control plasma (human) 
Control plasma (dog) Control plasma (human) 
Paracetamol sulphate (10µg/mm1) 
Comparison of the elution distances obtained in these studies with those obtained from 
analysis of solutions (Chapter 2). showed that they were broadly similar. This indicated 
that there was no interference with the chromatography caused by any endogenous 
material co-extracted from the plasma. 
Estimated limits of detection for the compounds extracted from plasma are shown in 
Table 3.17. The peak areas of the analytes were calculated by subtraction of the area 
from the plasma control if the analyte co-eluted with an endogenous component. The 
limits of detection were in the range 1-50µg/ml, but most compounds would have been 
detected between 1 and 10pcg/ml. The background interference from urine was much 
greater than from plasma therefore the limits of detection from urine would be higher. 
3.4 Discussion 
The aims of the studies described in this chapter were to assess strategies for a general 
extraction procedure, to select a procedure, and to examine its general applicability. 
A general procedure for the extraction of drugs and metabolites from biological fluids in 
a form suitable for analysis by HPTLC/MMD has been developed. A general liquid- 
liquid extraction method and two liquid-solid strategies have been examined to determine 
their applicability measured against criteria required of a general extraction procedure. 
The data from the liquid-liquid extraction based upon the work of Horning et al. (1974) 
showed that the model compounds were recovered only moderately well from plasma and 
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Table 3.17 
Estimated detection limits of model compounds from plasma after liquid-solid 
extraction on Bond Elut CertifyTM II cartridges and analysis by HPTLC/MMD 
Compound Estimated limit of 
detection (µg/ml) 
4-Hydroxycoumarin 5 
7; Hydroxycoumarin 10 
4 4-Biphenol 4 
Aspirin 50 
Salicylic Acid 20 
Gentisic Acid 25 
5-Hydroxyindole 10 
Indole-3-carboxylic acid 5 
Ondansetron <1 
N-desmethyl ondansetron <1 
7-Hydroxy-N-desmethyl ondansetron <1 
4-Methylumbelliferone (4MeU) 5 
4-MeU glucuronide 10 
4-MeU sulphate 3 
Chloramphenicol 2 
Chloramphenicol glucuronide 2 
Naphthol 10 
Naphthol glucuronide 5 
Naphthol sulphate 3 
Paracetamol 2 
Paracetamol glucuronide 10 
Paracetamol sulphate 5 
Phenolphthalein 5 
Phenolphthalein glucuronide 10 
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poorly from urine. Paracetamol glucuronide did not appear to be recovered from either 
matrix. This was inconsistent with the results reported by Horning et al. (1974) where 
recoveries of 84-104% were obtained for all drugs and metabolites extracted using ethyl 
acetate/ammonium carbonate, and where propan-2-ol/ammonium carbonate was reported 
as being an excellent salt-solvent pair as far as recovery was concerned. The recovery 
obtained with paracetamol and its metabolites was dependent upon the solvent in which 
the extract was reconstituted for application to the HPTLC plate, and was lower in the 
case of methanol which would be expected to dissolve drug-related material more readily. 
This suggested that the methanol extracts contained so much material that compounds 
were held up on the origin of the plate due to local overloading, if they were in fact 
present in the extracts. It was concluded from the investigation that the liquid-liquid 
approach using salting out, although simple, was inappropriate for use in combination 
with HPTLC/MMD largely because of the high background interference. Furthermore, 
because of incomplete extraction in the first stage, this approach did not discriminate 
between classes of compound, although this may have been improved by repeated 
extractions. No attempt was made to develop liquid-liquid extraction further because 
although many combinations of solvent and pH were available, it was considered that 
there was no rational approach based upon robust chemical interactions which could be 
applied in pursuit of a general extraction by this technique. In contrast however, liquid- 
solid extraction provided possibilities for an approach based upon chemical interactions. 
Initial studies with liquid-solid extraction using model compounds in buffer solutions, 
showed that the reversed-phase and ion-exchange interactions discussed in the proposed 
strategy did occur with paracetamol and its sulphate and glucuronide metabolites. It was 
also shown that paracetamol sulphate was retained very strongly by the strong anion- 
exchange (SAX) sorbent due to the strength of the sulphate anion, and that its elution 
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from that sorbent would be difficult. This confirmed that it would be possible to exploit 
the difference in the anionic strengths of glucuronides and sulphates to separate them 
within the extraction procedure as performed by Vanluchene and Vandekerckhove 
(1988). 
First attempts to extract the model compounds from plasma and urine using reversed- 
phase/ion-exchange combinations were unsuccessful. Extracts analysed by both 
HPTLC/MMD and HPLC were shown to contain no drug-related material. Subsequent 
extracts, prepared by the same extraction procedure and analysed by HPLC only, 
however, showed drug-related material to be present, and in further extracts paracetamol 
and paracetamol sulphate were found but paracetamol glucuronide was not. These 
variable data demonstrated the delicate nature of the ion-exchange process when being 
used with matrices of variable ion content and ionic strength such as biological fluids, 
and urine in particular. 
The use of dilution with buffer at pH6, designed to create solutions of uniform and low 
ionic strength, was shown to decrease the extraction efficiency. This indicated that the 
major mechanism by which the model compounds were being retained was not ion- 
exchange, but non-polar, even in the case of paracetamol sulphate. This non-polar 
interaction was enhanced by the high ionic strength of the undiluted biological fluids, 
probably due to a salting out effect. This assumption was given strength because when 
endogenous anions were removed from the biological fluids prior to extraction by 
precipitation as lead salts, the recovery of the conjugated metabolites was increased. This 
indicated that a different retention mechanism, presumably anion-exchange which was 
previously saturated by the high concentration of endogenous anions present in the 
matrix, had been made available. 
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Thus, it was shown that for an extraction procedure to be robust for conjugated 
metabolites in addition to drugs and their Phase I metabolites, it was necessary to remove 
endogenous anions before the anionic drug-related components reached the anion- 
exchange material. This could be achieved by precipitating the anions with lead acetate, 
but its use may also cause precipitation of glucuronide conjugates (Kamil, Smith and 
Williams, 1952; Mitchell, Idle and Smith, 1982) and would therefore be inappropriate for 
a general extraction procedure. Removal of endogenous anions was also found to be 
achieved by temporarily retaining conjugated metabolites by non-polar interaction either 
as ion-pairs or in protonated form at low pH (ion-suppression) while the endogenous 
anions were washed through the extraction cartridge. 
Initial examination of the ion-pair approach was not successful, and because it was 
considered that this approach would be less robust than ion-suppression, further 
investigations were not carried out. Use of ion-suppression on Bond Elut CertifyTM II 
sorbent material was successful, and had the advantage over both ion-exchange and ion- 
pairing of relying upon robust chemical interactions. When the pH of biological fluids 
was reduced to approximately 2.5 by the addition of formic acid, the glucuronide 
conjugates (pKa 3-4) (Martin and Reid, 1981) and endogenous anions such as citrate, 
fumarate and succinate were protonated. Glucuronides were then retained by non-polar 
interaction with the sorbent whereas the strongly hydrophilic endogenous acids remained 
in the aqueous phase and passed through the cartridge. Thus the relatively weak 
glucuronide anions were temporarily retained while the potential competitors for the 
anion-exchange sites on the sorbent material were removed. When the pH was raised 
during the water wash, conjugated metabolites reverted to their anionic state and were 
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retained by an anion-exchange interaction in the absence of competition, and hence were 
not eluted with methanol. 
Incorporation of an acid wash after initial retention of the conjugates, designed to make 
the extraction more robust, eluted the conjugates from the cartridge. The reason for this 
may have been that retention of these polar compounds by non-polar interactions from 
the high ionic strength biological fluids occurred by salting out, but when the ionic 
strength was reduced during washing with dilute hydrochloric acid, they were eluted 
because of their hydrophilicity, and were not retained by anion-exchange because their 
ionisation was suppressed by the low pH conditions. 
The use of HPLC to examine extracts during the development of the general extraction 
procedure enabled a distinction to be made between problems arising because of the 
extractions and those due to HPTLC/MMD such as local overloading of the HPTLC 
plate. Use of HPLC also decreased the time taken to analyse the extracts because 
automation allowed analyses to be carried out overnight. Furthermore, the use of a HPLC 
system designed specifically to separate the compounds of interest reduced the likelihood 
of interference from endogenous components. Although HPLC proved most appropriate 
for this specific application, use of HPTLC/MMD for the general case would still be 
favoured for the reasons discussed in Chapter 1. 
The coupling of the general extraction procedure with HPTLC/MMD was hampered 
initially by problems caused by local overloading of the HPTLC plate at the origin. This 
was overcome by reducing the proportion of the extract that was applied to the plate. The 
optimum application was 0.5% of the extract, equivalent to 5µl from aI ml, biological 
-197- 
fluid sample, which provided a fivefold increase in the amount which could be applied in 
comparison with untreated plasma (Chapter 2). 
The data obtained from HPTLC/MMD of Bond Elut CertifyTM II extracts showed that the 
model compounds were detected more easily in those extracts prepared using the ion- 
suppression mode than in those prepared using the ion-exchange mode. This was in 
agreement with the data obtained by HPLC. The Bond Elut CertifyTM II extraction based 
upon ion-suppression was therefore selected to be tested for general applicability using a 
range of compounds. The recovery data from these compounds showed that the 
extraction procedure which had been developed (Extraction Scheme 10) provided a 
general method suitable for the extraction of a range of different compounds, and for their 
detection by HPTLC/MMD. The method also provided clear and reproducible 
discrimination between classes of compound which was based upon robust chemical 
interactions. Basic and neutral compounds and some weak acids were eluted in 
methanol, glucuronides and carboxylic acids were eluted in methanol/formic acid and 
sulphates were eluted in methanol/ammonium acetate. The only compound which was 
not detected, presumably because it was not eluted, was a disulphate which may have 
required a stronger anion than acetate to displace it from the anion-exchange material. 
All the compounds tested were detected by HPTLC/MMD and estimated limits of 
detection varied between 1 and 50µg/ml, with most compounds having detection limits in 
the range 1-10µg/ml from plasma. Concentrations of drug-related material in excess of 
these concentrations would be expected in the plasma of laboratory animals after oral 
administration of drugs at high dose-levels. This can be considered simplistically using 
the rat as an example. If a drug is administered at a dose-level of 50mg/kg to a rat 
(200g), and is absorbed completely and rapidly from the gastrointestinal tract, the plasma 
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concentration of drug-related material (assuming a blood volume of 10% body weight 
and even distribution of drug-related material between the plasma and red blood cells) 
would be 500µg/ml if distribution was limited to the blood. If the drug-related material 
was generally and evenly distributed throughout the whole body, the concentration would 
be 50µg/ml. If a blood sample is taken soon after maximum concentrations occur, and 
before much material has been excreted, concentrations of drug-related material in plasma 
should be in the range 50-500µg/ml. These concentrations are likely to be detected by 
HPTLC/MMD. 
The background endogenous material from urine was greater than from plasma, 
particularly in the methanol/formic acid and methanol/ammonium acetate eluents making 
the detection of conjugated metabolites in urine difficult. The detection limits for drugs 
and metabolites in urine would be between 10 and 50 times greater than in plasma, but in 
the case of drugs for which renal excretion is a major route, the concentrations of drug- 
related material in urine would be expected to be high. The concentrations which might 
be found in urine can also be estimated using the rat as an example. If a drug is 
administered orally to a rat (200g) at a dose-level of 50mg/kg, is completely absorbed and 
50% of the dose is excreted via the urine (5-10ml in 24h), the concentration of drug- 
related material would be 1-2mg/ml. It is therefore likely under these circumstances that 
drug-related material would be detected in the urine by HPTLGMMD if the number of 
different metabolites formed was not too great. 
A general extraction procedure has been developed which enables drugs and metabolites 
to be extracted from plasma and be detected by HPTLGMMD down to concentrations of 
1-10µg/ml in most cases. The procedure is also applicable to urine, but the limits of 
detection would be higher than for plasma. Furthermore, the extraction procedure 
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provides discrimination between classes of compound, which when combined with 
HPTLC/MMD increases the capability of the screening method to predict the nature of 
metabolites, particularly glucuronides and sulphates. An assessment of the likely 
applicability of the system to drug metabolism studies has indicated that it is likely to be 
applicable for the analysis of plasma and urine after administration of drugs to animals at 
high dose-levels. The system may be more sensitive for compounds which absorb 
ultraviolet radiation at wavelengths in excess of 280nm, but the metabolites formed may 
not retain the characteristics of the parent compound. 
The screening method, combining the extraction procedure developed during the present 
studies and HPTLC/MMD (Chapter 2), requires testing by analysing samples of plasma 
and urine from animals after administration of drugs at high dose-levels. 
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CHAPTER FOUR 
METABOLISM OF IBUPROFEN AND LOXTIDINE IN THE 
RAT AND DOG, AND OF ANTIPYRINE AND 
DIAZEPAM IN THE RAT 
4.1 Introduction 
It has been shown previously (Chapter 2) that high-performance thin-layer 
chromatography (HPTLC) in combination with manual multiple development (MMD) 
provides a useful chromatographic system for the separation of drugs and drug 
metabolites. In addition, it was shown that the elution distance of a metabolite relative to 
the parent drug may be used to indicate the chemical structure of the metabolite. 
An extraction procedure has been developed (Chapter 3) which gave good recovery from 
plasma of the model compounds tested, and differentiation of metabolite types through 
selective elutions. Analysis of spiked plasma samples by HPTLC/MMD, following 
extraction, indicated that limits of detection in plasma and urine would be low enough to 
detect drugs and drug metabolites in samples which may be obtained following high 
doses of drugs to animals. In combination, HPTLC/MMD and the extraction procedure 
may provide a method suitable for use as a general screen for drugs and drug metabolites 
in biological fluids. 
The studies described in this chapter were designed to investigate the utility of the 
screening method by analysing samples of plasma and urine obtained following 
administration of drugs to animals at high dose-levels. 
4.1.1 Criteria for the Selection"of Test Drugs 
The following criteria were considered before selecting drugs which would be suitable to 
use as test substances. 
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1. The metabolism of the drug must be known and documented. 
2. High oral dose-levels of the drug must be tolerated in animals. 
3. The Phase I and II metabolic transformations used in the work with model 
compounds (Chapters 2 and 3) must be encompassed by the range of drugs 
selected. 
4. The drug should not be metabolised via a large number of routes which might 
result in very low concentrations of many compounds in plasma and urine. 
5. Following oral administration of the drug, a reasonable proportion of the dose 
must be excreted via the urine. 
6. Species differences in metabolism must occur in some of the selection. 
7. Not all the compounds selected should interact strongly with silica. 
8. At least one acidic, basic and neutral drug should be selected. 
9. Ideally, the drug should be available radioisotopic ally labelled with 
14C to 
provide an independent means of testing the results obtained from the screening 
method. 
4.1.2 Test Drugs 
Four drugs; ibuprofen, loxtidine, antipyrine and diazepam were selected using the criteria 
described above. Ibuprofen and loxtidine were selected for administration to rats and 
dogs, and the other compounds for administration to rats only. The oral route of 
administration was used so that metabolism would be maximised by the first-pass effect 
and thus provide the highest concentrations of drug metabolites in plasma and urine 
possible. The rationale for selecting these drugs is described in the following sections. 
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4.1.2.1 Ibuprofen 
Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a nonsteroidal compound with anti- 
inflammatory, analgesic and antipyretic properties (Adams, Cliffe, Lessel and Nicholson, 
1967), which has value in the treatment of rheumatoid arthritis and other rheumatic 
conditions (Busson, 1986) and is presently available "over the counter" as a general pain 
relieving remedy. 
The toxicity of ibuprofen in various animal species was described by Adams, Bough, 
Cliffe, Lessel and Mills, (1969). The oral LD50 in the rat is 1600mg/kg, and repeated 
oral dosing for 6 months at a dose-level of 180mg/kg produces only moderate toxicity. In 
the dog, no ill effects are observed following single oral doses at dose-levels of 20 and 
50mg/kg, and dogs given ibuprofen orally at a dose-level of 16mg/kg daily for 30 days 
show no gross or clinical signs of toxicity. Thus, ibuprofen can be administered orally as 
a single dose to both rats and dogs at high dose-levels. 
The metabolism of ibuprofen is shown in Figure 4.1. Metabolism studies in various 
species showed differences in the metabolism of ibuprofen between the rat and dog 
(Mills, Adams, Cliffe, Dickinson and Nicholson, 1973). 
Following oral administration of ibuprofen to Wistar rats at a dose-level of 20mg/kg, the 
major component in the plasma at 1.5 hours after dosing is ibuprofen (I) with the 
hydroxylated metabolite (II) and the carboxylic acid metabolite (III) also present. In dog 
plasma, only ibuprofen is detected at 1.5 hours following oral administration to Beagle 
dogs at a dose-level of 8mg/kg. 
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Figure 4.1 
The metabolism of ibuprofen 
OH H3C 
CH 3 
3C 
vI 
OH II H 3C 
CHg 
OH 
H 3c 
Conjugate Conjugate 
Both the rat and dog excrete more than 50% of the dose via the urine (Mills et at., 1973), 
but different metabolites are excreted by each. Rat urine contains primarily Phase I 
metabolites of ibuprofen, whereas dog urine contains predominantly glucuronide 
conjugates. 
Ibuprofen is an acidic drug, and from its structure, would not be expected to interact very 
strongly with silica. The compound is not available radioisotopically labelled, however it 
was considered to fit the remaining criteria and was therefore selected. It was decided to 
administer ibuprofen to both the rat and dog to assess whether the differences in 
metabolism would be detected using the screening method. 
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4.1.2.2 Loxtidine 
Loxtidine (1-methyl-5-[3-[3-[(1-piperidinyl)methyl]phenoxy]propyl]amino- lH-1,2,4- 
triazole-3-methanol) is a potent, long acting histamine H2-receptor antagonist which was 
investigated as a potential anti-ulcer drug (Brittain and Jack, 1983). The drug can be 
administered orally to both rats and dogs at dose-levels up to 50mg/kg (Bell et al., 1983). 
The metabolism of loxtidine is different in the rat and dog (Bell et al., 1983). The 
metabolic scheme is shown in Figure 4.2. In the rat, Phase I metabolism predominates, 
whereas in the dog, Phase I metabolism is limited and loxtidine is extensively conjugated 
with glucuronic acid. The concentration of unchanged loxtidine in the plasma of male 
rats at 1 hour after oral administration at a dose-level of 50mg/kg is about 5µg/ml 
(Jenner, 1988). The identity of any other drug-related material circulating in the plasma 
has not been examined. In the dog, following the same oral dose, levels of radioactive 
material in the plasma are about 50µg/ml at 1 hour after dosing (Bradbury, Rosendale and 
Bell, 1983). The concentrations of unchanged loxtidine are about 15µg/ml, the majority 
of the radioactive material comprising polar material. 
In both species following oral administration of 14C-loxtidine at a dose-level of 50mg/kg, 
urinary excretion of radioactive material accounts for 50 to 75% of the dose. 
Loxtidine is a basic molecule which interacts strongly with silica as shown by the low 
elution distances achieved during multiple development (Chapter 2). The compound is 
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Figure 4.2 
The metabolism of loxtidine 
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available radioisotopically labelled with 
14C. Loxtidine fits the criteria and was therefore 
selected. It was decided to administer the drug to both the rat and dog to assess whether 
the differences in metabolism would be detected using the screening method. 
4.1.2.3 Antipyrine 
Antipyrine (1,2-dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one) is an analgesic which 
is used extensively as a probe for assessing mixed function oxygenase activity in man and 
animals (Vesell, 1979). The compound can be administered orally to animals at high 
dose-levels, the LD50 in the rat being 1.8 g/kg (Hart, 1947). 
Antipyrine has a number of pharmacokinetic properties which make it a suitable model 
compound for studying metabolism. It is rapidly and completely absorbed from the 
gastrointestinal tract, has a low volume of distribution equivalent to total body water 
which results in high concentrations in the plasma, and has negligible binding to plasma 
proteins (Vesell, 1979). In addition, antipyrine is metabolised extensively to both Phase I 
and Phase II metabolites, almost all of which are excreted in the urine. The metabolic 
scheme for antipyrine in the rat is shown in Figure 4.3. 
Antipyrine is a weakly basic compound, and is available labelled with 14C. This 
compound fits the criteria and was selected for administration to rats. 
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Figure 4.3 
The metabolism of antipyrine in the rat 
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4.1.2.4 Diazepam 
Diazepam (7-chloro-1,3-dihydro-l-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one) is used 
clinically as an anticonvulsant, skeletal muscle relaxant, antidepressant and anxiolytic 
agent (Svenson and Gordon, 1965). The drug can be administered to rats at high oral 
doses, the LD50 being 700mg/kg (Goldenthal, 1971). 
A general scheme for the metabolism of diazepam in the rat is shown in Figure 4.4. 
Various studies have been carried out to investigate the metabolism of diazepam in 
animals and man (Schwartz, Koechlin, Postma, Palmer and Krol, 1965; Schwartz, 
Bommer and Vane, 1967; Andrews and Griffiths, 1984; Trennery and Waring, 1985). 
The results obtained in these studies differed quantitatively, however the general pattern 
shows that diazepam undergoes extensive Phase I metabolism by hydroxylation and 
demethylation followed by conjugation with glucuronic acid. Some evidence of 
sulphation was found at high dose-levels in the rat. Excretion occurs primarily via the 
bile in the faeces with the remainder of the dose being excreted in the urine. 
Diazepam is a fairly lipophilic, basic molecule, available labelled with 14C, which is 
metabolised extensively and excreted predominantly in the faeces. Despite its low 
excretion in urine, diazepam was considered a useful compound to use for testing the 
screening method because compounds similar in properties to diazepam will need to be 
studied in the future. It was thus important that the method was tested with a more 
difficult compound. Diazepam was selected for administration to rats. 
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Figure 4.4 
The metabolism of diazepam in the rat 
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4.2 Materials and Methods 
4.2.1 Animals 
Adult male AHA rats (190 ± 12g) and adult male Beagle dogs (10.1 and 10.8kg) were 
bred and supplied by the Animal Services Department, Glaxo Group Research Limited, 
Ware, Herts. 
4.2.2 Chemicals 
Ibuprofen (Lot No. 117F0797), antipyrine (Lot No. 37F0643), 3-14C antipyrine, specific 
activity 5.7MBq (154µCi)/mg, (Lot No. 021H9229) and diazepam (Lot No. 105F0451) 
were supplied by Sigma Chemical Company, Poole, UK. 
14C-Diazepam, specific activity 6.9MBq (187uCi)/mg, (Batch 20) was supplied by 
Amersham International p1c, Aylesbury, UK. 
Loxtidine hemisuccinate (AH23844A) (Batch No. C215/153) was synthesised by the 
Chemical Research Department, Glaxo Group Research Limited, Ware. 
14C_Loxtidine hemisuccinate (AH23844D), specific activity 0.5MBq (14.0, uCi)/mg salt, 
0.6MBq (16.3MCi)/mg base, Batch No. C782/58/l, was supplied by the Radioisotope 
Laboratory, Process Research Department, Glaxo Group Research Limited, Ware. 
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Non-radiolabelled loxtidine was analysed by nuclear magnetic resonance spectroscopy 
and was greater than 99% pure. Other non-radiolabelled drugs were received as >98% 
pure standards. 
All other chemicals and solvents were of AnalaRTM grade or equivalent. 
4.2.3 Dosing Solutions 
4.2.3.1 Dogs 
For ibuprofen administration: 750mg of ibuprofen was formulated as a solution 
containing sodium carbonate (420mg) and distilled water (15. Oml) to give a final 
concentration of 50mg/ml. 
For loxtidine administration: approximately 4.5mg 14C-AH23844D (equivalent to 3.9mg 
14C-3844 base) and 869mg AH23844A (equivalent to 746mg AH23844 base) were 
dissolved in distilled water (15m1) to give a final concentration of 50mg base/ml, 
approximately 0.155MBq (4.2uCi)/ml. 
4.2.3.2 Rats 
For ibuprofen administration: 200mg of ibuprofen was formulated as a solution 
containing sodium carbonate (120mg) and distilled water (10ml) to give a final 
concentration of 20mg/ml. 
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For loxtidine administration: approximately 4.2mg 14C-AH23844D (equivalent to 3.6mg 
14C-AH23844 base) and 54mg AH23844A (equivalent to 46.4mg AH23844 base) were 
dissolved in distilled water (5m1) to give a final concentration of 10mg base/ml, 
approximately 0.372MBq (10µCi)/ml. 
For antipyrine administration: approximately 0.3mg 3-14C antipyrine and 500mg 
antipyrine were dissolved in distilled water (10ml) to give a final concentration of 
50mg/ml, approximately 0.372MBq (10µCi)/ml. 
For diazepam administration: approximately 0.3mg 14C-diazepam and 50mg diazepam 
were dissolved in lml 0.5M hydrochloric acid and made up to 5m1 with distilled water. 
The excess acid was neutralised by adding l50µ1 of 2.5Msodium hydroxide solution, and 
the solution was made up to 10ml with distilled water to give a final concentration of 
5mg/ml, approximately 0.186MBq (5MCi)/ml. 
4.2.3.3 Analysis 
Aliquots of each dosing solution (lµl) were analysed by HPTLC to determine their 
purity. Analyses were carried out on silica gel 60 HPTLC plates (Merck, Poole, UK) 
using the solvent systems shown in Table 4.1. After development, the plates were dried 
at room temperature. The material on the HPTLC plates was quantified by ultraviolet 
absorption (ibuprofen 220nm, others 250nm) to determine the chemical purity, and using 
a TLC-linear analyser (Isomess IM3016 linked to a 68000 data system, Raytest Limited, 
Sheffield, UK) to examine the radiochemical purity where appropriate. 
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Table 4.1 
Thin-layer chromatography systems used to determine the purity of the dosing 
solutions 
Drug System Components Proportion Distance 
By Volume (cm) 
Ibuprofen Plate Pre-wash Methanol: Acetic Acid 9: 1 10 
Development 1 Methanol: Acetic Acid 9: 1 1 
Development 2 Toluene: Acetic Acid 9: 1 8 
Loxtidine Plate Pre-wash Methanol 10 
Development 1 Methanol 1 
Development 2 Ethyl Acetate: Propan-2-ol: 
Water: Ammonia (33%) 5: 3: 1.6: 0.4 8 
Antipyrine Plate Pre-wash Methanol 10 
Development 1 Methanol 1 
Development 2 Chloroform: Ethanol 9: 1 9 
Diazepam Plate Pre-wash Methanol 10 
Development 1 Methanol 1 
Development 2 Hexane: Chloroform: Ethanol 5: 5: 0.5 8 
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4.2.4 Animal Experimentation 
4.2.4.1 Dogs 
Two male Beagle dogs were denied access to food overnight and housed in individual 
stainless steel metabolism cages to collect control urine. The dogs were weighed prior to 
dosing and control blood samples (10ml) were taken. One dog was dosed orally with 
ibuprofen (50mg/kg) and the other was dosed orally with 14C-loxtidine (50mg/kg). The 
dog which received ibuprofen was fed immediately after dosing and the other was denied 
access to food for a further 1.5 hours. Blood samples (10ml) were taken into heparinised 
containers from each dog at 1.5 hours after dosing. The dogs remained in metabolism 
cages for 24 hours after dosing and urine was collected during this period. The blood 
samples were centrifuged and the plasma was removed and stored at approximately 
-20' C prior to analysis. The urine was collected into containers cooled with dry ice in 
order to minimise degradation of metabolites, and was stored at approximately -20' C 
prior to analysis. 
4.2.4.2 Rats 
Twenty male AHA rats were starved overnight. Groups of four rats were dosed orally 
with ibuprofen (100mg/kg), 
14C-loxtidine (50mg/kg), 14C-antipyrine (250mg/kg) or 
14C-diazepam (50mg/kg). The remaining animals were used to collect control plasma 
and urine. Two animals from each group were placed into stainless steel metabolism 
cages immediately after dosing in order to collect urine over a 0-24 hour period. 
Terminal blood samples were taken into heparinised containers from the remaining 
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animals at approximately 1.5 hours after dosing. The blood and urine samples were 
treated as described above. 
4.2.5 Liquid Scintillation Counting 
Samples of each dosing solution (541) were diluted to 10ml with distilled water and 
aliquots of the diluted solutions (50µ1) were mixed with scintillation cocktail (8m1, 
Picofluor 30, Canberra Packard Limited, Pangbourne, UK) and the level of radioactivity 
was determined by liquid scintillation counting (Packard 2200A liquid scintillation 
system, Canberra Packard Limited, Pangbourne, UK). The levels of radioactivity in the 
dosing solutions were used to determine the specific activity; i. e. the number of counts 
which corresponded to 1 µg drug. 
Aliquots of plasma and urine samples taken following administration of radiolabelled 
drug (100µl) were mixed with scintillation cocktail (8m1) and the level of radioactivity 
was determined as described above. The counts obtained were used to calculate the 
levels of radioactive material in the samples and final results were expressed as µg drug 
equivalents/ml of sample. 
4.2.6 Sample Preparation 
Plasma and urine samples, controls, and standards (10µg/ml in plasma and 100pg/ml in 
urine) were prepared by solid-phase extraction on 130mg Bond Elut CertifyTM II 
extraction cartridges prior to analysis by HPTLC/MMD. The cartridges were conditioned 
with methanol (4ml) followed by water (4m1), during which, the cartridges were not 
allowed to dry. Plasma or urine samples (1ml) mixed with 98% formic acid (20µl for 
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plasma and l0µ1 for urine) were applied to the cartridges and allowed to pass through at 
approximately one drip every 3 seconds with the aid of vacuum. The cartridges were 
then dried under vacuum, washed with water (2m1) and dried again. Three separate 
elutions were then carried out using methanol (2ml), then 0.5% formic acid in methanol 
(2m1) and 5% ammonium acetate in methanol (2m1). Each eluent was collected 
separately and dried to residue in a Savant speed vac concentrator (Stratech Scientific 
Limited, London, UK). The dried eluents were stored at approximately -20' C prior to 
analysis. 
The portion of sample which passed through the cartridge, and the water wash from 
samples containing radioactive material were collected together and analysed by liquid 
scintillation counting. Portions of the eluents (100µl) from the same samples were also 
taken for analysis by liquid scintillation counting before the remainder of the eluents were 
dried to residue. The counts obtained were used to determine the extraction efficiencies 
and the amount of radioactive material recovered in each eluent. 
4.2.7 HPTLC/MMD Analysis 
Residues obtained from the methanol and methanol/formic acid eluents were dissolved in 
methanol (100µ1) by sonication for 5 minutes followed by vortex mixing. The residues 
from the methanol/ammonium acetate eluents contained more material and were 
dissolved in 200µl methanol so that the proportion of the sample applied to the HPTLC 
plate was less, and disturbance of the solvent front during plate development was 
avoided. Portions of each sample, control or spiked sample (1 µl) were applied to the 
HPTLC plates (silica gel 60 without fluorescent indicator, Merck, Poole, UK) and 
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allowed to dry prior to development. MMD was performed as described previously 
(Chapter 2, Section 2.2.1). 
Portions of lmg/ml drug solutions in methanol (1 µl) were analysed by HPTLC/MMD 
using MMD Scheme 3 (Appendix I, Table 3) to define the elution distances of the drugs 
and enable suitable MMD gradients to be designed for analysis of the samples. The 
elution distances of the standards obtained using MMD Scheme 3 are shown below. 
Elution distances of standards following development on silica gel 60 HPTLC plates 
using MMD Scheme 3 
Ibuprofen : 12mm (broad peak) 
Loxtidine : 6mm 
Andpyrine : 27mm 
Diazepam : 51mm 
These data indicated that MMD Scheme 3 would not be a suitable gradient for analysis of 
the samples from this study with the exception of those obtained following administration 
of diazepam. This conclusion was drawn because drug metabolites are generally more 
strongly retained than the parent drug, being more polar. Thus the majority of peaks due 
to drug-related material in samples obtained following administration of ibuprofen, 
loxtidine and antipyrine would probably be concentrated in the bottom 25-30% of the 
plate. In the case of ibuprofen, an acidic compound, a poor peak shape was obtained with 
MMD Scheme 3, indicating that addition of acetic acid to the developing solvents would 
be beneficial. It had been shown previously (Chapter 2) that addition of triethylamine 
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(TEA) was required for loxtidine to migrate a reasonable distance up the plate. The 
following MMD gradients were therefore used to analyse the samples. 
MMD gradients used for analysis of plasma and urine samples 
Ibuprofen : MMD Scheme 3+ 1% acetic acid 
Loxtidine : MMD Scheme 7+ 1% TEA 
Antipyrine : MMD Scheme 13 (Elutropic strength range 0.73 - 0.48) 
Diazepam : MMD Scheme 3 
The compositions of the solvents and development distances are shown in Appendix I, 
Tables 3,7,13 and 3 respectively. 
4.2.8 Detection 
Following MMD, the HPTLC plates were scanned using a Camag Scanner II (BDH, 
poole, UK). Material on the plates was detected by ultraviolet absorbance, and each plate 
was scanned at 230,250 and 280nm. The ibuprofen plates were scanned at 220nm only 
because of the limited ultraviolet absorbing properties of the drug. The scanner settings 
used are shown in the table overleaf. 
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HPTLC scanner settings used for detection following HPTLC/MMD 
Parameter Setting 
Wavelength : 220,230,250 or 280nm (as described above) 
Band width : 30nm 
Slit width : 0.2mm 
Slit height : 3mm 
Scanning speed : 1mm/sec 
Sensitivity : 250 (220 or 225 for urines) 
Span : 250 (220 or 225 for urines) 
Offset : 50 
The analog signal from the scanner was captured using a Trilab 2000 Chromatography 
Data System (Trivector, Sandy, UK) from which chromatograms were printed and peak 
areas calculated. A signal filter box (MH Scientific, Aylesbury, UK) was placed between 
the scanner and the integrator to remove electrical noise. 
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4.3 Results 
4.3.1 Analysis of Dosing Solutions 
The dosing solution purity data obtained are shown in Table 4.2. 
The chemical purities of the dosing solutions ranged from 90.4% to 99.0%. With the 
exception of the ibuprofen solution used for administration to the dog, all purities were 
94% or greater. The radiochemical purities of the dosing solutions ranged from 95.7% to 
100%. These levels of purity were considered acceptable to enable the objectives of the 
study to be met. 
4.3.2 Liquid Scintillation Counting 
4.3.2.1 Dosing solutions 
The levels of radioactive material measured in the dosing solutions, and the specific 
activities of the solutions are shown below. 
Sample Level of Radioactive Material Specific Activity 
in Solution (µCi/ml) per pg drug (dpm) 
Loxtidine (Dog) 4.0 173.6 
Loxtidine (Rat) 11.5 2532 
Antipyrine 24.7 1089 
Diazepam 7.4 3248 
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Table 4.2 
Dosing solution purities determined by HPTLC after animal experimentation was 
complete 
Purity 
Dosing Solution Chemical Radiochemical 
Ibuprofen 50mg/ml (Dog) 90.4% - 
Ibuprofen 20mg/ml (Rat) 94.0% - 
Loxtidine 50mg/ml (Dog) 98.9% 95.7% 
Loxtidine 10mg/ml (Rat) 99.0% 96.4% 
Antipyrine 50mg/ml 96.0% 100.0% 
Diazepam 5mg/ml 93.9% 99.6% 
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The levels of radioactive material in the dosing solutions were approximately equal to, or 
higher than the levels expected. The higher levels obtained for antipyrine and diazepam 
result from the inaccuracies of weighing small amounts of material experienced by the 
suppliers. The differences between the target and actual levels achieved did not cönflict 
with the aims of the study. 
4.3.3.2 Plasma and urine samples 
The levels of radioactive material measured in the plasma and urine samples are shown in 
Table 4.3. All the plasma samples from animals which received radiolabelled drug 
contained radioactive material, and thus showed that drug was absorbed from the 
gastrointestinal tract into the systemic circulation. The levels of radioactive material in 
the plasma ranged from 5.8 to 7.2µg equivalents/ml in the rat after administration of 
loxtidine and diazepam, to 50.6ug/ml in the dog after dosing with loxtidine and 171 to 
207 µg/ml in the rat after administration of antipyrine. 
The levels of radioactive material in the 0 to 24 hour urine samples were approximately 
10 to 70 times those found in the plasma. Levels ranged from about 107µg/ml in the rat 
after administration of diazepam (corresponding to between 12 and 14% of the dose) to 
about 500µg equivalents/ml in the rat after dosing with loxtidine (44 to 56% of the dose), 
1150µg equivalents/ml in the dog after dosing with loxtidine (50% of the dose) and about 
2600µg equivalents/ml in the rat after administration of antipyrine (62 to 75% of the 
dose). In all cases except after dosing with diazepam, a high proportion of the dose was 
excreted in the urine in the first 24 hours. Lower levels of radioactive material were 
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Table 4.3 
Levels of radioactive material in plasma and urine samples following oral 
administration of 
14C-loxtidine, 14C-antipyrine 
or 
14C-diazepam to AHA rats or 
Beagle dogs 
Drug Species Animal Dose-level Sample Time After Level of Radioactive 
Number (mg/kg) Dose (h) Material (µg equiv. /ml) 
Loxtidine Dog OLK5 50 Plasma 1.5 50.6 
Urine 0-24 1150 
Loxtidine Rat 99 50 Plasma 1.5 7.2 
100 50 Plasma 1.5 6.9 
97 50 Urine 0-24 615 
98 50 Urine 0-24 479 
Antipyrine Rat 103 250 Plasma 1.5 171 
104 250 Plasma 1.5 206 
101 250 Urine 0-24 2690 
102 250 Urine 0-24 2540 
Diazepam Rat 107 50 Plasma 1.5 5.8 
108 50 Plasma 1.5 7.0 
105 50 Urine 0-24 106 
106 50 Urine 0-24 107 
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expected in the urine following administration of diazepam, and those obtained in the 
present studies (12 to 14%) were similar to the 17% reported previously (Andrews and 
Griffiths, 1984). 
4.3.2.3 Extraction washes and eluents 
The levels of radioactive material in the washes and eluents from the solid-phase 
extractions carried out to prepare the samples for analysis by HPTLC/MMD were 
determined, and used to calculate the efficiencies of the extractions. The rat plasma and 
urine samples containing the highest levels of radioactive material were analysed. All 
samples were analysed on two occasions separated by approximately four weeks. The 
results obtained are shown in Table 4.4. 
The overall recoveries were all in excess of 94% with only small amounts being lost 
either by break-through on sample application or in the washes. The total amounts of 
radioactive material in the washes and eluents were approximately equal to the amounts 
applied in the samples to the cartridges, indicating that essentially all of the material had 
been eluted. In addition to the high recoveries obtained, the repeat extractions 
demonstrated that the system was reproducible both in terms of overall recovery and in 
specificity between eluents. 
Previous studies (Chapter 3) indicated that following extraction of drugs and drug 
metabolites from biological fluids on Bond Elut CertifyTM II cartridges, the eluent in 
which a compound eluted from the cartridge was indicative of its chemical nature. Thus, 
non-acidic or weakly acidic drugs and Phase I metabolites eluted in methanol, acidic 
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Table 4.4 
Extraction efficiencies on Bond Elut CertifyTM II cartridges following extraction of 
drugs and drug metabolites from plasma and urine after oral administration of 
14C-loxtidine to rats and dogs and 14C-antipyrine and 14C-diazepam to rats 
Samples Following Administration of Loxtidine 
Sample Washes Methanol Methanol/FA MethanolINH4Ac Recovery 
Rat Plasma 1 4.2% 93.0% 1.2% 1.7% 95.8% 
Rat Plasma 2 1.9% 95.2% 1.3% 1.7% 98.2% 
Rat Urine 1 3.6% 92.1% 2.4% 1.9% 96.4% 
Rat Urine 2 3.3% 92.1% 4.0% 0.6% 96.7% 
Dog Plasma 1 3.2% 92.7% 3.7% 0.4% 96.8% 
Dog Plasma 2 3.5% 92.1% 2.4% 2.0% 96.5% 
Dog Urine 1 4.0% 92.2% 3.1% 0.7% 96.0% 
Dog Urine 2 3.3% 92.1% 4.0% 0.6% 96.7% 
Samples Following Administration of Antipyrine 
Sample Washes Methanol Methanol/FA Methanol/NH4Ac Recovery 
Rat Plasma 1 1.1% 86.4% 3.0% 9.4% 98.9% 
Rat Plasma 2 0.7% 85.8% 3.0% 10.6% 99.4% 
Rat Urine 1 5.7% 36.9% 14.1% 43.3% 94.3% 
Rat Urine 2 4.7% 44.7% t 50.6% 95.3% 
Samples Following Administration of Diazepam 
Sample Washes Methanol Methanol/FA Methanol/NH4Ac Recovery 
Rat Plasma 1 5.8% 46.2% 9.0% 39.0% 94.2% 
Rat Plasma 2 4.9% 43.7% 8.8% 42.6% 95.1% 
Rat Urine 1 0.4% 10.7% 14.3% 74.7% 99.6% 
Rat Urine 2 0.3% 12.8% 13.3% 73.6% 99.7% 
Methanol and methanol/formic acid washes were counted together. 
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drugs or Phase I metabolites and glucuronide conjugates eluted in methanol/formic acid, 
and sulphate conjugates eluted in methanol/ammonium acetate. These observations can 
be used to predict the general nature of the material which eluted from the extraction 
cartridges in the present studies. 
In the samples obtained following administration of loxtidine, most of the radioactive 
material was eluted in the methanol eluents from both the plasma and urine samples from 
the rat and dog. Thus the results obtained previously (Chapter 3) suggest that the 
material comprised either non-acidic or weakly acidic compounds, probably Phase I 
metabolites. 
The plasma and urine samples obtained following administration of antipyrine to the rat 
had different elution patterns. From the plasma, most of the radioactive material eluted in 
the methanol (about 86%) with low amounts in the methanol/formic acid (3%) but higher 
levels in the methanol/ammonium acetate eluent (about 10%). This suggests that the 
majority of the drug-related material in the plasma comprised Phase I metabolites, and 
that sulphate conjugates may have been present. In urine, the highest levels of 
radioactive material were eluted in the methanol/ammonium acetate eluent (about 50%) 
with about 37% in the methanol and 14% in the methanol/formic acid. These data 
suggest that drug-related material in the urine comprised sulphate conjugates with lower 
concentrations of Phase I metabolites and glucuronides also present. 
Following administration of diazepam, plasma and urine again showed different elution 
patterns. Similar amounts of radioactive material in plasma were eluted in the methanol 
(about 45%) and methanol/ammonium acetate (about 41%), and a small amount (9%) 
was eluted in the methanol/formic acid. This suggests that drug-related material in the 
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plasma comprised largely Phase I metabolites and sulphate conjugates with some 
glucuronide conjugates also present. In urine the majority of the drug-related material 
(about 74%) was eluted in the methanol/ammonium acetate with similar amounts of the 
remaining material being eluted in the other two eluents. This suggests that the urine 
contained mainly sulphate conjugates with lower concentrations of Phase I metabolites 
and glucuronide conjugates also present. 
4.3.3 HPTLC/MMD 
Chromatograms obtained following HPTLC/MMD of the plasma and urine extracts were 
studied to identify peaks which were present in sample extracts, but absent in controls. 
All extracts from both extractions were analysed. The analyses of samples from each set 
of extractions were carried out on different occasions separated by approximately four 
weeks. The results of these analyses are described in detail for each test substance in the 
following sections. 
The peak areas of drug-related material were -obtained either directly from the 
chromatograms, or by subtracting the area of the control sample from the sample area 
when peaks co-eluted with endogenous material. Estimated concentrations were obtained 
by comparing peak areas of drug-related components with those of standards, assuming 
linearity of response and that the extinction coefficients of the parent drug and 
metabolites are the same. 
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4.3.3.1 Ibuprofen 
The peaks detected following HPTLC/MMD analysis of the samples obtained after 
administration of ibuprofen are shown in Table 4.5 and are summarised graphically in 
Figures 4.5 and 4.6. Typical chromatograms are shown in Figures 4.7 and 4.8. The 
letters in the following description of the results correspond with those on Figures 4.7 
and 4.8. 
In rat plasma, three peaks were detected in sample extracts which were not in controls 
and were therefore assumed to be drug-related components. The major component (A) 
had the same elution distance as parent drug and was present at a concentration in excess 
of 100µg/ml. The second component (B) had a relative elution distance (relative to the 
elution distance of parent compound, RED) of 0.909 to 0.924 and its concentration was 
about 70 to 80µg/ml assuming a similar extinction coefficient to ibuprofen. These major 
components were eluted in the methanol eluent. A third component (C), present at about 
15 to 20µg/ml had a RED of 0.939 to 0.955 and was eluted in the methanol/formic acid 
eluent. No peaks were detected in the methanol/ammonium acetate eluent. 
In rat urine, no component was observed with the same elution distance as ibuprofen. A 
major component (D) with a RED of 0.890 to 0.897 was eluted in the methanol, and was 
present at a concentration in excess of lmg/ml. A second major component (E) with a 
RED of 0.658 to 0.706 was eluted in both the methanol and methanol/formic acid eluents. 
The concentration of this component was also in excess of lmg/ml. A third component 
(F) with a RED of 0.918 to 0.926 was eluted in the methanol/formic acid, and had a 
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Table 4.5 
Peaks detected by HPTLC/MMD of plasma and urine samples from rats and dogs after 
oral administration of ibuprofen 
Sample Peak Elution Distances, mm (Area) 
First Analysis Second Analysis 
Spiked Plasma (10ug/ml) 66 (30) (100µg/ml) 66 (535) 
Rat Plasma (MeOH) 60 (443); 66 (789) 61(386), 66 (835) 
Rat Plasma (MeOH/FA) 62 (77) 63 (93) 
Rat Plasma (MeOH/NH4Ac) No peaks detected No peaks detected 
Spiked Urine (100µg/ml) 73 (28) 68 (132) 
Rat Urine (MeOH) 48 (598); 65 (707) 48 (563); 61(1873) 
Rat Urine (MeOH/FA) 24 (64); 48 (353); 
67(89) 
48 (701); 63 (265) 
Rat Urine (MeOH/NH4Ac) No peaks detected No peaks detected 
Spiked Plasma (10gg/ml) 66(30) 66 (80) 
Dog Plasma (MeOH) 60 (22); 66 (516) 64 (485); 66 (760) 
Dog Plasma (MeOH/FA) 21(62); 31(385) 32 (445) 
Dog Plasma (MeOH/NH4Ac) 28 (66) 28 (42) 
Spiked Urine (100µg/ml) 73 (28) 67 (92) 
Dog Urine (MeOH) 48 (1190); 64 (379); 
73(62) 
48 (2320); 58 (817); 
66(131) 
Dog Urine (MeOH/FA) 47(255) 47(155) 
Dog Urine (MeOH/NH4Ac) 15 (1528) 16 (1738) 
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Figure 4.5 
Summary of peaks detected by HPTLC/MMD of rat plasma and urine samples 
obtained after oral administration of ibuprofen at a dose-level of 100mg/kg 
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Figure 4.6 
Summary of peaks detected by HPTLC/MMD of dog plasma and urine samples 
obtained after oral administration of ibuprofen at a dose-level of 50mg/kg 
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Figure 4.7 
Typical HPTLC/MMD chromatograms obtained from rat plasma and urine after 
oral administration of ibuprofen at a dose-level of 100mg/kg 
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Figure 4.8 
Typical HPTLC/MMD chromatograms obtained from dog plasma and urine after 
oral administration of ibuprofen at a dose-level of 50mg/kg 
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Dog Plasma (MeOH / NH4Ac Eluent) 
Dog Urine (MeOH / NH4Ac Eluent) 
concentration of about 200µg/ml. No peaks were detected in the methanolammonium 
acetate eluent. An additional peak in the methanol/formic acid eluent in the first analysis 
was not detected in the second analysis. 
In dog plasma, two major peaks were detected in the first analysis, but one of the peaks 
split, giving three components in the second analysis. The major peaks common to both 
analyses were one with an elution distance equal to ibuprofen (A) and a concentration of 
about 100µg/ml, and a second (B) with a RED of 0.470 to 0.485, present at about 
50µg/ml. The first component eluted in the methanol eluent and the second in the 
methanol/formic acid. In addition to two major components observed in both analyses, a 
minor component (C) was observed in the methanol/ammonium acetate eluent with a 
RED of 0.424, at a concentration of about 10µg/ml. 
In the second analysis, a component was detected in the methanol eluent with a RED of 
0.970, at a concentration of about 50µg/ml which was absent in the first analysis. It 
seemed unlikely that this component was drug-related, and apparently being present at 
such high concentrations, was not observed in the first analysis. The peak may have been 
due to a defect in the surface of the HPTLC plate or to a change in the constituents of 
plasma with time. A peak with a RED of 0.318 was observed in the methanol/formic 
acid eluent in the first analysis at a low concentration, however was not detected in the 
second analysis. 
The major component in dog urine (D) had a RED of 0.658 to 0.706 (the same as 
component E in rat urine) and was eluted in the methanol and methanol/formic acid 
eluents. The concentration of this component was in excess of 2mg/ml. A second 
component (E) with a RED of 0.205 to 0.239 was eluted in the methanol/ammonium 
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acetate and was present at a concentration of 1400 to 1600µg/ml. Another component (F) 
with a-RED of 0.866 to 0.877 was eluted in the methanol and was present at a 
concentration of 700 to 800µg/ml. A small amount of material with the same elution 
distance as ibuprofen was detected at a concentration of 100 to 200µg/ml. This was 
eluted in the methanol. 
There was broad agreement in the results obtained between the two analyses. All of the 
major components would have been characterised similarly on both occasions. The only 
differences were some additional peaks which may have been due to plate irregularities or 
sample matrix changes. 
4.3.3.2 Loxtidine 
The peaks detected following HPTLC/MMD analysis of the samples obtained after 
administration of loxtidine are shown in Table 4.6 and are summarised graphically in 
Figures 4.9 and 4.10. Typical chromatograms are shown in Figure 4.11. The letters in 
the following description of the results correspond with those on Figure 4.11. 
In rat plasma, two components were detected in the methanol eluent during the first 
analysis, and three during the second. The components found in the first analysis were 
both present at concentrations of less than 5µg/ml as would be expected from the 
radioactivity measurement (7.2µg/ml). The components had RED values of (A) 1.0 and 
(B) 0.681. In the second analysis, the same components were detected (REDs 1.0 and 
0.723), but at much higher concentrations which may indicate that interfering 
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Table 4.6 
Peaks detected by HPTLC/MMD of plasma and urine samples from rats and dogs after 
oral administration of loxtidine 
Sample Peak Elution Distances, mm (Area) 
First Analysis Second Analysis 
Spiked Plasma (10µg/ml) 47(290) 47(65) 
Rat Plasma (MeOH) 32 (105); 47 (103) 21(375); 34 (700) 
47(53) 
Rat Plasma (MeOH/FA) No peaks detected No peaks detected 
Rat Plasma (MeOH/NH4Ac) No peaks detected No peaks detected 
Spiked Urine (100ug/ml) 45 (88) 45 (60) 
Rat Urine (MeOH) 31 (11)*; 46 (251) 31 (30)*; 45 (539) 
Rat Urine (MeOH/FA) No peaks detected, No peaks detected 
Rat Urine (MeOH/NH4Ac) 17 (124)*; 24 (96) 25 (74) 
Spiked Plasma (10tcg/ml) 47(290) 45 (65) 
Dog Plasma (MeOH) 13 (180); 46 (137) 17 (16); 22 (113); 
45 (17) 
Dog Plasma (MeOH/FA) No peaks detected No peaks detected 
Dog Plasma (MeOH/NH4Ac) No peaks detected No peaks detected 
Spiked Urine (100µg/ml) 45 (88) 45 (73) 
Dog Urine (MeOH) 16 (689); 46 (170) 17 (749); 46 (336) 
Dog Urine (MeOH/FA) No peaks detected No peaks detected 
Dog Urine (MeOH/NH4Ac) No peaks detected No peaks detected 
* Peaks detected after scanning at 250nm, sens/span 220. 
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Figure 4.9 
Summary of peaks detected by HPTLC/MMD of rat plasma and urine samples 
obtained after oral administration of loxtidine at a dose-level of 50mg/kg 
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Figure 4.10 
Summary of peaks detected by HPTLC/MMD of dog plasma and urine samples 
obtained after oral administration of loxtidine at a dose-level of 50mg/kg 
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Figure 4.11 
Typical HPTLC/MMD chromatograms obtained from rat and dog plasma and 
urine after oral administration of loxtidine at a dose-level of 50mg/kg 
Rat Plasma (MeOH Eluent) 
Spik 
Con 
Rat Urine (MeOH / NH4Ac Eluent) 
Con 
Dog Plasma (MeOH Eluent) 
Control 
Dog Urine (MeOH Eluent) 
Control 
Sample 
B 
A (Loxtidine) 
Sample 
Sample 
Sample 
T) 
-vT.. - 
Rat Urine (MeOH Eluent) 
components were also present. A third component was detected in the second analysis 
with a RED of 0.447 which was not detected during the first analysis. Nothing was 
detected in the methanol/formic acid or methanol/ammonium acetate eluents. 
The major component of rat urine had an RED of 1.0 and was present at a concentration 
of about 300 to 500µg/ml. This component eluted in the methanol. A small amount of 
material with a RED of 0.689 also eluted in the methanol at a concentration of less than 
50µg/ml, which was only detected at 250nm. No peaks were detected in the 
methanol/formic acid eluent. A component (C) eluted in the methanol/ammonium 
acetate eluent with a RED of 0.522 to 0.566 at a concentration of 100 to 120µg/ml. 
Another peak was detected in the methanol/ammonium acetate eluent (RED 0.378) 
during the first analysis, but was not detected in the second analysis. 
In dog plasma and urine two components were detected. These had REDs of 1.0 and 
0.277 to 0.378, and were both eluted in the methanol eluent. In plasma, the concentration 
of the component with the same elution distance as loxtidine was 5 to 10; 1g/ml which is 
consistent with previous data (Bradbury et al.; 1983).; The concentration of the other 
component (D) was greater. In urine, the major component (D) had a RED of 0.356 to 
0.378 and a concentration of 800µg to lmg/ml. The concentration of the component, co= 
eluting with loxtidine, was 200 to 500µg/ml 
In dog plasma a third component was detected during the second analysis which was not 
present during the first analysis. ' The same material was also detected in rat plasma 
during the second analysis but not during the first analysis. This compound could 
therefore have been a breakdown product of an endogenous component formed either 
during storage or freeze-thaw cycles. 
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There was broad agreement in the results obtained between the two analyses, although 
there was some difference in absolute areas obtained between analyses which may have 
been due to the detector lamp alignment or inaccuracies in positioning the spots onto the 
HPTLC plates. All of the major components would have been characterised similarly on 
both occasions. 
4.3.3.3 Antipyrine 
The peaks detected following HPTLC/MMD analysis of the samples obtained after 
administration of antipyrine are shown in Table 4.7 and are summarised graphically in 
Figure 4.12. Typical chromatograms are shown in Figure 4.13. The letters in the 
following description of the results correspond with those on Figure 4.13. 
In rat plasma, two components were eluted in the methanol. These had REDs of (A) 
1.020 to 1.065 and (B) 0.824 to 0.870, being present at concentrations of 60 to 70µg/ml 
and about 20µg/ml respectively. Two components eluted in the methanol/formic acid 
with REDs of (E) 0.235 to 0.304 and (D) 0.314 to 0.413. The concentrations of these 
components were about 5µg/ml and <1 µg/ml respectively. Two components were also 
eluted in the methanol/ammonium acetate eluent with REDs of (C) 0.588 to 0.644 and 
0.765 to 0.866, and concentrations of 4 to 10µg/ml, the latter having the same RED as 
component B. A component with a RED of 1.059 to 1.087 was detected in the 
methanol/ammonium acetate eluent at a concentration of about 3µg/ml in the first 
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Table 4.7 
Peaks detected by HPTLC/MMD of plasma and urine samples from rats after oral 
administration of antipyrine 
Sample Peak Elution Distances, mm (Area) 
First Analysis Second Analysis 
Spiked Plasma (lOug/ml) 51(316) 46 (544) 
Rat Plasma (MeOH) 42 (930); 52 (3535) 40 (1003); 49 (3651) 
Rat Plasma (MeOH/FA) 12 (320); 16 (30) 14 (280); 19 (20) 
Rat Plasma (MeOH/NH4Ac) 30 (112); 39 (386) 
54(92) 
31(148); 38 (293); 
50(672) 
Spiked Urine (100Mg/ml) 51(316) 47(455) 
Rat Urine (MeOH) 10 (907); 31(50); 
43 (774); 50 (272); 
55(20) 
11(2900); 32 (127); 
42 (2127); 48 (946) 
Rat Urine (MeOH/FA) 11(828); 17 (91) 13 (700); 19 (183) 
Rat Urine (MeOH/NH4Ac) 22 (46); 33 (1036); 
42 (1710); 56 (1668) 
34 (1098); 41(2050); 
53 (2224); 61(99) 
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Figure 4.12 
Summary of peaks detected by HPTLC/MMD of rat plasma and urine samples 
obtained after oral administration of antipyrine at a dose-level of 250mg/kg 
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Figure 4.13 
Typical HPTLCIMMD chromatograms obtained from rat plasma and urine after 
oral administration of antipyrine at a dose-level of 250mg/kg 
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analysis and 20µg/ml in the second analysis. This had the same RED as component A. 
In rat urine, six components were detected, some of which were eluted in more than one 
eluent. The major components had REDs of (E) 0.196 to 0.277 and (B) 0.824 to 0.894 
and were present at concentrations of 700 to 1000µg/ml respectively. These components 
were both eluted in two eluents, the first in methanol and methanol/formic acid and the 
second in methanol and methanol/ammonium acetate. Two other components with 
concentrations of 400 to 800µg/ml had REDs of (C) 0.608 to 0.703 and (A) 1.098 to 
1.128. The first of these was eluted in the methanol and methanol/ammonium acetate 
eluents, and the second was eluted in methanol/ammonium acetate only. A further 
component with a RED of 0.98 to 1.021 was eluted in methanol at a concentration of 100 
to 200µg/ml, and the final component with a RED of 0.333 to 0.444 was eluted in 
methanol/formic acid at a concentration of <50µg/ml. 
There was good agreement in the results obtained between the two analyses. All of the 
major components would have been characterised similarly on both occasions. One 
additional peak was detected during the second analysis in the methanol/ammonium 
acetate eluent but was smaller than the remaining peaks. 
4.3.3.4 Diazepam 
The peaks detected following HPTLC/MMD analysis of the samples obtained after 
administration of diazepam are shown in Table 4.8 and are summarised graphically in 
Figure 4.14. Typical chromatograms are shown in Figure 4.15. The letters in the 
following description of the results correspond with those on Figure 4.15. 
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Table 4.8 
Peaks detected by HPTLC/MMD of plasma and urine samples from rats after oral 
administration of diazepam 
Sample Peak Elution Distances, mm (Area) 
First Analysis Second Analysis 
Spiked Plasma (l0, Lg/ml) 55 (885) 55 (788) 
Rat Plasma (MeOH) 19 (186); 32 (34); 
47 (152); 50 (16); 
55 (89) 
18 (109); 34 (53); 
46 (244); 50 (33); 
56(75) 
Rat Plasma (MeOH/FA) 12(93) 12(40) 
Rat Plasma (MeOH/NH4Ac) 19 (197) t 18 (159) t 
Spiked Urine (100µg/ml) 55 (895) 55 (723) 
Rat Urine (MeOH) 18 (101) 18 (144) 
Rat Urine (MeOH/FA) No peaks detected No peaks detected 
Rat Urine (MeOH/NH4Ac) 18 (990) t 18 (576) t 
Single peak also detected following development using MMD Scheme 7 
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Figure 4.14 
Summary of peaks detected by HPTLC/MMD of rat plasma and urine samples 
obtained after oral administration of diazepam at a dose-level of 50mg/kg 
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Figure 4.15 
Typical HPTLC/MMD chromatograms obtained from rat plasma and urine after 
oral administration of diazepam at a dose-level of 50mg/kg 
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In rat plasma, the majority of the material detected was in the methanol eluent, five 
components being found on both occasions. The relative proportions varied slightly on 
each occasion, but all five components were present at concentrations of less than 5µg/m1 
with most being less than 1 pg/ml. The major component during the fast analysis (E) had 
a RED of 0.345 and was eluted in the methanol/ammonium acetate as well as the 
methanol eluent. In the second analysis this component was present at a lower 
concentration, but one other component (C) with a RED of 0.836 to 0.855 was present at 
a correspondingly higher concentration. This may indicate that a conjugated metabolite 
was present which was hydrolysed to a Phase I metabolite in plasma on storage or during 
the freeze-thaw process. Other components, all present at concentrations of less than 
1µg/ml had REDs of (A) 1.0 to 1.018, (B) 0.909 and (D) 0.582 to 0.618. One component 
(F) eluted in the methanol/formic acid with a RED of 0.218 at a concentration of less than 
l µg/ml. 
In rat urine, only one peak (E) was observed at a RED of 0.327, which eluted partially in 
the methanol, but predominantly in the methanol/ammonium acetate eluent. The 
concentration was about 100µg/ml which was in agreement with the levels of 
radioactivity measured in the urine. A single peak was detected after samples containing 
this component were analysed using an expanded linear gradient (MMD Scheme 7). 
Samples containing component E were developed using MMD Scheme 3 with 1% acetic 
acid or 1% TEA. The RED values were 0.323 and 0.292 respectively. 
There was good agreement in the results obtained between the two analyses. All of the 
major components would have been characterised similarly on both occasions. 
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4.4 Discussion 
The aim of the studies described in this chapter was to investigate the 'utility of the 
method developed to screen for drugs and drug metabolites in biological fluids by 
analysing plasma and urine samples obtained after administration of drugs to animals. 
The results have shown that the method detected drugs and drug metabolites in all of the 
samples analysed. In the following discussion, the results from the present studies are 
interpreted using the data from Chapters 2 and 3 on relative elution distances (REDs) and 
solid-phase extraction with selective elution. The routes of metabolism predicted by the 
screening system are then compared with published data. 
4.4.1 Ibuprofen 
In the following discussion, the letters describing drug-related components correspond 
with those on Figures 4.7 and 4.8. The Roman numerals refer to the chemical structures 
in Figure 4.1. 
Ibuprofen had an elution distance of 66mm and a sharp peak when MMD Scheme 3 with 
1% acetic acid was used. This was a suitable elution distance to allow detection of the 
more polar metabolites. Being acidic, ibuprofen might have been expected to be eluted 
from the extraction cartridges in the methanol/formic acid eluent rather than the methanol 
eluent in which it was found. However, indole-3-carboxylic acid, one of the acidic 
compounds tested previously, was eluted in methanol so the presence of a 'carboxylic acid 
group does not guarantee retention on the extraction cartridge by an anion-exchange 
mechanism. 
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In the rat, circulating drug-related material comprised components with mean REDs of; 
(A) 1.0, (B) 0.917 and (C) 0.947. Components A and B were eluted in methanol and 
component C was eluted in methanol/formic acid. The concentrations showed that the 
relative abundance of these components was A>B>C. The system predicted that A was 
unchanged ibuprofen, both from its RED and it being eluted in methanol. The RED of B 
was consistent with a metabolite formed by aromatic hydroxylation, and this was 
supported by the compound's elution in methanol. Component C was eluted in 
methanol/formic acid and was therefore more strongly anionic than the parent compound. 
The RED did not suggest that the compound was a glucuronide conjugate, and the value 
was not as small as would have been expected for a metabolite formed by oxidation to a 
carboxylic acid. The structural change predicted by the RED value was aromatic 
hydroxylation, possibly in a position which caused the carboxylic acid group present on 
the molecule to be more strongly anionic. 
Unchanged ibuprofen was not detected in rat urine. Three main components detected had 
mean REDs of (D) 0.894, (E) 0.682, (F) 0.922 the relative concentrations being E>D» 
F. Component E was incompletely eluted by the methanol eluent, the remainder being 
eluted in methanol/formic acid. This suggested that it was a stronger anion than 
ibuprofen. The RED of the compound was consistent with a metabolite formed by 
oxidation to a carboxylic acid, probably aliphatic because the value was lower than would 
have been expected for an aromatic carboxylic acid. Intuitively from the structure of 
ibuprofen the most likely compound to be formed is that obtained by oxidation of the 
isopropyl group. Component D had a RED consistent with a metabolite formed by 
hydroxylation, probably aromatic, but was close to the range of REDs associated with 
aliphatic hydroxylation. The compound was eluted in the methanol which suggested that 
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the change in structure did not markedly alter the anionic strength of the carboxylic acid 
group. A likely position for hydroxylation was on the tertiary butyl group especially as 
two aromatic hydroxylations had already been postulated for components found in the 
plasma. The relatively large RED could in that case be explained by the steric hindrance 
around the hydroxyl group caused by the tertiary butyl. This would reduce interaction 
with the silica layer. The third component (F) had a RED consistent with a metabolite 
formed by aromatic hydroxylation and its elution in the methanol/formic acid indicated 
that hydroxylation occurred at a position which increased the anionic strength of the 
carboxylic acid group. 
The extraction data combined with the RED values indicated that components B and D 
may have been the same and that C and F may have been also. The RED values differed 
slightly, which could have been due to the different endogenous components present in 
the plasma and urine extracts affecting the chromatography. The overall metabolic 
pattern for ibuprofen in the rat indicated by the method was therefore Phase I metabolism 
by aliphatic hydroxylation of the tertiary butyl group and oxidation of the tertiary butyl 
group to a carboxylic acid, with a small amount of aromatic hydroxylation also occurring. 
The three metabolites formed were found in the urine, but no unchanged ibuprofen was 
detected. The drug-related material circulating in the plasma comprised unchanged 
ibuprofen primarily with the aliphatic and aromatic hydroxylated metabolites also 
present. There was no evidence of the carboxylic acid metabolite in the plasma. 
These data compared favourably with the published data (Mills et al., 1973). Following 
oral administration of ibuprofen to Wistar rats at a dose-level of 20mg/kg, the major 
component in the plasma at 1.5 hours after dosing was ibuprofen (I, 24µg/ml) with the 
hydroxylated metabolite (II, 151ig/ml) and the carboxylic acid metabolite (III, 3.6µg/ml) 
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also present. Rat urine contained the hydroxylated metabolite (II, 42% of dose), the 
carboxylic acid metabolite (111,18%) and small amounts of ibuprofen glucuronide (6%). 
Thus, in rat plasma, unchanged ibuprofen was the major component with the aliphatic 
hydroxylated metabolite also present at high concentrations. The carboxylic acid 
metabolite was detected by Mills et al., but at low concentrations, and they found no 
evidence for aromatic hydroxylation. The major urinary components found by Mills et 
al. were the aliphatic hydroxylated metabolite and the carboxylic acid metabolite which 
were also detected in the present studies. A small amount of ibuprofen glucuronide was 
found in the urine by Mills et al., but was not detected in the present studies. Neither 
studies showed evidence for unchanged ibuprofen in the urine. In the present studies an 
aromatic hydroxylated metabolite was found which was not detected previously. 
In the present studies, the pattern of metabolism in the dog was different to that found in 
the rat although there were some similarities. Three circulating drug-related components 
were detected with mean REDs of; (A) 1.0, (B) 0.478 and (C) 0.424, the relative 
concentrations being A>B>C. The method indicated that A was unchanged ibuprofen, 
both from its RED and it being eluted in methanol. Component B was eluted in 
methanol/formic acid and was therefore more strongly anionic than ibuprofen, so could 
have been a glucuronide conjugate. The RED value was greater than would have been 
expected of a glucuronide conjugate relative to a phenolic precursor, however larger 
REDs might be expected for a glucuronide relative to a carboxylic acid precursor. The 
reason for this is that the carboxylic acid would have a smaller elution distance than its 
corresponding alcohol or phenol. Component C was eluted in methanol/ammonium 
acetate which indicated that it was strongly anionic, possibly a sulphate. The RED 
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although a little larger than expected could have been indicative of a sulphate in this case 
for the reasons discussed above. 
A small amount of ibuprofen was detected in dog urine. Three other components were 
present with REDs of; (D) 0.682, (E) 0.222 and (F) 0.872, the relative concentrations 
being D>E>F. Components D and F corresponded to the metabolites formed by 
oxidation of the tertiary butyl group to a carboxylic acid and aliphatic hydroxylation of 
the same group respectively. The reasons for these assignments were as described for the 
rat samples. Component E had a RED which was characteristic of a glucuronide 
conjugate, however it was eluted in methanol/ammonium acetate which suggested it may 
have been a sulphate. The method was not clear in this case because either a glucuronide 
or sulphate of the tertiary butyl alcohol could have been formed theoretically. In the case 
of a glucuronide with a carboxylic acid also present the strongly anionic nature might 
mean that formic acid was not a sufficiently strong anion for the compound to be eluted 
in methanol/formic acid. From this and the RED value, the most likely structure of this 
component was a glucuronide. 
Thus, the screening method indicated that unchanged ibuprofen was the major circulating 
drug-related component and that glucuronides were also present. The urinary data 
showed that both Phase I and Phase II metabolism occurred in the dog, unlike the rat. 
These data are in broad agreement with the published data (Mills et al., 1973). Following 
oral administration of ibuprofen to Beagle dogs at a dose-level of 8mg/kg, only ibuprofen 
(35µg/ml) was detected in the plasma at 1.5 hours after dosing. Dog urine contained 
predominantly glucuronide conjugates of II (23% of dose) and III (13%) with some non- 
conjugated 11 (9%) and ibuprofen glucuronide (7%). 
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HPTLC/MMD of plasma and urine obtained after administration of ibuprofen detected 
the main metabolites of ibuprofen. In addition the method showed that whereas Phase I 
metabolism predominated in the rat resulting in high concentrations of circulating Phase I 
metabolites, in the dog Phase II metabolism also occurred. There were no circulating 
Phase I metabolites in the dog, but a component considered to be ibuprofen glucuronide 
was found at high concentrations.. The data. from the present studies were in broad 
agreement with reported data, and an additional metabolite was found in the rat. This 
may have been formed following administration of ibuprofen at a high dose-level when 
the routes of metabolism which occur at lower dose-levels may be saturated. The dose- 
level in the present studies was 100mg/kg compared with 8mg/kg in the published data. 
4.4.2 Loxtidine 
In the following discussion, the letters describing drug-related components correspond 
with those on Figure 4.11. The Roman numerals refer to the chemical structures in 
Figure 4.2. 
Loxtidine is a basic molecule which interacts strongly with silica and hence a MMD 
gradient with TEA was required for it to migrate a reasonable distance on a HPTLC plate. 
An elution distance of 47mm was achieved with the gradient used, which enabled 
separation from metabolites to occur and the more polar metabolites to be detected. 
Loxtidine was eluted from the extraction cartridge in the methanol eluent as would be 
predicted from its structure which contains no anionic groups. 
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In the rat, the concentration of circulating drug-related material was low, nevertheless two 
components were detected at concentrations of less than 5µg/ml. These components had 
mean REDs of (A) 1.0 and (B) 0.702. Component A was considered to be unchanged 
loxtidine from its elution distance and it being eluted in the methanol eluent. The RED of 
component B suggested that it was a carboxylic acid metabolite, however its elution in 
methanol indicated that it did not have a very strong anionic group. An acidic metabolite 
of loxtidine would however be zwitterionic, possessing both anionic and cationic groups, 
which might combine to prevent retention by an anion-exchange mechanism. By 
inspection of the loxtidine molecule it is apparent that carboxylic acid formation can take 
place either by N-dealkylation to form the propionic acid derivative, or by oxidation of 
the methanol group. Oxidation of a methanol group was shown to produce REDs of 
about 0.8 (Chapter 2), however the RED of component B was 0.7. Thus, N-dealkylation 
was considered the more likely route as it would result in a greater change in the polarity 
of the molecule than would be achieved by methanol oxidation. 
The major drug-related component in rat urine was considered to be loxtidine from its 
elution distance and it being eluted in methanol. Other components were detected with 
REDS of (C) 0.689 and (D) 0.544. Component C was considered to be the propionic acid 
metabolite formed by N-dealkylation, corresponding to component B in the plasma. 
Component D eluted in the methanol/ammonium acetate and therefore had greater 
anionic strength than the propionic acid derivative, possibly being a sulphate. The RED 
did not suggest that the compound was a sulphate metabolite because it was larger than 
would be expected, however on a molecule such as loxtidine which itself interacts 
strongly with silica, sulphation may result in smaller changes in retention. The identity of 
component D could not therefore be predicted unambiguously by the screening method 
from the data obtained. 
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In summary, the screening method indicated that Phase I metabolism of loxtidine 
predominated in the rat, with the propionic acid metabolite formed by N-dealkylation 
being the primary metabolite. Small amounts of a more anionic metabolite were also 
found in the urine. 
In previous studies, the concentration of unchanged loxtidine in the plasma of male rats at 
1 hour after oral administration at a dose-level of 50mg/kg was 5.2ug/ml (Jenner, 1988), 
however the identity of any other drug-related material circulating in the plasma has not 
been examined. The concentration of unchanged loxtidine measured in rat plasma during 
the present studies was thus consistent with previous data, and whereas the identity of the 
circulating metabolites had not been identified previously, the present studies indicated 
that the main component was the propionic acid derivative. 
The major components of 0-24 hour urine following oral administration of loxtidine to 
rats at a dose-level of 50mg/kg are loxtidine (75% of urinary radioactive material) and the 
propionic acid derivative (II) formed by N-dealkylation of loxtidine (15%). Small 
amounts of the carboxylic acid metabolite (V, <5%), a phenolic metabolite (IV, <1%), 
loxtidine glucuronide (VI, <5%) and the phenolic glucuronide (VII, <5%) are also present 
(Bell et al., 1983). The data from the present studies were in broad agreement with 
previous data, although the detailed metabolic information determined by radiolabelled 
studies was not shown by the screening method. 
In the present studies, only two components were found in dog plasma and urine, one of 
which was considered to be unchanged loxtidine. The other component was present in 
plasma and urine in greater amounts than loxtidine, and had a mean RED of 0.328. The 
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RED suggested that the compound was either a glucuronide or sulphate conjugate, 
however it was eluted in methanol and therefore did not have strong anionic 
characteristics. As discussed previously however, a glucuronide or sulphate metabolite of 
loxtidine would be zwitterionic and may not be retained by anion-exchange. A sulphate 
group is a very strong anion, and would be unlikely to show no anionic character, 
therefore it is more likely that this compound was a glucuronide. The method could not 
indicate more specifically the precise glucuronide. metabolite formed. 
The data from the present studies were similar to previous results. Following oral 
administration of loxtidine to dogs at a dose-level of 50mg/kg, levels of radioactive 
material in the plasma at 1 hour after dosing were about 50µg/ml (Bradbury et al., 1983). 
The concentrations of unchanged loxtidine were about 15µg/mi, the majority of the 
radioactive material comprising polar material. The major components of 0 to 24 hour 
urine following oral administration of loxtidine to dogs at a dose-level of 50mg/kg were 
loxtidine (20% of urinary radioactive material) and loxtidine glucuronide (up to 75%). 
In summary, the screening method indicated that loxtidine was metabolised in the dog 
primarily by conjugation to a glucuronide. The data obtained from the dog samples were 
in agreement with the published metabolism of loxtidine in the dog (Bell et al., 1983). 
The concentrations of loxtidine measured in the plasma were similar to previous 
concentrations measured (Bradbury et al., 1983), and the screening method confirmed 
that the metabolite circulating in dog plasma was the same as that excreted in the urine. 
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4.43 Antipyrine 
In the following discussion, the letters describing drug-related components correspond 
with those on Figure 4.13. The Roman numerals refer to the chemical structures in 
Figure 4.3. 
Antipyrine eluted to a distance of between 46 and 51mm using MMD Scheme 13, which 
was a suitable distance to allow more polar metabolites to be separated and detected. The 
drug was eluted from the extraction cartridges in methanol as would be predicted from its 
structure which contains no anionic groups. 
Unchanged antipyrine was not detected in rat plasma. This may have been due to poor 
separation from a large component (A) which had a mean RED of 1.043. Four other 
components were present in the plasma at lower concentrations than A, and had REDs of; 
(B) 0.847, (C) 0.616, (D) 0.364 and (E) 0.270. Component A was eluted mostly in 
methanol although some was detected in the methanol/ammonium acetate eluent. The 
RED of this component, being greater than 1.0, suggested that it was an N-demethylated 
metabolite (norantipyrine). Component B was also eluted in methanol and is therefore 
likely to have been a Phase I metabolite. Its RED of 0.847 was characteristic of aliphatic 
hydroxylation and it could therefore have been the 3-hydroxymethyl metabolite. 
Component C was eluted in methanol/ammonium acetate indicating that it may have been 
a sulphate metabolite. Its RED however did not support it being a sulphate, but could 
indicate that it was a metabolite formed by more than one Phase I oxidation. This did not 
explain why the compound was eluted in methanol/ammonium acetate unless it was 
present in plasma as a sulphate. which was decomposed prior to analysis either on the 
HPTLC plate or during the drying down stage. Components D and E were present in 
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very small amounts and were eluted in methanol/formic acid which indicated that they 
were glucuronide conjugates. The RED of component E supported it being a 
glucuronide, but the RED of component D was more characteristic of a sulphate. 
In rat urine, most components detected were eluted in more than one eluent, some in the 
methanol suggesting that they were Phase I metabolites and then also in 
methanol/ammonium acetate indicating that they were sulphates. The REDs of these 
components, however,, were characteristic of Phase I metabolites. This gave further 
support to the suggestion that the sulphate metabolites of antipyrine were unstable, and 
subsequent to their extraction from biological fluids as sulphate conjugates, were 
hydrolysed to the Phase I metabolites from which they were formed. 
The components detected in urine had similar REDs to those found in plasma, and in 
addition, unchanged antipyrine was also detected. The most abundant component in 
urine had a RED of 0.859, which was characteristic of a metabolite formed by aliphatic 
hydroxylation and may therefore have been the 3-hydroxymethyl metabolite, 
corresponding with component B in plasma. This was present in urine as the sulphate as 
well as the free Phase I metabolite. A component of similar magnitude had a RED of 
0.270, and being eluted partly in methanol with the remainder in methanol/formic acid, 
may have been a glucuronide metabolite, corresponding to component E in plasma. The 
component in next abundance corresponded with component C in plasma, and may have 
been a metabolite formed by more than one Phase I transformation. This was present 
both as the free metabolite and the sulphate conjugate. The component predicted to be N- 
demethylated antipyrine was detected with a RED similar to the free metabolite found in 
plasma, but was eluted in methanol/ammonium acetate. This indicated that it was present 
in urine as the sulphate metabolite. 
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The screening method indicated that antipyrine was metabolised in the rat by Phase I 
metabolism to norantipyrine and 3-hydroxymethyl antipyrine primarily, with other Phase 
I transformations also taking place. The Phase I metabolites then underwent further 
metabolism to form mainly sulphate conjugates but also some glucuronides. 
This was in broad agreement with published data on the metabolism of antipyrine in the 
rat, although some variation was found within the literature. 
The metabolism of antipyrine in the rat has been studied following intraperitoneal 
administration to Wistar rats at a dose-level of approximately 50mg/kg (Boucher, 
Bassmann and Schuppel, 1982a). The concentrations of drug and metabolites in plasma 
were not determined in these studies, but the urinary metabolic profile was examined. 
More than 60% of the dose was excreted in the urine within 24 hours of dosing. The 
principal metabolite was 4-hydroxyantipyrine (II), representing up to 31% of the dose. 
Two other Phase I metabolites, 3-hydroxymethyl antipyrine (III, up to 28% of the dose) 
and 4,4'-dihydroxy antipyrine_ (IV, up to . 18% of the dose) were present in the urine. The 
majority of the three hydroxylated metabolites appeared in the urine as sulphate 
conjugates (Boucher, Bassmann and Schuppel, 1982b) although some glucuronides were 
also formed. Norantipyrine (V) was not quantified in these studies. 
In further studies, following oral administration of 3-14C antipyrine to the rat, 
approximately 93% was recovered in the 0-24 hour urine (Huetter, Albert, Bayer, Zeller 
and Hartmann, 1987). This material was identified mainly as 3-hydroxymethyl 
antipyrine (III, 21.7%), norantipyrine (V) sulphate (20%), 4-hydroxyantipyrine (II) 
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sulphate (14%), 4,4'-dihydroxyantipyrine (IV) sulphate (15%), 4-hydroxyantipyrine (II) 
glucuronide (9.2%) and 3-hydroxymethyl antipyrine (III) glucuronide (12.8%). 
In more recent studies, the metabolism and pharmacokinetics of antipyririe was studied in 
various animal species including the rat (Witkamp, Lohuis, Nijmeijer, Kolker, 
Noordhoek and Van Miert, 1991). Following administration of antipyrine 
intraperitoneally at a dose-level of 50mg/kg to Wistar rats, concentrations of unchanged 
drug in the plasma ranged from about 60 to 20µg/ml during the first 4 hours after dosing. 
The predominant metabolite in urine from male rats, following hydrolysis of conjugates, 
was 3-hydroxymethyl-antipyrine (III, 75.6%) with 4-hydroxyantipyrine (II, 19.3%) and 
norantipyrine (V, 11.1%) also present. The 4,4'-dihydroxy metabolite (IV) was not 
detected in male rat urine, but was detected in urine from female rats in small amounts 
(2.2%). 
Witkamp et al. (1991) found that 3-hydroxymethyl antipyrine and norantipyrine were the 
major components of rat urine which was in agreement with the present studies. The 
presence of 4-hydroxyantipyrine was reported previously, however it was not detected in 
the present studies which may have been due to the different strain of rat used. The 
present studies showed that conjugation occurred to form mostly sulphate metabolites 
which was in agreement with the studies carried out by Boucher et al. (1982b). The 
screening method thus indicated the main routes by which antipyrine is metabolised but 
missed some detail. 
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4.4.4 Diazepam 
In the following discussion, the letters describing drug-related components correspond 
with those on Figures 4.15. The Roman numerals refer to the chemical structures in 
Figure 4.4. 
Diazepam had an elution distance of 55mm using MMD Scheme 3. This was a suitable 
distance to allow more polar metabolites to be separated and detected. The drug was 
eluted from the extraction cartridges in methanol as would be predicted from its structure 
which contains no anionic groups. 
Six drug-related components were detected in rat plasma with REDs of; (A) 1.009, (B) 
0.909, (C) 0.846, (D) 0.60, (E) 0.345 and (F) 0.218. Component A was one of the minor 
components present, and was considered to be unchanged diazepam from its RED and it 
being eluted in methanol. Components B, C and D were eluted in methanol and were 
therefore likely to be Phase I metabolites. The RED of component B, being 0.909, was 
" consistent with a metabolite formed by aromatic hydroxylation, which is most likely to 
occur on the phenyl ring of the diazepam molecule. Component C had a RED of 0.846 
which was characteristic of a metabolite formed by aliphatic hydroxylation. This 
transformation can occur on the benzodiazepine ring of diazepam between the ketone and 
the unsaturated nitrogen. Component D, with a RED of 0. '60, was likely to be a 
metabolite formed by more than one Phase I transformation, possibly aromatic and 
aliphatic hydroxylation. Component E had a RED characteristic of a sulphate and was 
eluted partially by methanol with the remainder in methanol/ammonium acetate. This 
was also consistent with a sulphate metabolite which was perhaps incompletely retained 
by anion-exchange because of its lipophilic character. Component F was eluted in 
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methanol/formic acid which indicated that it was a glucuronide. The RED of this 
component was also consistent with it being a glucuronide. 
In urine, only one component was detected which was partially eluted in methanol, but 
mainly in methanol/ammonium acetate. The RED of this component was characteristic 
of a sulphate metabolite, corresponding to component E in plasma. The RED of 
component E was unchanged when a gradient. with acetic acid was used, but was 
reduced, by the addition of TEA. This did not assist' the assignment of component E 
as a sulphate from the HPTLCGMMD data obtained previously (Chapter 2, Section 2.4.1: 3). 
The screening method predicted that diazepam was metabolised in the rat by aromatic 
and aliphatic hydroxylation to Phase I metabolites which were conjugated to form 
glucuronide and sulphate conjugates. Only one sulphate metabolite was excreted in the 
urine. 
The results obtained in plasma from the present studies indicated the main routes of 
diazepam metabolism, and were in: general agreement with published data, however the 
urinary results differed in the assignment of the main metabolite in urine. 
Following intraperitoneal administration of diazepam to rats at a dose-level of 100mg/kg 
(Schwartz et al., 1967), the intestinal contents were examined by thin-layer 
chromatography, and the metabolites characterised by mass spectroscopy and nuclear 
magnetic resonance. Four metabolites (II - V) of diazepam (I) were identified in the 
intestinal contents as either glucuronide or sulphate conjugates. 
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In studies carried out by Andrews and Griffiths (1984), male Wistar rats received 2-14C 
diazepam orally at a dose-level of approximately 13mg/kg. Only 17% of the dose was 
excreted in the urine and over 70% was present as glucuronic acid conjugates as shown 
by enzyme hydrolysis. The major metabolites were glucuronide conjugates of 4'- 
hydroxyoxazepam (VII, 26.8%), 4'-hydroxydiazepam (III, 16.2%), oxazepam (VI, 
15.6%), 4'-hydroxytemazepam (N, 11.9%), 4'-hydroxydesmethyldiazepam (V, 5.7%) 
and temazepam (II, 4.2%). Very low concentrations of Phase I metabolites were found. 
Similar results were obtained by Trennery and Waring (1985) except the major 
metabolite in urine was oxazepam (VI) glucuronide (38.0%) with glucuronides of 4'- 
hydroxydesmethyldiazepam (V, 22.7%), 4'-hydroxydiazepam (III, 19.2%), 4'- 
hydroxytemazepam (IV, 5.0%), 4'-hydroxyoxazepam (VII, 3.9%) and temazepam (II, 
2.9%) also present. 
The screening method indicated which metabolites of diazepam were present in the 
systemic circulation of the rat which had not been determined in the previous studies 
cited. In urine, a sulphate metabolite was detected, however previous studies have 
reported various glucuronide metabolites being. excreted: in the urine. In this case, the 
data from the screening method may have led to the incorrect assignment of the urinary 
metabolite being made. Possible other reasons for the difference between the present and 
previous studies include the dietary status of the animals, the strain and the higher dose- 
level used in the present studies. . 
In the present studies the animals were fasted overnight prior to administration of 
diazepam which may have resulted in low blood glucose concentrations and a depletion 
of the substrate UDPGA required for glucuronylation. This, in combination with the 
higher dose-level of diazepam administered may have led to a greater proportion of 
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sulphation occurring. However, only a low proportion of the dose (12 to 14%) was 
excreted in the urine, therefore the sulphate metabolite may have been a minor metabolite 
with glucuronides being excreted in the bile. 
4.4.5 Overall Conclusions 
The present studies showed that the data obtained from the screening method were in 
broad agreement with published data on the metabolism of ibuprofen, loxtidine, 
antipyrine and diazepam. The species differences which occur in the metabolism of 
ibuprofen and loxtidine were detected, although in both cases the precise nature of the 
metabolites formed may not have been elucidated from the data obtained without prior 
knowledge. The general patterns of metabolism elucidated from the data obtained for all 
four compounds were generally consistent with published data in terms of the extent of 
Phase I or Phase II metabolism which occurs. Thus the method was found to be useful in 
broad terms and was also able to provide some detailed information. There were, 
however, a number of cases where the "rules" proposed from the work carried out with 
model compounds were not upheld in the analysis of real samples. 
The screening method has been shown to provide data on the extent of drug metabolism 
and the number of metabolites formed. The structures of the metabolites formed have 
been proposed by using relative elution data and the behaviour of the compound during 
sample preparation. The data obtained during the present studies indicated that a 
reasonable likelihood of successful structural assignment can be expected. 
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CHAPTER FIVE 
GENERAL DISCUSSION 
5. General Discussion 
The general aim of the present studies was to assess the value of high-performance thin- 
layer chromatography (HPTLC) for the detection and characterisation of drugs and 
metabolites in biological fluids. The assessment comprised investigations of gradient 
development techniques on HPTLC plates and of sample preparation techniques suitable 
for extracting drugs and metabolites from plasma and urine. These investigations 
resulted in the development of novel linear normal-phase gradients which separated drugs 
and metabolites, and an efficient general extraction procedure. The gradient development 
system and extraction were combined to provide a method which in principle met criteria 
for a general screening method for drugs and metabolites in biological fluids. 
The hypothesis was proposed that particular metabolite types have a characteristic 
retention relative to their parent compound following development using linear normal- 
phase gradients. The existence of a correlation between metabolite type and relative 
retention would thus enable prediction of the structure of a metabolite to be made from its 
retention data. A full investigation of the correlation between metabolite type and 
retention may be considered, however because of the wide range of metabolic 
transformations which occur, and the structural diversity of drugs, this would be 
impractical. Thus in the present studies, model compounds were selected which were 
representative of the major metabolic pathways and included structural components found 
in many drugs. The correlation between metabolic change and retention was investigated 
using these models and was found to support the hypothesis. This showed the potential 
of the method to predict the structures of unknown metabolites from their retention data. 
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The utility of the method was examined by analysing samples of plasma and urine 
obtained from animals following oral dosing with four drugs which have documented 
metabolic data; ibuprofen, loxtidine, antipyrine and diazepam. The aim of these studies 
was to determine how much information about the metabolism of a drug would be 
provided by analysing plasma and urine samples using the method which had been 
developed. Major themes of this thesis were, therefore, an assessment of how much 
information about the nature, and extent of metabolism of a drug could reasonably be 
expected to be provided by the screening method, and identification of its limitations. In 
addition, Quantitative Structure Retention Relationships (QSRR) of drugs and 
metabolites following development on linear gradients were examined as a means of 
obtaining information about the nature of metabolites. 
The potential utility of a general screening method to detect drugs and metabolites in 
plasma and urine of animals during drug research or at an early stage in the drug 
development process was discussed in Chapter 1. HPTLC was considered to have a 
number of advantages which made it an appropriate technique to use as the basis for such 
a method, and consideration of the chromatographic options and modes of development 
available using HPTLC led to the opinion that normal-phase chromatography on silica 
would provide the interactions required to separate drugs and metabolites. It was 
considered that gradient elution would be needed to overcome the general elution 
problem (Snyder and Kirkland, 1979) which is often associated with isocratic 
chromatographic separation of compounds with widely differing polarities. 
Formation of normal-phase gradients on silica HPTLC plates was carried out by an 
adaptation of the automated multiple development (AMD) method described by Burger 
(1984) which was originally derived from the programmed multiple development 
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technique proposed by Perry et al. (1973). The main changes to the AMD method in the 
present studies were the use of manual rather than automated procedures, and use of 
gradients with linear elutropic strength : distance profiles in contrast to those used in the 
previously employed universal gradients which were described by Jaenchen and Issaq 
(1988). The method used was therefore referred to as manual multiple development 
(MMD). 
Initially the resolution and sensitivity of HPTLC/MMD were assessed using a series of 
compounds selected to model typical drug metabolism transformations. These studies, 
described in Chapter 2, showed that HPTLC/MMD provided the resolution required to 
separate drugs and metabolites. Furthermore, the chromatographic data provided 
evidence of a correlation between metabolite type and retention relative to parent 
compounds. Thus "rules" were proposed concerning the ranges of relative retention 
which were characteristic of particular metabolic changes. The inherent sensitivity of 
HPTLC was also shown to be sufficient for the purpose of these studies, with 5ng of 
paracetamol being detected against the plate background. This was not a particularly low 
limit of detection, and reflected the low ultraviolet absorbing properties of paracetamol. 
However it was a rigorous test for the technique and demonstrated that the method would 
be suitable for most compounds rather than only those with high extinction coefficients or 
with fluorescent properties. The inherent sensitivity of HPTLC is great as shown by 
analytical methods which quantify drugs in plasma down to ing/ml, however the 
endogenous background obtained from untreated plasma and urine was found to be so 
great that detection of small amounts of drug in these matrices, following direct 
application to the HPTLC plate, was not possible. This indicated that some sample 
preparation would be required prior to HPTLC/MMD analysis. 
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The methods available for preparing biological fluid samples prior to chromatographic 
analysis in general were reviewed and a number of approaches, consistent with criteria for 
a general extraction procedure, were evaluated. From the studies described in Chapter 3, 
a general extraction procedure based on methods described by Vanluchene and 
Vandekerckhove (1988) and Wilson and Nicholson (1987) was developed. The method 
used Bond Elut CertifyTM II solid-phase extraction cartridges, a new product which had 
been used previously for the isolation of 11-nor-A-9-tetrahydrocannabinol-9-carboxylic 
acid from human urine (Dixit and Dixit, 1990). The mixed reversed-phase and anion- 
exchange properties of the CertifyTM II bonded phase were utilised to retain drugs and 
metabolites, and subsequently to elute them in stages depending upon their anionic 
strength. Thus compounds with no, or only weak anionic character were eluted in the 
first eluent, glucuronides and weak acids were eluted in the second eluent and sulphates 
were eluted in a third eluent. This provided a means for discriminating between 
metabolite type during sample preparation. Extractions of model compounds from 
plasma resulted in extraction efficiencies of greater than 45% for all compounds tested, 
and in excess of 90% for most of the compounds when extracts were analysed by 
HPTLC/MMD. During these studies it was found that the HPTLC plates were easily 
overloaded if too much of a plasma or urine extract was applied. This led to disruption of 
the chromatography in the early stages of the MMD procedure due to failure of the 
sample spots to wet with methanol in particular. It was thus necessary to apply small 
proportions of the sample extracts and rely on the inherent sensitivity of HPTLC to detect 
the resulting small amounts of material on the plates. Despite the need to limit the 
amount of sample analysed by HPTLC/MMD, limits of detection for the model 
compounds ranged between 1 and 50µg/ml with most compounds being detected in the 
range 1 to 10µg/ml. 
-271- 
It was established that HPTLC/MMD in combination with an extraction using Bond Elut 
CertifyTM II cartridges would meet the criteria for a general screening method in principle. 
An assessment was was then carried out to determine how much information about the 
metabolism of a drug the method would provide from plasma and urine samples obtained 
from animals. Criteria were established prior to selecting suitable drugs for 
administration to animals. The objective was to select drugs which would provide a 
reasonable likelihood of success, ensure that a variety of compound classes was studied, 
provide an independent means of establishing reasons for failure should that occur and 
provide species differences to test whether they would be predicted by the method. The 
drugs selected were ibuprofen, loxtidine, antipyrine and diazepam. Plasma and urine 
samples were collected following oral administration of all four compounds to rats and 
ibuprofen and loxtidine to dogs. 
The studies, described in Chapter 4, showed that the data obtained from the screening 
method were in broad agreement with published data on the metabolism of the 
compounds. The species differences which occur in the metabolism of ibuprofen (Mills 
et al., 1973) and loxtidine (Bell et al., 1983) were detected, although in both cases the 
precise nature of the metabolites formed may not have been elucidated from the data 
obtained without prior knowledge. The general patterns of metabolism elucidated from 
the data obtained for all four compounds were generally consistent with published data in 
terms of the extent of Phase I or Phase II metabolism which occurs. Thus the method was 
found to be useful in broad terms and was also able to provide some detailed information. 
There were, however, a number of cases where the "rules" proposed from the work 
carried out with model compounds were not upheld in the analysis of real samples. 
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In the following sections, the differences observed between model compounds and "real" 
drugs are discussed with respect to the MMD procedure and the extraction. The possible 
impact on this thesis of recent work in the fields of multiple development on HPTLC, 
QSRRs and sample preparation are also discussed. An assessment of the utility of the 
screening method is made and the value of the information which it may provide is 
placed into the context of drug research and development processes. Finally, future 
directions are proposed for the further development and use of the technique. 
5.1 Separation of Drugs and Metabolites by HPTLC/MMD 
In a recent review by Poole and Belay (1991), Automated Multiple Development (AMD) 
was described as a technique still in its infancy with optimisation strategies for method 
development remaining difficult. AMD method development strategies based on trial 
and error experiments have been employed (Menziani, Tosi, Bonora, Reschiglian and 
Lodi, 1990) and the use of preliminary isocratic developments of selected standards with 
binary solvent mixtures has been proposed as a means of obtaining preliminary data to 
aid gradient design (Lodi, Betti, Kahie and Mahamed, 1991; Lodi, Betti, Menziani, 
Brandolini, and Tosi, 1991). In the latter approach, retention data obtained from isocratic 
developments were expressed as plots of Rm values (Rm = log((1-Rf)/Rf)) against 
solvent composition and used to predict the optimum solvents for the gradient and the 
composition of the start and end points. Both the trial and error, and Rm plot approaches 
required a significant amount of experimental work, the latter using up to 20 isocratic 
developments before an initial gradient was defined. Furthermore, standards were needed 
to carry out the preliminary experimentation, a requirement which could not be fulfilled 
when attempting the separation of a novel drug and its unknown metabolites. Except in 
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one case, where the gradient was formed using two solvents only, all the applications 
reported used universal gradients. 
In the studies described in Chapter 2 of this thesis, an example was found where two 
components (resorcinol and m-hydroxybenzoic acid) were not resolved following 
development using a universal MMD gradient, despite previous examples of their 
separation by isocratic TLC (Dietz et al., 1976). Their co-elution was attributed to the 
large change in solvent elutropic strength which occurred during the universal gradient 
when use of the strong solvent was discontinued and solvent mixtures with the non-polar 
solvent were started. Similar large changes in elutropic strength occur in many universal 
gradients, therefore it was concluded that biological fluids would be likely to contain a 
number of components, including drugs and metabolites, which might co-chromatograph 
under these conditions. Alternative multiple development systems were therefore 
developed which had linear elutropic strength profiles from the beginning to the end of 
the gradient. It was found that the linear gradients provided conditions under which a 
large number of compounds with widely differing polarity were separated. The use of a 
single linear gradient also overcame the need for optimisation. A single multiple 
development run provided data to indicate the elutropic strength range over which 
development was required, and a subsequent run over a reduced elutropic strength range 
increased the separation if required. 
5.2 Quantitative Structure-Retention Relationships 
Quantitative Structure-Retention Relationships (QSRR) describe the process by which 
chromatographic system and solute properties are used for precalculation of retention, 
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and have been the subject of a recent report (Kaliszan, 1992). QSRR is analogous to the 
methodology used for quantitative structure-biological activity relationships (QSARs) 
used in drug design (Hansch and Fujita, 1964). It would be more useful with respect to 
the aims of this thesis if the QSRR concept could be inverted so that chromatographic 
system and retention data could be used to predict solute structure. This possibility has 
been examined recently for a series of benzodiazepines (Dimov and Moskovkina, 1991), 
however has not previously been applied to drugs and their metabolites in general. 
In the present studies, the chromatographic properties of a number of compounds, 
selected to model typical metabolic transformations, were examined using the linear 
multiple development gradient described in this thesis (Chapter 2). A correlation was 
observed between metabolite type and retention relative to the parent compound. Thus 
addition of a hydroxyl group, a glucuronic acid moiety or a sulphate group resulted in a 
characteristic change in retention of the new compound relative to the parent. The 
potential impact of this finding is that the chemical structures of metabolites may be 
predicted from their retention on linear MMD gradients. 
In the following paragraphs, the development and principles of QSRR are reviewed, and 
the data from the present studies are discussed and placed into context with conclusions 
drawn by other workers. 
Correlation between the Rf of compounds on partition chromatographic systems (paper 
chromatography and reversed-phase TLC) and their partition coefficients has been 
established (Consden, Gordon and Martin, 1944; Bate-Smith and Westall, 1950; Green 
and Marcinkiewicz, 1963). Consden et al. (1944) proposed the following mathematical 
relationship between the partition coefficient (P) and Rfe. 
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Am 
R -1 As f 
where Am/As is the effective ratio of the cross sectional areas of the mobile and 
stationary phases. They showed that for six amino acids, the partition coefficients 
calculated by means of the above relationship agreed well with those measured directly. 
Denoting log[(1-Rf)/Rf] as Rm, the equation may be rewritten as follows: 
logP =1og(Am/AS) + Rm 
Thus Rm is proportional to the partition coefficient. It was shown further that addition of 
a group X to a substance A should change the partition coefficient by a given factor 
depending upon the nature of the group and the pair of phases employed, but not upon the 
rest of the molecule. It thus follows that when a compound A is substituted with mX 
groups and nY groups to give compound B, the following correlation exists between the 
Rm values of A and B in the same chromatographic system: 
Rm, B = Rm, A +m. Rm, X +', n. Rm, y 
The validity of this relationship has been studied by paper chromatography and reversed- 
phase thin-layer chromatography using numerous compound types. The results of these 
investigations were summarised by Tomlinson (1975) who concluded that the Rm change 
caused by the introduction of a particular group into a parent structure is only of constant 
value providing that its substitution into the parent structure does not result in any 
intramolecular interactions with other functions in the structure. In practice, 
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intramolecular interactions occur often and therefore a range of Rm values will 
correspond with the substitution or addition of any particular group. 
Knowledge of the group Rm values and the Rf value of the original compound in a given 
chromatographic system, therefore, theoretically permits the possibility of drawing 
conclusions about the structures of unknown derivatives from their chromatographic 
behaviour. 
The expressions derived for partition chromatography were later applied to adsorption 
chromatography (Sporer and Trueblood, 1959). It was postulated that the standard free 
energy of the adsorption process (the energy required for one mole of solute to pass from 
solution to the adsorbed state) is, to a first approximation, expressible as the sum of the 
free energy changes of the component groups of atoms which comprise the molecule. 
The Rf of a compound under given chromatographic conditions is related to the 
adsorption energy, thus a relationship between retention and structure can in principle be 
expected in adsorption chromatography as was described for partition chromatography. 
Group adsorption affinities have been calculated for various functional groups and the 
theory has been tested with a number of groups of compounds. The data were 
summarised by Snyder (1968b). The group adsorption energies on silica are ranked as 
follows: 
Al-CONH2 > Al-NH2 > Al-COOH > Ar-CONH2 > Ar-COOH > Al-OH > Ar-NH2 > 
Ar-OH » Ar-CH3 and Al-CH3 
where A1= Aliphatic and Ar = Aromatic. 
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The relative elution data obtained in the present studies (Chapter 2) were in agreement 
with the order of the group adsorption energies. Thus, the smallest changes in retention 
were found following aromatic hydroxylation with aliphatic hydroxylation resulting in 
larger changes. Greater changes in elution distance were obtained following oxidation to 
carboxylic acids, and the change observed with the aliphatic acid metabolite of ibuprofen 
was greater than that observed with the aromatic acid derivatives of indole. Evidence for 
the strong adsorption energies of unsaturated amines was obtained from the low elution 
distances achieved with ranitidine and loxtidine. The low elution found with ondansetron 
showed that the imidazole group exhibits a high adsorption energy on silica. 
It has been shown that the additive nature'of adsorption energies is true for some 
compounds. However there are numerous cases where the theory breaks down, and the 
reasons for this have been discussed in detail (Snyder, 1968b). Principally, there are two 
causes for deviation from the theoretical situation, these being the properties of the 
stationary phase and intramolecular interactions within the solute itself. These are 
discussed in the following two paragraphs. 
The surface of silica is covered with discrete sites (free silanol groups) where interaction, 
principally by hydrogen bonding, can take place. A series of compounds containing only 
one group capable of interacting with the silica surface is likely to obey the additivity 
theory because sites for adsorption will be found easily. In more complex molecules 
containing a number of groups which may hydrogen bond with sites on the silica, it may 
not be possible for each group to be held at the optimum distance from the site of 
adsorption for the process to occur. The reason for this is the finite distances between the 
silanol groups on the silica surface and the inflexibility of the medium. 
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Similarly, in the case of a molecule containing only one group capable of hydrogen 
bonding, intramolecular interactions will not occur. When a molecule contains a number 
of groups it is possible for intramolecular hydrogen bonding to take place. This would 
have the effect of apparently weakening the adsorption energy of that particular molecule 
in comparison with that predicted by adding the adsorption energies of the individual 
groups. Whether or not intramolecular interactions occur depends upon the position of 
the groups within the molecule and the flexibility of the molecule in terms of bond 
rotation. It is thus difficult to predict differences in adsorption energies (and hence 
retention) accurately in adsorption chromatographic systems. 
In recent studies (Dimov and Moskovkina, 1991) the structures of fifteen 
benzodiazepines were related to chromatographic retention using QSRRs. The present 
problems with modelling in QSRR studies were stated as; (i) uncertainty regarding the 
correct representation of solute structures, (ii) absence of adequate mathematical 
handling, and (iii) lack of reproducibility of the experimental retention data for 
compounds of interest. Empirical linear equations were derived by Dimov and 
Moskovkina to describe quantitatively the retention data of the benzodiazepines. This 
was achieved by selecting the fragments of the solute molecules which were responsible 
for the chromatographic retention; these were termed chromatophores. The contributions 
of the chromatophores were additive, but in some instances the fragment contributions 
differed from unity depending upon the influence of neighbouring atoms so the equations 
were derived by data interpolation. The requirement for interpolation of data from known 
compounds meant that the equations would not be useful in their present form to assist in 
structure elucidation of unknown compounds from retention data alone. 
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In a recent report on QSRR (Kaliszan, 1992) it was concluded that the QSRR approach 
has been useful with retention data obtained by partition chromatography, however the 
modelling of solute behaviour in more structurally sensitive chromatographic systems 
(i. e. adsorption chromatography) is much more difficult and has been reported only 
occasionally. The main problem was cited as the inadequacy of the available 
mathematical descriptors for representing the structural features that determine retention. 
A major reason for this difference between partition and adsorption systems is the fluidity 
of solutions versus the rigidity of solid surfaces. In solution, solvent molecules are free to 
adjust their relative positions for optimum interaction regardless of the shape of the 
molecule, whereas for adsorption onto a solid surface the situation is quite different as 
described previously. Thus intramolecular and sorbent effects are more important in 
adsorption chromatography. 
Studies have been undertaken to minimise the problem stated by Dimov and Moskovkina 
that variation in the chromatographic conditions has lead to imprecise measurements of 
R f. One approach taken to increase the precision of Rf measurement was use of circular 
thin-layer chromatography by Bidlo-Igloy (1978) who studied aniline derivatives using a 
normal-phase system. This method provided control of the adsorbent layer properties, 
constant development velocities and consistent chamber saturation. Good reproducibility 
of Rf values was obtained, however compounds such as drugs and metabolites with wide 
polarity differences may be difficult to separate isocratically because of the general 
elution problem. In the present studies, it has been shown that multiple development 
(particularly when automated) is able to provide reproducible elution distances (Chapter 
2). The controlled conditions under which the development is carried out in terms of 
solvent mixing, development time and chamber saturation are ideal for ensuring 
reproducibility. In addition modern HPTLC plates are manufactured to high standards 
- 280 - 
ensuring reproducible layer thickness and tight control of the stationary phase particle 
size distribution. The use of gradient development enables drugs and their metabolites to 
be separated. 
The retention data obtained in the present studies from model compounds (Chapter 2) and 
also drugs and metabolites (Chapter 4) have shown the difficulties in attempting to 
correlate discrete retention changes in adsorption chromatography with the addition of 
particular groups. The ranges of relative elution distances (REDs) obtained from model 
compounds following hydroxylation, oxidation to carboxylic acids, glucuronylation and 
sulphation were broad, but generally separable. This may have been due in part to the 
relative simplicity of the compounds used and their having only one functional group in 
most cases. It is pertinent to note that the RED values for aromatic hydroxylation which 
were at the extremes of the range found (Section 2.4.1) were those from compounds 
which contained two or more groups capable of forming hydrogen bonds. Thus it would 
seem that retention was either enhanced due to efficient alignment of interacting groups 
with the silanols on the silica surface, or reduced by intramolecular interactions or poor 
alignment with the silica surface. 
The RED values of the metabolites detected following administration of drugs to animals 
(Chapter 4) showed the need to consider the total structure of molecules when 
interpreting the data. Glucuronylation of a carboxylic acid was shown to result in a larger 
RED (i. e. a smaller change in retention) than glucuronylation of a phenol. This is rational 
with respect to the additivity rule of free energies of adsorption if the order of free 
energies is: 
glucuronic acid > carboxylic acid > aromatic OH 
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Thus, addition of the free energy for glucuronic acid at the expense of carboxylic acid 
results in a smaller free energy change than addition of glucuronic acid at the expense of 
the aromatic hydroxyl group. 
Similarly, loxtidine glucuronide had a larger RED than would have been predicted from 
the work with model compounds. _ Loxtidine itself however has functional groups capable 
of strong hydrogen bonding. In this case, intramolecular interactions may have been 
responsible for the higher RED. 
The present studies have shown that caution is needed when using changes in retention as 
a means of predicting chemical structure. It has been shown however that retention data 
from the method described in this thesis can be used successfully as a guide to structure, 
and the use of essentially one MMD system based on the same solvent mixtures decreases 
the possibility of large variations arising because of changes in selectivity. If the data 
generated are used in conjunction with knowledge of the types of intramolecular 
interactions that are likely to occur, and with reference to functional groups present on the 
molecule, the method is able to provide useful information. Sufficient data have been 
obtained to show the potential utility of the method, and as more data are generated in 
future, the data base from which to draw conclusions will enlarge and the likelihood of 
correct structural assignment being made may increase. 
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5.3 Sample Preparation Strategies 
There have been recent advances in the techniques used to prepare biological samples for 
analysis. These include development of new chemically bonded resins with anion- 
exchange properties, increased use of microdialysis as a means of sample preparation and 
use of immunochemical extraction procedures with non-specific antibodies. These are 
discussed in the following sections and-compared with the approach taken in the present 
studies. 
5.3.1 Bond Elut CertifyTM II Extractions 
The general sample preparation strategy using solid-phase extraction on Bond Elut 
CertifyTM II cartridges adopted for the present studies provided essentially complete 
recovery of drug-related material when used for analysis of plasma and urine samples 
from animals (Chapter 4), and demonstrated discrimination between classes of compound 
when model compounds were investigated (Chapter 3). 
A number of cases were found during the analysis of plasma and urine samples when the 
class discriminating properties of the extraction appeared to fail. In some cases this 
apparent failure was explained, as with the zwitterionic character of glucuronides of basic 
molecules. In other cases elution of the same compound occurred in two eluents, this 
being particularly noticeable when it involved the first (methanol) and third 
(methanol/ammonium acetate) eluents. This occurred in the cases of sulphate metabolites 
of both antipyrine and diazepam, and the most likely explanation is that the cartridges 
were overloaded. The number of sites available for anion-exchange (the mechanism by 
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which sulphates were expected to be retained) is finite, and may have been saturated 
because of the amount of material that was applied. The problem was most apparent 
during the analysis of urine which is known to contain large amounts of anionic material. 
Plasma and urine volumes of lml were extracted in all cases, but only 0.5 or 1% of the 
extract was applied to the HPTLC plate for analysis. It is therefore possible that the same 
sensitivity would be obtained if smaller sample volumes were used such as 100 to 200µl, 
and the residues from the extraction were reconstituted in correspondingly smaller 
volumes of methanol prior to analysis. Extraction of smaller samples would reduce the 
likelihood of overloading the column, and would also mean that smaller volumes of 
biological fluid would be needed for the assay to be carried out. This would have 
important ethical considerations because smaller blood samples could be obtained from 
rodents by tail bleeding without the need for exsanguination. Thus more than one blood 
sample would be obtained from each animal and the number of animals used would be 
reduced. 
5.3.2 Chemically modified resins 
The packings most widely used for liquid-solid extraction are chemically bonded silicas. 
Other materials are available such as porous polystyrene resins, but these are difficult to 
wet with aqueous samples and hence poor sample-surface contact can lead to low 
extraction efficiencies. Recently however, resins chemically modified by the addition of 
acetyl or hydroxymethyl groups have been shown to give extraction efficiencies superior 
to those obtained on chemically bonded silica packings (Sun and Fritz, 1992). Addition 
of the polar groups rendered the resins less hydrophobic and therefore able to be wetted 
by aqueous samples. The increased extraction efficiency was attributed to the greater 
surface area of the resins compared with silica. If this technology is pursued in future, 
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and wettable resins with anion-exchange properties are developed commercially, these 
materials may provide a useful alternative to silica based media. Possible advantages 
would be the lack of secondary interactions such as the weak cationic activity of silanol 
groups which causes mixed modes of extraction and leads to variability, and the increased 
surface area described previously. 
5.3.3 Microdialysis 
Advances have been made in the field of microdialysis. This has been the subject of a 
recent review (Lunte, Scott and Kissinger, 1991) and its use in bioanalytical sample 
preparation has been discussed (Linhares and Kissinger, 1992). A microdialysis 
sampling probe comprises a dialysis capillary through which low molecular weight 
substances can diffuse easily. Perfusion medium matched in ionic strength and pH to the 
sample is pumped through the capillary and collects the molecules which pass through 
from the sample. Microdialysis probes can be implanted into tissue or veins of living 
animals and thus provide a rapid means of sampling without withdrawing fluid from the 
animal with a concurrent clean-up of the biological matrix. More work needs to be 
carried out to assess the general applicability of such sampling, however it may provide a 
useful alternative as a general extraction procedure in the future. A disadvantage 
compared with the extraction method developed in the present studies is that no 
discrimination between sample type would be achieved. The extent of this disadvantage 
would depend upon how much endogenous material was present with analytes in the 
microdialysates. 
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5.3.4 Immunochemical Extraction 
The strategies for sample preparation discussed thus far have relied upon the 
physicochemical properties of drugs and metabolites to provide discrimination from 
endogenous components. An alternative strategy based upon molecular structure might 
be appropriate for isolating drugs and metabolites from biological fluids. As was 
discussed in Chapter 1, during metabolism the chemical structure of a drug is modified to 
form metabolites which are generally more polar in nature than the parent drug. Often 
however, the main structure of the parent molecule remains intact. during metabolism, 
and thus the molecular shape of the drug and its metabolites are similar. 
Immunochemistry provides a method of selecting molecules based upon their chemical 
structure and has been utilised in an approach to sample preparation. 
Immunochemistry has been used for drug analysis by radio-immuno assay (RIA) for 
many years. In RIA, antisera to the drug of interest are raised by inoculating animals 
with a foreign protein to which the drug has been bound covalently. The animal produces 
antisera which have the ability to recognise the drug and bind it in solution. A specific 
antisera is able to bind the drug but not its metabolites, and is thus able to provide a 
specific RIA, however less specific antisera can be raised which might have the ability to 
bind a drug and its metabolites. If the antisera are then covalently bound to a support 
medium such as Sepharose gel, the resulting material can be used as a structure-specific 
solid-phase extraction medium. This technique has been used for preparing human 
plasma samples for salbutamol analysis by high-performance liquid chromatography 
(Ong, Adam, Perreault, Marleau, Bellemare, Du Souich and Beaulieu, 1989). The 
resulting chromatograms were free from endogenous background, however the sulphate 
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metabolite of salbutamol was present, indicating the possibility of using the technique for 
extracting both parent drug and metabolites 
The immunochemical approach has the potential of providing very specific extractions, 
however there are a number of disadvantages. Preparation of antisera typically takes 
three to six months, therefore the advantage of early data which the screening method was 
designed to provide would be lost. (However if non-specific antisera could be developed 
for a range of compounds with similar structures, the disadvantage would be overcome. ) 
The status of the antisera in terms of specificity would not be known therefore it would 
not be possible to be certain that all drug-related material had been extracted. Finally, 
there would be no means of discriminating between metabolite types. 
5.4 Utility of the Screening Method 
The screening method was reliable in providing information about the extent and 
complexity of metabolism of a drug following administration to animals at high dose- 
levels. A reliable indication of whether a drug is cleared renally was also obtained from 
analysis of urine. The reliability of the method to provide data on the nature of 
metabolites was dependent upon the level of specificity required and the structure of the 
parent drug. 
In the following discussion, the utility of the screening method is considered. The 
strengths and weaknesses of the method are discussed and its limitations are defined. Use 
of the method for plasma and urine analysis is discussed, and implications of the 
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requirement for samples following administration of drug at high dose-levels, as defined 
in Chapter 3, are considered. 
5.4.1 Overall utility of the method 
The present studies have shown that the extraction method developed is efficient, 
reproducible and able to provide some discrimination between metabolite types. The 
linear MMD gradients have been shown to provide adequate separation of drugs and their 
metabolites, with relative retention giving an indication of metabolite structure. The 
method has been applied to the analysis of "real" samples, and patterns of metabolism 
shown were in broad agreement with previous studies. 
The method was able to show whether parent drug was present in plasma and urine, and 
indicate whether the drug was present in higher or lower concentrations than metabolites. 
It was apparent from the chromatograms whether only one metabolite was present, as was 
found in the dog following administration of loxtidine. It was also clear when 
metabolism occurred by a number of different pathways as was found following 
administration of diazepam to the rat. The method was therefore able to indicate how 
complex the metabolism of a drug might be. 
There are two levels of information which can be obtained about the nature of metabolites 
formed. At one level it is possible to determine whether the metabolites present are Phase 
I or Phase II. At the second level, the identity of the metabolite is defined more precisely 
as for example a hydroxylated metabolite, a glucuronide or a sulphate. The screening 
method has been shown to provide reliable information at the level of discriminating 
between Phase I and Phase II metabolites in most circumstances. Thus all Phase I 
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metabolites had RED values of >0.5 by HPTLC/MMD, and during the extraction 
procedure all except some carboxylic acids were eluted with methanol. By contrast, RED 
values of conjugated metabolites were <0.5, with most RED values being <0.4. During 
the extraction procedure conjugated metabolites were eluted in either the second or third 
eluent, except for glucuronides of basic compounds with strong silanol interacting 
groups, or as a result of possible cartridge overload. Elution in the later eluents 
confirmed the anionic nature of the conjugated metabolites. 
The screening method provided data which enabled a number of metabolites to be 
assigned to a particular class with a high degree of confidence. There were other 
instances where precise assignments could not be made, and one or two cases where the 
data led to incorrect assignments., This level of interpretation is concerned with QSRR, 
which as discussed previously is currently at best empirical in its application. 
Nevertheless, the high proportion of correct assignments which were made during the 
present studies indicate that the method is useful in this respect, and that its utility may 
increase with use as the data base increases. 
5.4.2 Plasma Analysis 
The method was highly applicable to the analysis of plasma samples for drugs and 
metabolites. The reasons for this conclusion and implications for the overall utility of the 
method are discussed below. 
The method was sensitive, with diazepam and its metabolites being detected at 
concentrations of <1 µg/ml, and loxtidine and a metabolite being present at concentrations 
of 2.5 to 5pg/ml in plasma. In samples obtained following administration of ibuprofen 
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and antipyrine, the major drug-related components would still have been detected if dose- 
levels had been 25% of those used in the present studies. The sensitivity in plasma was 
due largely to the low level of interfering material in the plasma extracts which were 
obtained following solid-phase extraction. 
The determination of drugs and metabolites in the plasma is of great importance 
toxicologically and pharmacologically. Systemic toxicity of a compound may be due to a 
metabolite rather than the parent drug, therefore the identification of circulating 
metabolites may assist interpretation of toxicological data. In general, the intensity and 
duration of drug action is proportional to the concentration of the drug at the site of action 
and the length of time it remains there. As drugs often reach their site of action via the 
systemic circulation, it is important to know whether any metabolites are present in the 
plasma in addition to parent drug. It is of further benefit to know whether any 
metabolites present are Phase I or Phase II because generally Phase I metabolites are 
more likely to be active pharmacologically. 
5.4.3 Urine Analysis 
The method was less useful for detecting metabolites in urine than in plasma. The 
reasons for this conclusion and implications for the utility of the method are discussed 
below. 
Generally, the sensitivity of the method for detecting drugs and metabolites in urine was 
lower than in plasma. This was expected from the studies described in Chapter 3, and 
was not considered too important because the concentrations of drug-related material in 
urine tend to be higher than in plasma except where renal excretion is very low. This was 
-290- 
confirmed by the levels of radioactive material determined in 0-24 hour urine from the 
present studies (Chapter 4) which were between 14 and 77 times higher than the levels in 
plasma at 1.5 hours after dosing. The main reason for the decreased utility of the method 
for urine analysis was the large variation in concentrations of endogenous material in 
urine. The majority of endogenous urinary components eluted in the bottom 25% of the 
HPTLC plate when MMD was carried out using the full gradient, and although resolution 
of the components could be increased by using expanded systems, close or co-elution of 
drug-related material with endogenous components still occurred in some cases. It was 
therefore more difficult to be certain whether a peak which was present in a sample 
chromatogram, and either absent or much smaller in the control sample, related to a 
metabolite unless it was present at high concentrations. 
During drug research or early stages of development, knowledge about the drug-related 
material in urine is less important than corresponding knowledge in plasma. The reasons 
for this are twofold; firstly relating to the importance of circulating drug and metabolites 
discussed previously, and secondly because the extent of urinary excretion relative to 
excretion via the faeces is not known until studies-with radiolabelled drug are undertaken. 
The urinary profile can therefore at best be only a guide to the overall metabolic fate of a 
drug in the absence of faecal data. In cases where urinary excretion is low, metabolites in 
the urine may be minor in terms of the overall metabolic profile as was found following 
administration of diazepam in the present studies, and may give an incorrect indication of 
the major metabolic routes of a drug. 
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5.4.4 Dose-Levels 
It was necessary to administer drugs at high dose-levels in order to obtain plasma and 
urine samples in which drugs and metabolites would be detected by the screening 
method. The implications of this requirement to the utility of the method are discussed 
below. 
The dose-levels used in the present studies ranged from 50 to 250mg/kg, although as 
discussed in Section 5.4.2, these could have been reduced by up to fourfold in some cases 
without affecting the level of information that was obtained. Nevertheless, the most 
appropriate animals from which to obtain samples for analysis by this method would be 
those in the high dose groups of toxicity studies. Analysis of these samples would give a 
useful indication of the extent of metabolism and the nature of metabolites formed, 
however different data may be obtained from subsequent studies at lower dose-levels 
using radiolabelled drug. Reasons for this are that the processes of absorption, 
distribution, metabolism and excretion may be capacity-limited such that at high doses 
the amount of absorption, the extent and pathways of metabolism or the route and rate of 
elimination may be changed significantly. Conversely however, ADME studies which 
are carried out at low dose-levels may not provide appropriate data to assist interpretation 
of toxicological findings at high dose-levels. Furthermore, analysis of samples obtained 
from high dose-level studies might lead to the identification of a metabolite which was 
either not formed or too minor for detection at low dose-levels. Reasons for this might be 
saturation of a particular metabolic pathway or metabolic switching at high dose-levels. 
If the metabolite concerned happened to be one which was later found to be formed in 
man, the information could be vital in assisting to validate the toxicity studies. 
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5.5 Utility with respect to other techniques 
The screening method developed in the present studies has been shown to be useful for 
detecting drugs and metabolites in biological fluids, and indicating the nature and extent 
of drug metabolism. A number of other techniques are used for metabolite screening, 
such as HPLC with diode array detection, HPLC-mass spectrometry and nmr. As 
described in Chapter 1 (Sections 1.4.1 and 1.4.2) these techniques can be classified 
broadly as those which provide indirect or direct evidence of metabolite structures. In 
addition, studies with radiolabelled drug are carried out. The screening method is 
compared with these techniques in the following discussion. 
HPLC with diode array detection has been used'to screen for drugs and metabolites, 
however reliance was placed upon ultraviolet spectra for classifying metabolites. 
Ultraviolet absorption spectra alone do not generally provide structural information, 
therefore chromatographic properties would also need to be considered. Thus 
development of a HPLC system capable of separating drug-related components and 
eluting them in a structurally related order would be necessary. It is considered that this 
would be more difficult to achieve using HPLC than HPTLC for the reasons discussed in 
Chapter 1. The screening method developed in the present studies has advantages, 
therefore, in terms of metabolite identification over HPLC with diode array detection. 
Mass spectrometry and nmr spectroscopy have the advantage that they provide direct 
characterisation of metabolites. A study was carried out using nmr which provides a 
comparison with the screening method described in this thesis. Wilson, Nicholson, 
Ghauri and Blackledge, (1991) described the use of 1H-nmr for the analysis of human 
-293- 
urine following administration of ibuprofen. Most of the known metabolites of ibuprofen 
could be assigned from the nmr traces using authentic standards, however the authors 
considered that less information would have been obtained had their study been the first 
on a new compound. It would have been ascertained that urine was a major route of 
excretion for drug-related material, a number of different metabolites were excreted and 
conjugation to form glucuronides occurred. In the present studies, at least the level of 
information reported for ibuprofen would have been obtained using the screening method 
developed. 
The lack of structural information obtained from the indirect chromatographic methods 
compared with that obtained with the direct spectroscopic techniques is evident. The 
screening method described in this thesis, although based upon a chromatographic 
technique may be consided to lie between techniques which provide indirect and direct 
evidence of metabolite structure. The method may thus have served to narrow the gap 
between chromatographic and spectroscopic techniques in this respect. 
The use of radiolabelled drug simplifies the study of drug metabolism. It provides a 
selective method of detecting drug-related material and means that all except minor 
components are detected. The presence of the radioisotope facilitates easier analysis of 
samples by HPLC because recovery can be calculated by collecting and counting the 
eluent. The chromatographer therefore knows whether components remain on the HPLC 
column at the end of a run, and if necessary can adjust the conditions to ensure complete 
elution. When radiolabelled drug is available, an element of uncertainty is removed, and 
different techniques become more appropriate. There would be little benefit in using the 
screening method developed in the present studies once radiolabelled drug is available. 
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5.6 Future Directions 
In this section the future directions for use of the screening method as it has been 
developed to date are discussed, and future studies which may build upon what has been 
achieved are proposed. 
In its current form the screening method can be used to analyse plasma and urine samples 
from studies with novel compounds in both the drug research and development 
environments. As the method is used in practice, information will be obtained which will 
prove either true or false when definitive metabolism studies with the drugs concerned 
are performed. A data base of information will thus be built up, and after a number of 
applications, a re-evaluation of the method's performance may be made. This may 
provide an indication of the types of compound to which the method is most suited, or 
show that for certain others the method is not applicable. From the larger data base of 
relative elution distances, construction of some more robust structure-retention 
relationships may be possible. 
Recently, dihydroxyalkyl-bonded silica gel ("diol") has been introduced into the range of 
phases available for HPTLC. Studies with diol plates have shown that it behaves like a 
deactivated silica gel and that it has some interesting differences in selectivity compared 
with silica (Witherow, Thorp, Wilson and Warrander, 1990; Martin, Taberner, Thorp and 
Wilson, 1992). It is possible that the diol phase would provide different structure- 
retention relationships and therefore be a useful alternative to silica for use with linear 
gradients. Further studies could be carried out to investigate the utility of the diol phase. 
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The general extraction procedure developed as part of the screening method may be of 
use for extracting samples from studies with radiolabelled drug. The class discriminating 
properties of the procedure may assist in assigning structures to metabolites which are 
isolated from these samples. Use of the extraction procedure to extract samples from 
these studies will enable a larger data base to be built up, and the relationships between 
structure and elution order proposed in the present studies may be refined further. 
In some extractions carried out during the present studies, cartridge overloading appeared 
to occur as discussed in Section 5.3.1. The sensitivity of the method and the small 
proportion of the sample that was applied to the HPTLC plates for analysis mean that the 
volumes of samples analysed could be reduced. Smaller blood samples would therefore 
be required, so use of tail bleeding for rodents could be considered. In future studies the 
use of smaller sample volumes for analysis could therefore be investigated. 
The MMD procedure used for the present studies was very labour intensive, and open to 
errors being made in the accuracy of development distances particularly. Studies carried 
out with Automated Multiple Development (AMD) showed that automation improves the 
reproducibility of the system, but that the current AMD instrument does not easily 
perform linear gradients. Studies to automate linear gradients would be beneficial in the 
future. 
The performance of the screening method would be increased significantly if proof of the 
structural assignments of metabolites made could be obtained easily. In recent years, the 
development of a new generation of smaller, high performance mass spectrometers, 
combined with renewed attention to methods of ionisation, and source and interface 
engineering have made possible a viable combination of TLC with mass spectrometry 
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(Busch, 1992a; Busch, 1992b). The use of laser desorption techniques (Zhu and Yeung, 
1989) in the future may also enhance the interface between TLC and mass spectrometry. 
Mass spectrometry has been combined successfully with TLC using an off-line procedure 
in recent studies (Wilson and Morden, 1991) in which polar molecules and conjugates 
were identified successfully from TLC plates by their mass spectra. Future work could 
include investigation of TLC-mass spectral techniques to confirm the data obtained using 
the screening method. 
Use of in vitro methods to study the metabolism of drugs has increased over the past few 
years particularly within academic research groups, but recognition of the potential 
benefits of these techniques is increasing within the industrial setting (Bell and Tarbit, 
1992). Analysis of incubation media from in vitro studies with microsomes, hepatocytes 
and liver slices during drug research when radiolabelled drug is not available could be 
carried out using the screening method developed in the present studies. In vitro studies 
enable useful information to be obtained early about the metabolism of drugs in different 
species and may thus aid the selection of toxicology species and decrease the use of 
animals. Investigation of the applicability of the screening method to the analysis of 
incubation media could form the basis of some future studies. 
5.7 Concluding Remarks 
The screening method described in this thesis has a place in drug research and the early 
development programme of a drug. The information which the system might provide is 
summarised and its potential value is discussed below. Other areas of study to which the 
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advances in understanding of linear gradients on HPTLC, QSRR and general extraction 
strategies described in this thesis may be applied are also considered. 
The screening method will provide data on the extent of drug metabolism and indicate the 
number of metabolites formed. The structures of the metabolites formed can be proposed 
by using relative elution data and the behaviour of the compound during sample 
preparation. The data obtained during the present studies indicated that a reasonable 
likelihood of successful structural assignment can be expected. 
The value of such information increases the earlier it is obtained. During research, 
identification of circulating metabolites might lead to the discovery of a better drug than 
the compound under evaluation, and may also provide a valuable commercial advantage 
if a new chemical entity is patented as a result of the studies. Even if metabolites are not 
potential drugs, knowledge of the routes of metabolism of a compound may assist in the 
design of a drug with a better pharmacokinetic profile, providing greater bioavailability 
and a longer duration of action. 
The information from the method would be less valuable once a compound has entered 
development because data from studies with radiolabelled compound would be available. 
However, the method may be of use in assisting the interpretation of toxicological 
findings if a drug is toxic at high dose-levels. Use of the method to obtain data following 
administration of drug at high dose-levels may result in identification of metabolites 
which are not formed, or are undetectable, at the lower ADME dose-levels. Data may 
therefore be provided which would assist in validating the toxicology species with respect 
to man. 
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The methods described in this thesis have the advantage of requiring only relatively 
inexpensive equipment and may provide a means of screening in fields other than drug 
metabolism research which have been hampered previously by equipment cost and the 
requirement for specialised scientists. There are numerous areas of scientific study where 
samples are analysed to screen for an unknown number of unidentified components and 
where application of linear MMD gradients and a general extraction procedure may be 
useful. Examples include agrochemical research, the food industry, examination of plants 
for novel drugs, water analysis and examination of samples for degradation products. In 
many cases a screen for a large number of known components is required, and the 
methods described in this thesis may prove advantageous over methodology currently in 
use. 
In conclusion, the preceding discussion has shown that the major objectives of this thesis 
have been achieved. High-performance thin-layer chromatography has been assessed, 
and found to be of value as an analytical tool for the detection and characterisation of 
drugs and metabolites in biological fluids. Generally applicable separation and extraction 
methods have been developed, and the method has been tested by analysing samples of 
plasma and urine following administration of drugs to animals. A general screening 
method for the detection and characterisation of drugs and metabolites had been devised 
which may provide valuable early information in drug research and development 
programmes in the future. 
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Table 1 
Manual Multiple Development Scheme 1 
Step Distance Solvent Composition 
(mm) 
1 4 Methanol 
2 8 Methanol 
3 12 Methanol 
4 16 Methanol (9) + Dichloromethane (1) 
5 20 Methanol (8) + Dichloromethane (2) 
6 24 Methanol (7) + Dichloromethane (3) 
7 28 Methanol (6) + Dichloromethane (4) 
8 32 Methanol (5) + Dichloromethane (5) 
9 36 Methanol (4) + Dichloromethane (6) 
10 40 Methanol (3) + Dichloromethane (7) 
11 44 Methanol (2) + Dichloromethane (8) 
12 48 Methanol (1) + Dichloromethane (9) 
13 52 Dichloromethane 
14 56 Dichloromethane 
15 60 Dichloromethane 
16 64 Dichloromethane (8) + Hexane (2) 
17 68 Dichloromethane (6) + Hexane (4) 
18 72 Dichloromethane (4) + Hexane (6) 
19 76 Dichloromethane (2) + Hexane (8) 
20 80 Hexane 
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Table 2 
Manual Multiple Development Scheme 2 
Step Distance Solvent Composition 
(mm) 
1 4 Methanol 
2 8 Methanol 
3 12 Methanol 
4 16 Methanol (8) + Chloroform (2) 
5 20 Methanol (6) + Chloroform (4) 
6 24 Methanol (4) + Chloroform (6) 
7 28 Methanol (2) + Chloroform (8) 
8 32 Chloroform 
9 36 Chloroform 
10 40 Chloroform 
11 44 Chloroform (9) + Hexane (1) 
12 48 Chloroform (8) + Hexane (2) 
13 52 Chloroform (7) + Hexane (3) 
14 56 Chloroform (6) + Hexane (4) 
15 60 Chloroform (5) + Hexane (5) 
16 64 Chloroform (4) + Hexane (6) 
17 68 Chloroform (3) + Hexane (7) 
18 72 Chloroform (2) + Hexane (8) 
19 76 Chloroform (1) + Hexane (9) 
20 80 Hexane 
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Table 3 
Manual Multiple Development Scheme 3 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.73 
2 12 Methanol (4.6) + Ethyl Acetate (5.4) 0.70 
3 20 Methanol (1.3) + Ethyl Acetate (8.7) 0.63 
4 28 Methanol (0.44) + Ethyl Acetate (9.56) 0.56 
5 36 Methanol (0.15) + Ethyl Acetate (9.85) 0.49 
6 44 Methanol (0.03) + Ethyl Acetate (9.97) 0.42 
7 52 Ethyl Acetate (6.86) + Chloroform (3.14) 0.35 
8 60 Ethyl Acetate (1.21) + Chloroform (8.79) 0.28 
9 68 
. 
Chloroform (3.5) + Hexane (6.5) ? 0.21 
10 76 Chloroform (0.95) + Hexane (9.05) 0.14 
11 84 Chloroform (0.22) + Hexane (9.78) 0.07 
12 92 Hexane 0.00 
Appendix I 
Page 4 of 14 
Table 4 
Manual Multiple Development Scheme 4 
Step Distance Solvent Composition 
(mm) 
1 4 Methanol 
2 12 Ethyl Acetate (2.7) + Chloroform (7.3) 
3 20 Ethyl Acetate (1.3) + Chloroform (8.7) 
4 28 Chloroform 
5 36 Chloroform (6.0) + Hexane (4.0) 
6 44 Chloroform (4.0) + Hexane (6.0) 
7 52 Chloroform (3.0) + Hexane (7.0) 
8 60 Chloroform (2.0) + Hexane (8.0) 
9 68 Chloroform (1.4) + Hexane (8.6) 
10 76 Chloroform (1) + Hexane (9) 
11 84 Chloroform (0.6) + Hexane (9.4) 
12 92 Chloroform (0.4) + Hexane (9.6) 
Strength 
0.73 
0.30 
0.28 
0.26 
0.24 
0.22 
0.20 
0.18 
0.16 
0.14 
0.12 
0.10 
Appendix I 
Page 5 of 14 
Table 5 
Manual Multiple Development Scheme 5 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (0.145) + Ethyl Acetate (9.855) 0.490 
3 20 Methanol (0.055) + Ethyl Acetate (9.945) 0.441 
4 28 Methanol (0.008) + Ethyl Acetate (9.992) 0.392 
5 36 Ethyl Acetate (6.19) + Chloroform (3.81) 0.343 
6 44 Ethyl Acetate (2.16) + Chloroform (7.84) 0.294 
7 52 Chloroform (6.87) + Hexane (3.13) 0.245 
8 60 Chloroform (2.45) + Hexane (7.55) 0.196 
9 68 Chloroform (0.965) + Hexane (9.035) 0.147 
10 76 Chloroform (0.37) + Hexane (9.63) 0.098 
11 84 Chloroform (0.114) + Hexane (9.886) 0.049 
12 92 Hexane 0.000 
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Table 6 
Manual Multiple Development Scheme 6 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol (1.0) + Ethyl Acetate (9.0) 0.613 
2 12 Ethyl Acetate (6.67) + Chloroform (3.33) 0.348 
3 20 Ethyl Acetate (4.41) + Chloroform (5.59) 0.323 
4 28 Ethyl Acetate (2.45) + Chloroform (7.55) 0.298 
5 36 Ethyl Acetate (0.77) + Chloroform (9.23) 0.273 
6 44 Chloroform (7.38) + Hexane (2.62) 0.248 
7 52 Chloroform (4.22) + Hexane (5.78) 0.223 
8 60 Chloroform (2.54) + Hexane (7.46) 0.198 
9 68 Chloroform (1.575) + Hexane (8.425) 0.173 
10 76 Chloroform (0.985) + Hexane (9.015) 0.148 
11 84 Chloroform (0.61) + Hexane (9.39) 0.123 
12 92 Chloroform (0.37) + Hexane (9.63) 0.098 
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Table 7 
Manual Multiple Development Scheme 7 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (7.08) + Ethyl Acetate (2.92) 0.718 
3 20 Methanol (5.27) + Ethyl Acetate (4.73) 0.706 
4 28 Methanol (4.06) + Ethyl Acetate (5.94) 0.694 
5 36 Methanol (3.19) + Ethyl Acetate (6.81) (0.682' 
6 44 Methanol (2.55) + Ethyl Acetate (7.45) 0.670 
7 52 Methanol (2.07) + Ethyl Acetate (7.93) 0.658 
8 60 Methanol (1.69) + Ethyl Acetate (8.31) 0.646 
9 68 Methanol (1.39) + Ethyl Acetate (8.61) 0.634 
10 76 Methanol (1.15) + Ethyl Acetate (8.85) 0.622 
11 84 Methanol (0.95) + Ethyl Acetate (9.05) 0.610 
12 92 Methanol (0.79) + Ethyl Acetate (9.21) 0.598 
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Table 8 
Manual Multiple Development Scheme 8 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (8.85) + Ethyl Acetate (1.15) 0.726 
3 20 Methanol (7.88) + Ethyl Acetate (2.12) 0.722 
4 28 Methanol (7.07) + Ethyl Acetate (2.93) 0.718 
5 36 Methanol (6.38) + Ethyl Acetate (3.62) 0.714 
6 44 Methanol (5.79) + Ethyl Acetate (4.21) 0.710 
7 52 Methanol (5.27) + Ethyl Acetate (4.73) 0.706 
8 60 Methanol (4.81) + Ethyl Acetate (5.19) 0.702 
9 68 Methanol (4.41) + Ethyl Acetate (5.59) 0.698 
10 76 Methanol (4.05) + Ethyl Acetate (5.95) 0.694 
11 84 Methanol (3.73) + Ethyl Acetate (6.27) 0.690 
12 92 Methanol (3.45) + Ethyl Acetate (6.55) 0.688 
Appendix I 
Page 9 of 14 
Table 9 
Manual Multiple Development Scheme 9 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (5.8) + Ethyl Acetate (4.2) 0.710 
3 20 Methanol (3.75) + Ethyl Acetate (6.25) 0.690 
4 28 Methanol (2.55) + Ethyl Acetate (7.45) 0.670 
5 36 Methanol (1.8) + Ethyl Acetate (8.2) 0.650 
6 44 Methanol (1.3) + Ethyl Acetate (8.7) 0.630 
7 52 Methanol (0.95) + Ethyl Acetate (9.05) 0.610 
8 60 Methanol (0.7) + Ethyl Acetate (9.3) 0.590 
9 68 Methanol (0.52) + Ethyl Acetate (9.48) 0.570 
10 76 Methanol (0.38) + Ethyl Acetate (9.62) 0.550 
11 84 Methanol (0.28) + Ethyl Acetate (9.72) 0.530 
12 92 Methanol (0.20) + Ethyl Acetate (9.80) 0.510 
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Table 10 
Manual Multiple Development Scheme 10 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (3.75) + Ethyl Acetate (6.25) 0.690 
3 20 Methanol (2.95) + Ethyl Acetate (7.05) 0.678 
4 28 Methanol (2.375) + Ethyl Acetate (7.625) 0.666 
5 36 Methanol (1.93) + Ethyl Acetate (8.07) 0.654 
6 44 Methanol (1.58) + Ethyl Acetate (8.42) 0.642 
7 52 Methanol (1.30) + Ethyl Acetate (8.70) 0.630 
8 60 Methanol (1.08) + Ethyl Acetate (8.92) 0.618 
9 68 Methanol (0.895) + Ethyl Acetate (9.105) 0.606 
10 76 Methanol (0.745) + Ethyl Acetate (9.255) 0.594 
11 84 Methanol (0.62) + Ethyl Acetate (9.38) 0.582 
12 92 Methanol (0.52) + Ethyl Acetate (9.48) 0.570 
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Table 11 
Manual Multiple Development Scheme 11 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (1.93) + Ethyl Acetate (8.07) 0.654 
3 20 Methanol (1.775) + Ethyl Acetate (8.225) 0.649 
4 28 Methanol (1.63) + Ethyl Acetate (8.37) 0.644 
5 36 Methanol (1.505) + Ethyl Acetate (8.495) 0.639 
6 44 Methanol (1.385) + Ethyl Acetate (8.615) 0.634 
7 52 Methanol (1.28) + Ethyl Acetate (8.72) 0.629 
8 60 Methanol (1.185) + Ethyl Acetate (8.815) 0.624 
9 68 Methanol (1.095) + Ethyl Acetate (8.905) 0.619 
10 76 Methanol (1.01) + Ethyl Acetate (8.99) 0.614 
11 84 Methanol (0.935) + Ethyl Acetate (9.065) 0.609 
12 92 Methanol (0.865) + Ethyl Acetate (9.135) 0.604 
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Table 12 
Manual Multiple Development Scheme 12 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (1.805) + Ethyl Acetate (8.195) 0.650 
3 20 Methanol (1.685) + Ethyl Acetate (8.315) 0.646 
4 28 Methanol (1.58) + Ethyl Acetate (8.42) 0.642 
5 36 Methanol (1.48) + Ethyl Acetate (8.52) 0.638 
6 44 Methanol (1.385) + Ethyl Acetate (8.615) 0.634 
7 52 Methanol (1.30) + Ethyl Acetate (8.70) 0.630 
8 60 Methanol (1.22) + Ethyl Acetate (8.78) 0.626 
9 68 Methanol (1.145) + Ethyl Acetate (8.855) 0.622 
10 76 Methanol (1.075) + Ethyl Acetate (8.925) 0.618 
11 84 Methanol (1.01) + Ethyl Acetate (8.99) 0.614 
12 92 Methanol (0.95) + Ethyl Acetate (9.05) 0.610 
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Table 13 
Manual Multiple Development Scheme 13 
Step Distance Solvent Composition Strength 
(mm) 
1 4 Methanol 0.730 
2 12 Methanol (5.39) + Ethyl Acetate (4.61) 0.707 
3 20 Methanol (3.38) + Ethyl Acetate (6.62) 0.685 
4 28 Methanol (2.213) + Ethyl Acetate (7.787) 0.662 
5 36 Methanol (1.503) + Ethyl Acetate (8.497) 0.639 
6 44 Methanol (1.044) + Ethyl Acetate (8.956) 0.616 
7 52 Methanol (0.744) + Ethyl Acetate (9.256) 0.594 
8 60 Methanol (0.525) + Ethyl Acetate (9.475) 0.571 
9 68 Methanol (0.37) + Ethyl Acetate (9.63) 0.548 
10 76 Methanol (0.258) + Ethyl Acetate (9.742) 0.525 
11 84 Methanol (0.181) + Ethyl Acetate (9.819) 0.503 
12 92 Methanol (0.122) + Ethyl Acetate. (9.878) 0.480 
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Table 14 
Automated Multiple Development Scheme 1 
Step Methanol Ethyl Chloroform Hexane Distance Time Strength 
Acetate (mm) (min) 
1* 100 - - - 6.0 0.2 0.73 
2 81.4 18.6 - - 0.1 
3* 52.6 47.4 - - 14.0 0.7 0.706 
4 34.0 66.0 - - 0.1 
5 22.0 78.0 - - 0.1 
6* 14.2 85.8 - - 22.0 1.5 0.635 7 9.2 90.8 - - 0.1 8* 5.9 94.1 - - 30.0 2.8 0.579 9 3.8 96.2 - - 0.1 10 * 2.5 97.5 - - 38.0 4.5 0.523 11 1.6 98.4 - - 1 0 12 * 
* 
1.0 99.0 - 
. 
46.0 6.5 0.469 
13 0.8 80.6 18.6 - 54.0 10.0 0.362 14 0.5 52.1 47.4 - 0.1 15 0.3 33.7 66.0 - 0.1 16 
* 
0.2 21.8 78.0 - 0.1 17 0.1 14.1 85.5 - 62.0 13.2 0.283 18 - - 100.0 - 0.1 19 - - 81.4 18.6 0.1 
20 - - 52.6 47.4 0.1 
21 * - - 34.0 66.0 70.0 15.1 0.213 
22 - - 22.0 78.0 0.1 
23 - - 14.2 85.8 0.1 
24 * - - 9.2 90.8 78.0 16.9 0.144 
25 - - 5.9 94.1 0.1 
26 * - - 3.8 96.2 86.0 20.5 0.099 
27 - - 2.5 97.5 0.1 
28 * - - 1.6 98.4 94.0 24.5 0.057 
* Steps used for multiple development 
